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Abstract 
 
The  integrin  αVβ5  is  a  receptor  for  sCD23  molecule  and  the  αVβ5 CD23 
interaction  sustains  proliferation  of  the  pre B  cell  line  SMS SB.  This  thesis 
describes further investigation into the role of αVβ5 integrin during human B cell 
development.  B  cell  development  in  the  bone  marrow  involves  stepwise 
maturation  of  progenitor  cells  through  different  defined  stages.  A  tight 
regulation  of  proliferation  and  differentiation  mediates  the  progression  of 
progenitor cells through this developmental pathway. A variety of signals from 
soluble  molecules  and  adhesive  interactions  regulate  this  balance  of 
proliferation and differentiation. The main aim of this work was to assess the 
importance  of  the  integrin  αVβ5  during  B  cell  development  by  defining  its 
expression and function during specific stages of B cell development in the bone 
marrow.  
The αVβ5 integrin was expressed by B cell precursors in the bone marrow, by 
different pre B cell lines and the αVβ5 CD23 interaction sustained proliferation 
of some pre B cell lines. The pre B cell lines SMS SB, RS4;11 and 697 showed a 
significant proliferative response to αVβ5 stimulation by sCD23, a sCD23 derived 
long peptide and anti αVβ5 MAb 15F11. Transitional and more mature B cell lines 
down regulated αVβ5 expression and did not show a proliferative response. Both 
αVβ5  and  αVβ3  integrin  could  be  detected  on  normal  bone  marrow  B  cell 
precursor populations, though αVβ5 was the more highly expressed integrin. In 
preliminary  functional  experiments,  stimulation  of  CD19
+/κ
   cells  with  sCD23 
induced cell proliferation whereas equivalent treatment of CD19
+/κ
+ cells did 
not.  The  data  are  consistent  with  the  interpretation  that  αVβ5  integrin  is 
expressed in B cell precursors but that its ability to sustain growth of these cells 
wanes as the cells mature towards a membrane immunoglobulin positive state. 
The  αVβ5 mediated  proliferation  was  enhanced  by  the  chemokine  SDF 1  and 
PDGF  but  not  by  the  cytokines  IL 3,  IL 4,  IL 7  or  IL 11.  This  effect  was 
apparently restricted to earlier B cell precursors and was independent of levels 
of expression of both αVβ5 and CXCR4. Stimulation of SMS SB cells with CD23, 
15F11  or  CD23 derived  long  peptide  provoked  ERK  phosphorylation  and  co 
stimulation  with  SDF 1  promoted  a  more  rapid  and  sustained  ERK  activation. 
PDGF  induced  a  similar  effect  on  αVβ5 mediated  activation  of 3 
ERKphosphorylation.  These  data  suggest  that  ligation  of  αVβ5  by  soluble, 
adhesion independent  stimuli  activates  ERK  phosphorylation  and  this  pathway 
can  be  modulated  by  inputs  from  G protein coupled  and  tyrosine  kinase 
receptors.   
The murine pro B cell line BAF03 also displayed αVβ5 mediated proliferation in 
response  to  human  CD23.  Murine  CD23  is  generally  regarded  as  lacking  the 
cytokine like activities found in human CD23. The aVb5 integrin binds an arg lys 
cys motif beginning at arginine 172 (arg 172) in human CD23 and the equivalent 
murine sequence is gln lys cys. Studies using CD23 derived peptides indicated 
that arg 172 is not required for binding to murine aVb5
+ BAF03 cells, but that it 
is  required  for  full  biological  activity.  Preliminary  experiments  showed  that 
human  CD23  sustained  growth  of  murine  bone  marrow  B  cell  precursors. 
Therefore, these data suggest that murine B cells can also use aVb5 integrin to 
sustain their growth and the studies described here in human cell lines could be 
translated into in vivo murine models. 
Further work is needed to confirm the proliferative response due to the αVβ5 
CD23 interaction in normal B cell precursors in the bone marrow and to define 
the exact stage of development where this interaction is critical. In addition to 
its  expression  in  the  bone  marrow  B  cell  precursors,  previous  work  has  also 
demonstrated the expression of αVβ5 integrin in B cells from patients with ALL. 
Therefore,  the  αVβ5 CD23  interaction  could  have  important  implications  not 
only  in  proliferation  of  normal  B  cell  precursors  but  also  in  proliferation  of 
neoplastic  B  cells.  These  data  identify  the  αVβ5 CD23  interaction  as  a 
potentially  important  interaction  during  early  B  cell  development,  as  αVβ5 
expression and function is stage specific, regulated by other molecules and can 
be demonstrated in both human and murine cell lines. 
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1  Introduction 
The mammalian immune system is a highly complex network of specialized cells 
and  soluble  factors  which  cooperate  to  protect  the  body  against  invasion  by 
pathogens. Lymphocytes (T or B lymphocytes) are types of cells of the immune 
system that are able to mount a specific immune response against virtually any 
foreign  antigen.  This  is  possible  because  each  individual  T  or  B  lymphocyte 
matures bearing a unique variant of a prototype antigen receptor resulting in a 
population of T and B lymphocytes that collectively bears a huge repertoire of 
receptors that are highly diverse in their antigen binding specificities. 
The B lymphocytes express membrane immunoglobulin (Ig) on their surface as 
the B cell receptor (BCR) and are activated when this receptor binds its specific 
antigen. To develop into plasma cells which secrete antibodies, B cells usually 
require T cell help, in the form of secreted interleukins and cell cell surface 
interactions.  Antibodies  mediate  humoral  immune  responses  by  binding  to 
specific  antigens  and  aiding  their  elimination.  Antibodies  possess  numerous 
protective biological effects including: neutralisation of soluble antigens (viruses 
and bacteria); activation of the classical complement pathway; opsonization of 
particulate  matter  to  allow  enhanced  phagocytosis;  and  antibody dependent 
cell mediated cytotoxicity (ADCC). In addition, antigen specific B cells are highly 
efficient  at  presenting  their  cognate  antigens  and  therefore  act  as  antigen 
presenting cells to activate T helper cells. Thus, B lymphocytes play a central 
role in the immune system and inappropriate cell activation or proliferation of B 
cells can lead to development of immunodeficiencies, allergy, autoimmunity or 
malignancies such as lymphomas and leukaemias. 
1.1 B cell development 
Haematopoietic stem cells (HSCs) with extensive self renewal potential generate 
all blood cell types and as they differentiate into progenitor cells they become 
more restricted in their differentiation potential. B lymphocytes develop from 
pluripotent HSCs in specialised microenvironments such as foetal liver and adult  Mridu Acharya,2008     Chapter 1, 15 
 
bone  marrow.  During  this  process  the  progenitor  cells  undergo  stepwise 
maturation  through  defined  stages  of  development.  This  dynamic  process  of 
growth, survival and differentiation is strictly regulated by multiple mechanisms 
including  sequential  changes  in  gene  expression,  signals  from  cytokines  and 
other soluble molecules and interactions between the progenitor cells and bone 
marrow adherent cells
 1. 
Several classification schemes for human and murine B cell development have 
been  described,  based  on  the  expression  of  cell  surface  markers  on  the 
progenitor  cells.  CD19  is  a  signal  transduction  molecule  which is  the earliest 
marker known to be expressed on B lineage cells and is expressed throughout B 
cell  development  except  on  plasma  cells
  2.
  Other  markers  that  define  early 
developmental  stages  include  CD34,  CD22  and  CD10  in  humans  and  B220 
(CD45R), the tyrosine kinase c kit, CD43 and CD24 in mouse. A model of human 
B cell  development  and  its  corresponding  counterparts  described  in  mouse  is 
represented  in  Figure  1.1.  Although  differences  exist  between  murine  and 
human B cell progenitors the key events occurring during B lymphopoiesis are 
known to be similar. The common lymphoid progenitor (CLP) arising from the 
HSC  is  defined  as  the  progenitor  with  the  capacity  to  develop  into  T,  B 
lymphocytes or NK (natural killer) cells. These cells do not express the T, B or 
NK lineage markers (CD2, CD4, CD8, CD16, CD19, CD20, CD58) but are CD34
+, 
CD10
+ (in humans)
 3.  
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Figure    1.1  Schematic  representation  of  a  model  of  B  cell  development  in  human  bone 
marrow. 
 
The B cell developmental stages are shown beginning from the CLPs to immature B cells with the 
key surface molecules expressed in each stage. Expression of the intracellular enzymes such as 
TdT and RAG and stages in immunoglobulin gene rearrangement are also indicated. The pre-BCR 
is indicated as the µ-ψLC and BCR as µ-k/λ. The approximate counterpart stages in murine B-cell 
development  are  represented  in  parenthesis  as  A-E  using  the  nomenclature  of  Hardy  and 
colleagues 
4,5. The arrows indicate the potential regulatory factors produced by stromal cells and 
the numbers represent surface expression of CD markers. Picture reproduced from LeBien 2000 
1. 
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1.1.1 Pro-B cells  
CLPs in the bone marrow enter the B lineage as pre pro B cells which further 
differentiate into pro B cells 
1. However there is no known surface marker that 
differentiates  CLPs  from  early  pro B  cells.  Murine  CLPs  are  known  to  be 
particularly sensitive to IL 7 signalling and signalling through the interleukin 7 
receptor (IL 7R) is required in the mouse to generate CD19
+, CD43
+ B220
+ pro B 
cells 
6,7. IL 7 signalling is not as crucial in humans, as patients with mutations in 
the IL 7Ra chain have normal numbers of peripheral blood B cells 
8,9. However 
IL 7 is known to induce pro B cells to expand and has been shown to up  regulate 
the expression of CD19 and the transcription factor Pax5 
6. Pro B cells represent 
the irrevocably committed B cell precursors and in humans are characterised by 
the surface expression of the B cell marker CD19 along with CD10 and CD34 
2.  
Some studies have shown that pro B cells express neither cytoplasmic nor cell 
surface     heavy  chain  ( HC) 
10,11  while  others  studies  have  shown  that  
cytoplasmic  HC can be detected on 5 10% of pro B cells 
12. Pro B cells have also 
been shown to express a precursor form of the BCR composed of immunoglobulin 
α (Igα), Igβ and calnexin termed pro BCR 
13 15. Cross linking the pro BCR with 
anti Igβ was shown to induce pro B cells to acquire some of the cell surface 
markers  of pre B cells,  therefore indicating  that  the  pro BCR is  potentially a 
functional receptor in pro B cells 
15. 
One  of  the  factors  guiding  B  lymphopoiesis  is  immunoglobulin  (Ig)  gene 
rearrangement leading to the generation of a functional antigen receptor. The 
antigen  receptor  (or  B  cell  receptor)  is  a  complex  of  an  antigen  recognition 
structure  composed  of  two  identical  heavy  and  light  chains  associated  non 
covalently with a signal transduction heterodimer of Iga and Igβ.  Each of the 
light and heavy chains can further be divided into the variable region (variable 
heavy VH and variable light VL regions) and constant regions. Variable regions for 
both the heavy and light chains are encoded by separate gene segments. These 
segments are brought together by somatic recombination to make a complete V 
region gene and are joined with the constant region genes by RNA splicing after 
transcription. This recombination of Ig genes is of fundamental importance for 
generation  of  diverse  antigen  receptor  repertoires.  The  variable  (antigen 
recognition)  domain  of  Ig  heavy  chain  (IgH)  is  encoded  by  many  scattered 
germline gene segments of three types variable (V), diversity (D) and joining (J)  Mridu Acharya,2008     Chapter 1, 18 
 
and the variable region of Ig light chain is encoded by V and J gene segments. 
These gene segments are appropriately rearranged before expression 
16. 
Immunoglobulin gene recombination begins with D to JH segment rearrangements 
in pro B cells 
17 19. The vast majority of pro B cells express the enzyme terminal 
deoxynucleotidyl  transferase  (TdT)  essential  during  immunoglobuline  gene 
recombination 
20 22.  Although  VDJH  gene  rearrangement  is  easily  detected  on 
many pro B cells, a minority of pro B cells have both heavy chain (HC) alleles in 
the germline configuration 
10. The DH JH rearrangement of immunoglobulin heavy 
chain gene segments is already initiated at the pre–pro B cell stage and pro B 
cells  express  B  lineage  specific  proteins  such  as the  Iga Igβ  heterodimer and 
VpreB 
23.  A  variety  of  transcription  factors  play  important  roles  in  B  lineage 
commitment  and  progression  by  activating  or  repressing  certain  genes.  
Transcription factors such as E2A, EBF and Pax5 are required for up regulation of 
pro B cell stage  specific proteins as well as for expression of lymphoid specific 
recombinase activating genes, RAG1 and RAG2 
24,25. These enzymes are essential 
for  rearrangement  of  the  immunoglobulin  genes.    Human  pro B  cells  may 
correspond  to  Hardy  fraction  B  ±  fraction  C  (murine  counterpart)  based  on 
analysis of VDJH rearrangement 
10. 
1.1.2 Pre-B cells  
A functional VDJH rearrangement of the gene segments coding for the variable 
region of immunoglobulin heavy chains is essential for the progression of pro B 
cells  into  the  pre B  cell  stage
1.  This  rearrangement  results  in  the  surface 
expression of µHC (heavy chain). Expression of surface   results in the assembly 
of the pre BCR and marks the transition to the pre B cell stage leading to the 
process  of  allelic  exclusion  which  results  in  the  productive  rearrangement  of 
only one of the two parental Ig HC alleles. Expression of membrane Ig  in pre B 
cells  has  been  shown  to  inhibit  further  V(D)JH  recombination 
26.  µHC  in 
association with the surrogate light chain (LC) components VpreB, λ5 and the 
signalling heterodimer Iga and Igβ comprise the pre BCR.   
 Mridu Acharya,2008     Chapter 1, 19 
 
In both humans and mouse the pre B cells can be divided into large proliferating 
pre BI and small post mitotic pre BII cells. The pre BI cells express cytoplasmic 
µHC while the pre BII cells express the pre BCR 
1. Human pre BI cells partially 
overlap with Hardy fraction C 
4.  
The genes encoding the two proteins VpreB and l5 were originally identified in 
mouse  and  their  organisation  differs  in  mouse  and  humans 
1.  Mice  with  a 
targeted  disruption  in  the  λ5  locus  exhibit  a  block  at  the  pro B  to  pre B 
transition 
27 but the number of B cells in secondary lymphoid tissue gradually 
increases over time so this block is not absolute. Moreover, the discovery of an 
agammaglobulinemia patient with mutations in both λ5 and a severe disruption 
in B cell development underscores the importance of the surrogate light chain 
components  in  human  B  cell  development 
28.  Expression  of  these  proteins  in 
human  cell  lines  has  been  defined  using  MAbs  (monoclonal  antibodies)  that 
recognise the specific components of the surrogate light chains. Expression of a 
signalling competent  pre BCR  is  an  important  checkpoint  for  developmental 
progression and survival. In mice, targeted mutations in the different pre BCR 
components  including  the  trans membrane  domains  of  Igα  or  Igβ  result  in 
developmental arrest at the pro to pre B cell checkpoint 
28 30.  Pre B cells lose 
TdT and CD34 expression. Pre BCR signalling is shown to be required for allelic 
exclusion  at the  heavy  chain  locus  and  phenotypic  changes in proliferating B 
cells in response to IL 7 signalling 
31.  
Igα  and  Igβ  are  immunoglobulin  superfamily  members  that  activate  cellular 
signalling  pathways  through  cytoplasmic  immunoreceptor  tyrosine activating 
motifs (ITAMS) by recruiting Src, Syk family kinases and  the Tec family kinase 
Btk (Burton’s tyrosine kinase) 
32 35.  Several Src kinases, including Lyn, Fyn and 
Blk and variety of other signalling molecules appear to contribute to BCR or pre 
BCR signalling in a redundant fashion as deletion of genes encoding individual Src 
kinases has little effect on B cell development 
36 38. However other components 
of the BCR signalling pathway such as Syk, Blnk , PI3K, Btk  have been shown to 
be non redundant as deletion of these components impairs B cell development 
39 44.  Signalling through the pre BCR regulate HC allelic exclusion and induce 
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occurs  in  the  absence  of  tyrosine  phosphorylation  of  ITAM  motifs  in  the 
cytoplasmic domain of Igα and Igβ 
45.  B cells that fail to assemble pre BCR fail 
to progress in development and are deleted. It is still debated whether pre BCR 
cross linking by an unknown ligand or simple surface expression is sufficient to 
trigger allelic exclusion and pre B cell development. 
Cells displaying the pre BCR expand through a proliferative burst and initiate 
light chain gene (k or λ) rearrangements. After clonal expansion the pre B cells 
arrest in G1 phase of cell cycle and RAG and Igκ germline gene transcripts are 
expressed for light chain gene recombination. Successful rearrangement of the 
light chain genes results in the expression of the BCR on the cell surface. These 
cells, termed immature B cells, express cell specific surface IgM and emigrate to 
secondary lymphoid organs. Here, they mature further into immunocompetent B 
cells (IgM
+ and IgD
+), which in response to primary antigen challenge and T cell 
support can differentiate into Ig secreting plasma cells.  
Immature B cells are particularly susceptible to BCR induced apoptosis 
46  and it 
is in this compartment that self reactive B cells failing to edit their receptors 
are deleted or anergized 
46 . The BCR is an essential regulator of immature B cell 
development  since  in  the  absence  of  cytoplasmic  domain  of  Igα,  BCR  with  a 
single functional Igβ produce few pre B cells and immature B cells and most of 
these fail to progress to mature B cell stage 
47. Immature B cells that emigrate 
from the bone marrow to the periphery are termed transitional B cells and can 
be distinguished from mature B cells by a series of cell surface markers such as 
CD10, CD38,  IgD and IgM  
48. 
Transitional B cells are short lived and only 10 30% of these cells enter the long 
lived mature peripheral B cell compartment 
49,50. The mechanisms that govern 
selection  of  newly generated  transitional  B  cells  to  the  long lived  B  cell 
compartment are poorly understood but once again BCR signalling appears to be 
an important determinant as loss of BCR expression by conditional IgM ablation 
inhibits this transition to mature B cell stage 
51.  In addition, in the absence of 
functional  Igα,  Syk,  Btk,  Vav,  Lyn,  CD45  or  CD19  molecules  BCR  signalling  is 
insufficient to induce differentiation of transitional B cells into mature B cells 
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1.1.3 B-1 B cells 
The predominant population of B lymphocytes, known as B 2 B lymphocytes, is 
present in the spleen and lymph nodes. These B 2 B cells are produced in the 
bone marrow during postnatal life and migrate to the spleen and lymph nodes 
where, after progressing through several transitional stages, they mature into a 
major follicular (FO) and  minor marginal zone (MZ) B lymphocyte populations. 
While  the  MZ  B  lymphocytes  do  not  circulate  and  respond  to  blood  borne 
antigens, the FO B lymphocytes respond to protein antigens and in response to 
T cell help undergo class switching and affinity maturation into B 2 lymphocytes. 
A  minor  population  of  B 1  B  lymphocytes  (about  5%)  is  localised  to  serous 
cavities.  Although  the  bone  marrow  retains  the  potential  to  produce  B 1  B 
lymphocytes  they  are  most  effectively  generated  from  progenitors  that  arise 
during foetal hematopoiesis. Similar to all B cells, B 1 cells express the B lineage 
antigens CD19 and CD45, although CD45R is present at lower levels on B 1 cells 
than  on  B 2  cells 
54.  Murine  B 1  cells  can  be  distinguished by  the  phenotype 
B220
low  CD23
   CD43
+  IgM
hi  and  IgD
low.  B 1  cells  in  the  peritoneal  and  pleural 
cavities also express CD11b. Therefore they are of the phenotype CD11b
+ IgM
hi 
IgD
low.  These  cells  can  further  be  sub divided  on  the  basis  of  differential 
expression of cell surface antigen CD5 as CD5
+ B 1a cells or CD5
  B 1b cells 
55. B 
1  cells  can  also  be  distinguished  from  conventional  B  cells  by  patterns  of 
anatomical localisation. In mice, B 1 cells are almost completely absent from 
lymph nodes and  make up about 5% of splenic B cells. However they constitute 
a substantial fraction of B cells in the peritoneal and pleural cavities 
56,57. In 
addition  to  surface  phenotype,  B 1  cells  have  a  number  of  distinguishing 
properties. In vitro they are long lived 
58, refractory to activation through BCR 
ligation 
59 61 and in contrast to B 2 cells they can be induced to proliferate by 
treatment with phorbol esters 
62. 
B 1  cells  are  effectors  of  innate  immunity  and  mainly  respond  to  T cell 
independent  immunogens  (thymus independent  type  2  antigens)  that  include 
carbohydrate antigens, by producing mainly IgM and some IgG3 antibodies. These  
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cells provide a first line of defence against pathogens by spontaneously secreting 
IgM antibodies. B 1 cells share many phenotypic characteristics of MZ B cells and 
like these latter cells appear to develop in response to T cell independent type 
2 antigens. The immunoglobulin repertoire of B 1 cells is less diverse compared 
to B 2 cells and this is reflected in their capacity to respond to antigens 
63,64. 
Studies have shown that CD5
+ cells produce natural polyreactive antibodies, that 
are often auto reactive, of the IgM isotype 
65.  
Although B 1 cell function in innate immunity is generally well established the 
origin of B 1 cells has been a controversial topic. The debate has centred around 
two models of B 1 cell development. The selection model proposes that B 1 and 
B 2 cells are derived from a common progenitor and antigen selection at the 
IgM
+ stage determines whether a B cell will follow the B 2 or B 1 differentiation 
pathway 
66,67.  This  model  is  based  on  experiments  demonstrating  that  cross 
linking of the BCR in the absence of antigen or T cell help resulted in expression 
of CD5 by splenic B 2 cells and conferred upon them the ability to proliferate in 
response to phorbol esters  
68,69. Further evidence for this model was provided by 
results from transgenic mice generated with the VH gene from the VH12 family, 
which is preferentially expressed by B 1 lineage cells and was inserted into the 
immunoglobulin heavy chain locus. The VH12 expressing mice mainly generated 
B 1  cells,  whereas  those  expressing  B 2 cell associated  VH  specificities  mainly 
generated B 2 cells 
67. 
By  contrast,  the  lineage  model  proposes  that  B 1  and  B 2  cells  are  separate 
lineages that derive from distinct haematopoietic progenitors. This is based on 
the  observation  that  foetal  tissues  most  efficiently  repopulate  B 1  cells  in 
irradiated immunodeficient recipients while  adult bone marrow preferentially 
repopulates  B 2  cells 
55,70,71.  Moreover,  recent  studies  identifying  B 1 cell 
progenitors 
72 and showing distinct cytokine requirements for B 1 cell and B 2 
cell development  provide further support for this model 
73,74 . The fact that the 
foetal B cell development is skewed to B 1 cells indicates interesting differences 
between foetal and adult hematopoiesis.  Although the adult HSCs preferentially 
generate B 2 cells, they retain the potential to generate B 1 cell progenitors.  
 Mridu Acharya,2008     Chapter 1, 23 
 
A  variety  of  influences  from  transcription  factors,  differences  in  the 
microenvironment  and  cytokine  expression  during  adult  and  foetal 
haematopoiesis will have important regulatory roles in guiding B 1 or B 2 cell 
development pathways. 
Another important factor in B 1 cell differentiation is the BCR. It is known that 
B 1  cell  development  is  promoted  by  strong  signalling  through  the  BCR 
75.  
Blockade  of  most  of  the  positive  regulators  of  BCR  signalling  such  as  BLNK, 
PLCγ2, VaV, Rac, PI3K, BCAP and CD19 leads to absence of peritoneal B 1 cells 
40,42,76 78, while disruption of some negative regulators of BCR signalling such as 
CD22  and  PIRB  which  leads  to  greater  strength  of  BCR  signalling,  leads  to  a 
greater  number  of  peritoneal  B 1  cells  only   
79,80.    This  indicates  that  the 
strength of BCR signalling regulates which mature subsets can develop.  
The murine B 1a cells have been considered the murine equivalent of human 
CD5
+ B cells. In humans, the CD5 marker was first identified on malignant B CLL 
(chronic lymphocytic leukaemia) cells and only subsequently demonstrated as a 
marker  for  normal  B  cells 
81.  Because  B 1  cells  often  produce  auto reactive 
antibodies,  although  non pathogenic  and  of  a  low  affinity,  this  has  led  to 
interest  in  these  cells  as  possible  sources  of  high  affinity  pathogenic 
autoantibodies  seen  in  polysystem  autoimmune  diseases.  Indeed,  there  are 
examples,  in  both  humans  and  mice,  of  an  association  between  autoimmune 
disease and B 1 cells. CD5
+ B cells emerge at a crossroad between malignant and 
auto reactive B cells. A monoclonal expansion of CD5
+ B cells is a feature of  
malignant  diseases  such  as  B CLL  and  MZ  lymphoma 
82,    while  a  polyclonal 
expansion  is  observed  in  systemic  autoimmune  diseases  like  RA,  SS  (systemic 
sclerosis) and occasionally SLE  (systemic lupus erythematosus) 
83,84 85. Therefore 
a study of B cell differentiation into B 1 or B 2 subsets could provide important 
information  in  understanding  malignant  transformations  as  well  as 
autoimmunity.  
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1.2 Haematopoietic microenvironment 
Hematopoiesis is known to take place in the intersinusoidal spaces of medullary 
cavities in the bone. HSCs are located at the stem cell niche in the  endosteal 
surface in association with osteoblasts 
86 and the HSCs destined to generate the 
different  blood  cell  types  ultimately  exit  from  this  niche  and  associate  with 
stromal cell populations that form a three dimensional network between venous 
sinusoids 
87,88.  The  bone  marrow  microenvironment  is  composed  of  a 
heterogeneous  population  of  stromal  cells  and  their  products,  such  as  extra 
cellular  matrix  components  and  various  cytokines  and  chemokines.  These 
cytokines, chemokines and adhesive molecules play a critical role in regulating 
the survival, proliferation and differentiation of the precursor cells.   Studies on 
mice and patients with human immunodeficiencies have led to the identification 
of  some  important  regulatory  molecules  including  IL 7,  Flt3  ligand,  the 
chemokine  SDF 1  (stromal  cell  derived  factor 1)  and  many  still  remain  to  be 
identified. The binding of Flt3 ligand (FL) to Flt3 receptor is important in normal 
B lymphopoiesis as the number of pre pro B and pro B lymphocytes is reduced in 
FL
 /  and Flt3
 /  mice 
89,90. Murine but not human B cell development is absolutely 
dependent on the presence of stromal cell derived IL 7 and the expression of its 
receptor on developing B cells 
91,92. Stromal cell derived factor is a chemokine 
that has been shown to have established roles in B cell development.  
1.2.1 SDF-1 
Stromal  cell  interactions  and  mobilisation  and  trafficking  of  haematopoietic 
precursors are thought to be controlled by cytokines, particularly chemokines 
93. 
In addition, some chemokines have been reported to modulate cell growth and 
survival 
94 99. Chemokines are a family of low molecular weight chemoattractant 
cytokines  that  bind  specific  G  protein coupled  transmembrane  receptors  on 
target cells.  
Stromal  cell  derived  factor 1  (SDF 1)  or  CXCL12  is  a  member  of  the  CXC 
chemokine family 
100 and binds to  its receptors CXCR4 and CXCR7 
101,102. Two 
alternate splice variants of the SDF 1 gene give rise to SDF 1α and SDF 1β which  
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are identical except for an additional four amino acid residues in the carboxy 
terminus  of  SDF 1β.  Gene  inactivation  of  SDF 1  and  CXCR4  in  vivo  leads  to 
embryonic lethality due to abnormal cerebellar and gastrointestinal vasculatures 
and haematopoietic development 
103 105. Studies by Ma, et.al., in knockout mice 
and in chimeric mice that transmitted the CXCR4 mutations in the genome, show 
that mice deficient for CXCR4 die perinatally and display profound defects in the 
haematopoietic  and  nervous  systems.  CXCR4 deficient  mice  have  severely 
impaired  B  lymphopoiesis  and  reduced  myelopoiesis  in  the  foetal  liver  and  a 
virtual absence of myelopoiesis in the bone marrow 
106.   
SDF 1 and CXCR4 are expressed constitutively in a wide range of tissue types 
including brain, heart, kidney, liver and spleen. CXCR4 is expressed not only on 
lymphocytes and monocytes in peripheral blood, but also on a variety of other 
cell  types  including microglia,  astrocytes  and  neurons.  SDF 1  is  constitutively 
produced  by  many  cell  types  including  immature  osteoblasts  and  endothelial 
cells within the bone marrow as well as by epithelial cells in many organs such as 
in the central nervous system 
107,108.  
The role of SDF 1 in migration and homing of haematopoietic progenitors is well 
established.  It  is  known  to  be  the  most  powerful  chemoattractant  for 
undifferentiated human CD34
+ haematopoietic progenitors 
109,110. A number of 
studies have shown that SDF 1 is essential for activation of the integrins LFA 1, 
VLA 4  and  VLA 5 
111,112  leading  to  enhanced  integrin mediated  adhesion  to 
ligands such as ICAM 1, VCAM 1 and in facilitating transendothelial migration as 
well as homing and  engraftment of  precursor B cells in the bone marrow of 
NOD/SCID  mice 
113,114.  In  addition  to  its  established  role  in  regulating  cell 
motility, a number of studies have shown that SDF 1 can also play a role in cell 
survival 
93,115 and proliferation 
116 often in synergy with other cytokines. SDF 1 
has been directly implicated in survival of pre B cells in vitro 
115. Lataillade, et. 
al., showed that SDF 1 enhances circulating CD34
+ cell proliferation with other 
cytokines and that SDF 1 acts as a survival factor in counteracting peripheral 
blood CD34 
+ cell apoptosis 
117.  
 Mridu Acharya,2008     Chapter 1, 26 
 
CXCR4  ligation  by  SDF 1  has  been  shown  to  induce  receptor  internalisation, 
elevation of cytoplasmic Ca
2+ levels, activation of phosphatidylinositol 3 kinase 
(PI3K), phosphorylation of MEK/ERK and phosphorylation of components of focal 
adhesion  complexes  including  paxillin,  p130
cas,  and  focal  adhesion  kinase  in 
many  cell  types 
118 121.  Work  by  Arai,  et.al.,  showed  that  SDF 1  and  IL 3 
synergistically  increase  the  number  of  viable  cells  and  induce  a  chemotactic 
response of haematopoietic cells, in an ERK dependent manner 
122. SDF 1 driven 
proliferative signals are thought to be mediated via the MEK/ERK and PI3K/AKT 
signalling pathways 
123,124 and survival signals through PI3K/AKT 
125. Recent work 
by  Bendall,  et.  al.,  also  shows  that  defective  p38  MAPK  signalling  impairs 
chemotactic  but  not  proliferative  responses  to  SDF 1  in  acute  lymphoblastic 
leukaemia  (ALL)  cells  indicating  a  distinct  role  for  SDF 1  in  leukemic  B  cell 
survival 
126.  
1.2.2 Signalling pathways mediating B cell survival 
B  cell  survival,  differentiation  and  maturation  involves  a  delicate  balance 
between apoptosis and proliferation. The complex mixture of growth factors, 
extracellular matrix and stromal cells provides extrinsic signals that can activate 
a variety of signalling pathways leading to growth, differentiation and survival of 
B cell precursors. Survival stimuli activate intracellular signalling through the 
ligation  of  transmembrane  receptors  which  either  possess  intrinsic  tyrosine 
kinase activity, are indirectly linked to tyrosine kinases (such as integrins) or are 
coupled  to  seven  transmembrane  G  –protein coupled  receptors.  Activation  of 
these receptors results in the recruitment of signalling molecules that activate 
signalling pathways such as the ERK/mitogen activated protein kinase (MAPK) 
pathway and the phosphatidylinositol 3 kinase (PI3K) pathway. 
1.2.2.1  ERK- mitogen activated protein kinase ( MAPK) pathway 
It is well established that many of the cytokines and growth factors regulating 
hematopoiesis activate MAP kinase sigalling pathways to generate their effects 
including  phosphorylation  of  transcription  factors,  regulation  of  transcription, 
nuclear chromatin remodelling, immediate gene induction as well as regulation 
of apoptosis and cell cycle progression 
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Three major groups of MAP kinases (MAPKs) exist: the p38 MAP kinase family, the 
extracellular signal regulated kinase (ERK) family, and c Jun NH2 terminal kinase 
(JNK)  kinase  family.  Biological  activities  vary  with  specific  family  of  MAPKs 
activated and stimulus initiating the activation. In general, the Ras/ERK pathway 
mediates primarily cell growth and survival signals and in certain circumstances 
is known to promote cell differentiation 
127 132. The p38 and JNK pathways are 
known  to  mediate  pro apoptotic  and  growth  inhibitory  signals  as  well  as 
proinflammatory  signals
128 132.  However,  the  p38  MAPK  pathway  may  also  be 
involved  in  inducing  anti apoptotic,  proliferative  and  survival  signals  under 
certain conditions, depending upon the tissue specific isoforms involved.  
One of the most extensively studied MAPK pathways is the Raf/MEK/ERK cascade 
and it has been implicated in many chronic and acute leukaemias. The upstream 
activators of ERK are the MEK (or Map kinase kinase) family of kinases which are 
dual specificity  kinases  that  can  phosphorylate  both  serine/threonine  and 
tyrosine residues on the MAPKs. A kinase responsible for activation of MEK is Raf 
and upstream  of  Raf  is  the  GTPase  Ras. Ras  is  an oncoprotein  and  has  been 
shown to be mutated in approximately 20% of all human malignancies 
133. ERK1 
and  ERK2  are  43/44  and  41/42  kDa  kinases,  respectively,  that  are  directly 
downstream  of  the  MEKs.  Phosphorylated  ERKs  in  turn  phosphorylate  and 
activate a number of transcription factors such as ELK 1,  CREB (cAMP) response 
element  binding  protein,  c Myc,  Nuclear  factor κB,  Activator  protein  family 
transcription factors 1(AP 1),  and Ets family members. They also activate other 
protein kinases such as p90
RSK and enzymes such as cytoplasmic phospholipase 
A2
127.  In  addition,  ERK1/2  are  also  known  to  regulate  apoptosis  by 
phosphorylation of  the pro apototic protein BIM (Bcl 2 interacting mediator of 
cell death) 
134. The duration and degree of MAPK activation is dependent on a 
delicate balance between the activating signals and inactivation mechanisms. 
Removal  of  a  phosphate  from  the  phosphorylated  residues  (tyrosine  and 
threonine),  through the action of phosphatases  results in decreased activity.  
Constitutive  ERK1/2  activation  has  been  reported  frequently  in  solid  tumors 
135,136as well as in hematological and neoplastic disease, particularly AML (acute 
myelogenous leukaemia) 
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was reported in ALL cell lines and in a limited number  of clinical ALL specimens 
138  Gregorj,  et.  al.,  demonstrated  constitutive  ERK  activation  in  leukemic 
samples and showed that ERK1/2 phosphorylation is an independent predictor of 
complete remission in newly diagonsed adult ALL 
139. Furthermore R115777, an 
enzyme specific inhibitor of farnesyl protein transfterase (FT), developed as a 
potential inhibitor of Ras signalling in ALL, was shown to have important anti 
leukemic activity in phase 1 clinical trials 
140.  
1.2.2.2  Phosphatidylinositol 3-kinase (PI3K)/ AKT pathway  
The PI3K/AKT pathway often transduces signals that are similar in nature to that 
of the Raf/MEK/ERK pathway. Phosphatidylinositol 3 kinase (PI3K) is found as a 
dimer  of  two  subunits  (p85  regulatory  subunit  and  p110  catalytic  subunit)  in 
resting  cells.  Upon  activation  of  receptor  tyrosine  kinases,  and  subsequent 
autophosphorylation, the SH2 domains of the p85 subunit bind to the receptor’s 
phosphorylated residue and PI3K then phosphorylates PIP2 (phosphatidylinositol 
4,5  bisphosphate)  generating  PIP3  (phosphatidylinositol  3,4,5  triphosphate)  at 
the cytoplasmic membrane 
141. PIP3 in turn activates and  phosphatidyl inositol 
dependent  kinases  (PDKs)  and  their  downstream  substrate  AKT/PKB 
142.  AKT, 
activated by phosphorylation by the PDKs, in turn phosphorylates a variety of 
downstream  substrates  including the  pro apoptotic BCL 2  family  member  BAD 
143. BCL 2 is the prototype for a large family of related proteins that regulate 
cell death in mammalian cells 
144. Some of these proteins such as BCL 2 and BCL 
XL promote cell survival whereas other proteins in the family such as BAX and 
BAD promote cell death. AKT phosphorylation of BAD on serine 136 results in its 
inactivation and cell survival. When BAD is dephosphorylated in the absence of 
survival  signals  it  interacts  with  the  pro survival  BCL 2  family  members  and 
inactivates them causing cell death. Two pharmacological inhibitors of PI3K have 
been used extensively: Wortmannin and LY294002 [2 (4 morpholinyl) 8 phenyl 
4H 1 benzopryran 4 one] 
145,146. Although both of these inhibitors are useful in 
blocking PI3K signalling neither of them has the capacity to directly inhibit AKT.  
Abrogation  of  oncogenic  signals  from  PI3K  occurs  mainly  via  the  tumour 
supressor gene product PTEN which is a phosphatase 
147. 
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Cross talk  between  PI3K  and  Raf/MEK/ERK  pathways  has  been  reported  on 
multiple levels  
148-150. In addition to controlling Raf kinases, Ras has also been 
shown to interact and stimulate PI3K activity leading to AKT activation. Some 
studies  suggest  that  the  PI3K  pathway  enhances  and/or  synergises  with 
Raf/MEK/ERK  pathway  to  provide  robust  signalling  through  ERK 
151 153,  while 
there  is  also  conflicting  evidence  that  AKT  phosphorylates  Raf  abrogating 
downstream signalling pathway activation 
153 155. However, this effect may be 
dependent  on  the  differentiation  state  of  the  cell 
156.  Regardless  of  the  cell 
type, differentiation state or assay conditions used it is apparent that there is a 
varying  degree  of  cross talk  between  these  two  pathways  important  in  cell 
proliferation  and  survival.  Study  of  the  activation  and  inhibition  of  these 
pathways in B cell proliferation and survival is instrumental in the development 
of new agents designed to treat leukaemias. 
1.3 Precursor cells and stromal cell interactions 
A  second  general  means  by  which  stromal  microenvironment  regulates  B  cell 
development is via direct cell contact. Direct contact of the progenitor cells 
with bone marrow stromal cells is particularly important during the early B cell 
developmental stages 
157. Developing B cells have been observed to grow in close 
association with stromal cells and the contact between the progenitor cells and 
bone  marrow  adherent  layers  is  maintained  by  a  combination  of  adhesion 
molecules including VCAM 1, ICAM 1 on bone marrow stromal cells and the b1 
integrins VLA 4, VLA 5 and b2 integrin LFA 1 on the B cell surface 
158,159.  
Stromal  cell  and  B  cell  interactions  possibly  involve  a  variety  of  mechanisms 
important for regulating growth survival and differentiation of B cell precursors. 
CD23 is a glycoprotein known to be expressed on human bone marrow stromal 
cells 
160 and the  membrane bound or soluble CD23 could potentially  play an 
important regulatory role in growth and survival of B cell precursors.  Mridu Acharya,2008     Chapter 1, 30 
1.3.1 CD23 
CD23 was initially identified as a B cell differentiation antigen and subsequently 
established as the low affinity receptor (FcεRII) for immunoglobulin E (IgE). It is 
a  surface  antigen expressed  by haematopoietic  cells  and  some  epithelial  cell 
subsets.  CD23  is  expressed  weakly  on  a  minority  of  freshly isolated  resting  B 
cells from peripheral blood or tonsils and is both dramatically and rapidly up 
regulated  on  the  B  cell  surface  following  activation  by  stimuli  such  as  EBV 
(Epstein Barr Virus), phorbol esters and interleukin 4 (IL 4), IL 3 and CD40 
161 165. 
Furthermore, CD23 expression is a requisite marker for susceptibility to growth 
transformation by EBV and indeed all EBV immortalized B cell lines are CD23 
positive 
166,167. CD23 expression was said to be a feature restricted to primary B 
cells expressing IgM/IgD 
168, however CD23 was also shown to be expressed by 
pro B cells after triggering of CD40 in the presence of IL 3 
169. 
CD23 functions both as a receptor and a ligand. As the low affinity receptor for 
IgE, it is a focus for IgE immune complexes leading to modulation of allergic 
responses. As an adhesive molecule, CD23 interacts with CD21 to regulate IgE 
production, germinal centre B cell survival and presentation of soluble protein 
antigen by B cells to T cells. Membrane bound CD23 can be cleaved into soluble 
fragments  that  act  as  cytokines  in  vitro.  Potentially  different  forms  of  the 
membrane bound and soluble forms of CD23 have been described, making it an 
important player in allergic, autoimmune and lymphoproliferative disorders. 
1.3.1.1  CD23 Structure  
CD23 is the only FcR which does not belong to the immunoglobulin super family 
170.  The  CD23  gene  on  chromosome  19 
171  codes  for  two  isoforms  (a  and  b) 
differing in their 5’ untranslated sequence and in their intracytoplasmic region. 
The CD23a isoform expression is restricted primarily to B cells but CD23b isoform 
is inducible by IL 4 on a variety of haematopoietic cells 
172. Human CD23 is a 45 
kDa glycoprotein member of the C type lectin family, with a long C terminal 
extracellular  domain  (277  residues),  a  short  cytoplasmic  N terminus  (23 
residues) and is anchored by a single transmembrane domain (20 residues). As a 
type  II  integral  transmembrane  protein  it  has  the  COOH  terminus  oriented 
extracellulary and the short NH2 terminus oriented intracellularly 
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Figure   1.2 Schematic representation of membrane bound CD23. 
 
The  important  structural  features  shown  are  the  lectin  head  domain,  leucine  zipper  motif  that 
mediates  formation  of  trimers  and  the  arrows  indicate  the  cleavage  sites  for  soluble  CD23 
fragments. Sequences differing in the two isoforms at the N-terminal region are also shown. Figure 
reproduced from Schwarzmeier J. D, et.al., (2005) 
177. 
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A model of membrane bound CD23 is represented in Figure 1.2. The extracellular 
region of CD23 comprises three important features:  
(a) The leucine zipper motif near the transmembrane domain consists of seven 
amino acid motifs that are repeated five times in case of the human CD23 and 
forms  an  α helical  coil  stalk  region.  This  region  mediates  the  formation  of 
trimers. 
(b) The lectin head domain that comprises IgE binding site 
178 consists of four 
highly conserved and two partially conserved cysteine residues that interact by 
disulphide bonds and contain the Ca
2+ and sugar binding amino acids. The region 
delimited by Cys163 and Cys282 encodes all the structural information required 
to form the IgE binding site 
179. The cytokine effects of CD23 are mediated by an 
epitope distinct from the IgE binding site 
180.  
(c) A DGR sequence, which in inverse is a common recognition site for integrins 
is located near the C terminus of the molecule.  
Similar  to  most  FcR,  CD23  exists  in  soluble  and  membrane bound  forms. 
Membrane bound  CD23  is  cleaved  into  soluble  fragments 
181  by  mechanisms 
involving matrix metalloproteases. Soluble CD23 is first released as an unstable 
37 33 kDa molecule which is subsequently transformed into more stable 25 kDa 
fragments 
182. 
IgE plays a central role in allergic diseases and the first receptor identified for 
this molecule, termed FcεRI, binds IgE with such a high affinity (Ka~ 10
10M
 1)  on 
cells  bearing  FcεRI   are  permanently  coated  with  IgE  and thus  sensitized  for 
rapid release of molecules promoting immediate inflammatory response  when 
cross linked with allergen. CD23 binds to IgE with lower affinity (Ka~ 10
7M
 1) and 
this interaction is involved in both IgE regulation and antigen presentation by B 
cells.  
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Binding  of  IgE  to  CD23  is  calcium dependent  and  appears  to  involve  protein 
protein interactions since deglycolysated native IgE peptides are able to bind 
CD23 
183.  However,  Delespesse,  et.  al.,  1992  showed  an  ability  of  fucose 1 
phosphate to inhibit binding of native IgE to soluble CD23, therefore CD23 IgE 
binding probably involves protein protein and protein carbohydrate interactions 
184. IgE CD23 interactions have been implicated in many IgE dependent roles, 
including combating parasitic infestations 
185, induction of IgE synthesis 
186 and 
maintenance/modulation of IgE responses 
187. 
CD23  is  known  to  play  a  regulatory  role  in  IgE  production  with  positive  and 
negative effects. CD23 acts as a buffer in negative feedback regulation of IgE, as  
membrane bound CD23 delivers a down regulatory signal for IgE synthesis by B 
cells when engaged by IgE allergen complexes 
188, while sCD23  is known to act 
as a B cell growth factor up regulating the production of IgE when in trimeric 
forms. It has been proposed that trimeric sCD23 promotes IgE synthesis by cross 
linking membrane IgE and CD21 on B cells committed to IgE synthesis 
189. CD21, 
the EBV and complement receptor 2 (CR2) were identified as second ligands for 
CD23 
190  .  Engagement  of  B  cell  CD21  by  either  anti CD21  antibodies  or  by 
recombinant CD23 leads to IgE secretion by B lymphocytes in the presence of IL 
4 
190,191. The CD23 CD21 interaction is known to be critical for enhancing contacts 
between T and B cells and other molecules such as CD40 provide co signals for 
this interaction 
192,193.  
CD23 has been shown to be physically associated with the MHC class II molecule, 
HLA DR on B cells which indicated that it could act as an accessory molecule in T 
cell interactions with antigen presenting cells 
194,195. CD23 occupancy by anti 
CD23 antiboides (MHM6 and EBVCS4) and IgE  was shown to prevent B cells from 
stimulating  allogeneic  T  cells 
194  and  further  investigation  showed  that  the 
CD23/CD21  interaction  is  required  for  presentation  of  conventional,  soluble 
protein  antigens  by  B  cell  lines  to  CD4
+  T  cell  clones 
196.  This  antigen 
presentation function requires the binding of antigen IgE immune complexes to 
CD23, internalization of the complexes and transport to compartments of the 
endosomal network containing proteolytic enzymes and MHC class II antigens.  
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CD23  on  macrophages,  eosinophils  and  platelets  mediates  IgE dependent 
cytotoxicity  and  promotes  phagocytosis  of  IgE coated  particles 
185.  Various 
studies  have  shown  that  engagement  of  membrane  CD23,  on 
monocytes/macrophages  leads  to  production  of  important  inflammatory 
modulators;  for  example,  production  of  cyclic  AMP  (cAMP),  TNF α  and  lipid 
mediators after ligation of CD23 in IL 4 activated monocytes 
197,198,  nitric oxide 
production  (NO)  in  human  monocytes,  macrophages  and  eosinophils 
198 200. 
Furthermore,  CD23  engagement  in  pro monocytes  was  shown  to  induce 
differentiation as well as activation of the transcription factor NF κB, induction 
of the proto oncogenes c fos, c jun and junB and production of TNF α 
201. 
The fact that not all of the activities of CD23 can be attributed to its interaction 
with IgE or CD21 has led to research on novel ligands for CD23. β2 integrins 
CD11b/CD18 and CD11c/CD18 and the vitronectin receptor avβ3 integrins were 
identified  as  receptors  for  CD23 
202,203.  Triggering  CD11b  and  CD11c  on 
monocytes with recombinant CD23 was shown to cause an increase in production 
of proinflammatory cytokines IL 1a, IL 1β, Interferon g (INF γ), IL 6 and tumour 
necrosis factor a (TNFa) as well as marked increase in nitrite (NO2
 ) and H2O2 
production 
202,204. Another study showed triggering of the β2 integrins on primary 
human monocytes provides activation signals leading to nuclear translocation of 
NF kB  and  subsequent  secretion  of  MIP1a  (macrophage  inflammatory  protein) 
and  MIP 1β 
205.  This  may  have  important  roles  in  recruitment  of  other 
inflammatory cells during initiation of an inflammatory response. The vitronectin 
receptor avβ3 in association with CD47 was shown to induce sCD23 mediated 
pro inflammatory function by production of TNF a, IL 12 and IFN g 
203. 
1.3.1.2  sCD23 and B cell growth 
CD23 can be described as a multifunctional cytokine. Soluble fragments of CD23 
retain the capacity to bind IgE but have also been ascribed numerous cytokine 
like  activities.  CD23  induces  various  growth  promoting  and  differentiation 
effects  on  haematopoietic  cells  in  synergy  with  the  cytokine  IL 1α.    In  vitro 
experiments  show  that  sCD23  in  synergy  with  IL 1α  prevents  centrocyte 
apoptosis and drives the cells towards a plasmacytoid phenotype 
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maturation  of  precursor  T  cells  in  the  thymus 
207,208  as  well  as  increasing 
proliferation  of  mature  CD4
+  T  cells  in  response  to  mitogens  such  as  PHA 
(phytohemagluttinin) 
209  and  drives  proliferation  and  maturation  of  bone 
marrow derived  CD34
+  myeloid  precursors 
210.  The  significance  of  these 
observations is underlined by in situ detection of CD23 producing cells in the 
thymus (on a subset of epithelial cells) 
207, in bone marrow (on stromal cells) 
160 
and in the light zone of germinal centres ( on follicular dendritic cells) 
203.  
1.3.1.3   CD23 and EBV 
Growth promoting  effects  of  the CD23  molecule  are  closely  related  with  EBV 
transformation.  EBV  belongs  to  Herpesvirus  family 
211  and  has  been  closely 
associated with endemic forms of Burkitt’s lymphoma (BL), while the majority of 
sporadic BL are not EBV related. Although this virus is known to be the causative 
agent in endemic BL its precise role is not fully understood. CD23 is associated 
with the immortalising properties of the virus and as mentioned above the non 
immortalising  strains  of  this  virus  do  not  up regulate  CD23  expression.  The 
Epstein Barr virus nuclear antigen (EBNA 2) and latent membrane protein 1(LMP 
1) are two latent genes essential for immortalisation of human B cells and both 
of these genes are involved in CD23 expression 
212,213. B cell infection by EBV is 
often considered as a model for B cell activation 
167. Following transformation by 
EBV,  B  cells  are  activated  to  release  sCD23  that  contains  autocrine  growth 
promoting activity 
214,215. In vitro experiments clearly demonstrated that sCD23 
acts as a growth factor for both EBV immortalised cell lines and antigen receptor 
stimulated normal B lymphocytes 
215. 
Apart from the cases of EBV transformed lymphblastoid cell lines (LCLs,) Gordon, 
et. al., have shown that anti CD23 MAb provided a progression signal to human B 
cells primed by phorbol ester to enter the G1 phase of cell cycle 
216. CD23 was 
also shown to enhance growth promoting effects of IL 4 and antibodies to CD40 
214,217. Work by Fournier, et. al., showed that CD23 could play a role in leukemic 
B cell disease, especially chronic lymphocytic leukaemia (CLL); since IFN α and 
IL 2 selectively upregulated CD23b and stimulated growth of  malignant B cells  
while IL 4 and IL 2 upregulated CD23a and had no growth promoting activities 
but suppressed B CLL apoptosis 
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1.3.1.4  CD23 in disease  
CD23  is  involved  in  a  variety  of  allergic  diseases  owing  to  its  role  in  IgE 
regulation. However sCD23 levels are known to be increased in diseases in which 
IgE is not implicated. As mentioned above, a characteristic feature of CLL is high 
serum concentrations of sCD23 which can be 500 times higher than in normal 
individuals and  sCD23 appears to be an independent prognostic variable in this 
disease 
220.  Interestingly  it  was  also  shown  that  CD23  expression  is  markedly 
stronger in proliferating CLL cells located in splenic white pulp and proliferating 
centres in lymph nodes in comparison to CLL cells outside these proliferation 
centres 
221.  Increased  CD23  levels  have  been  reported  in  various  chronic 
inflammatory  diseases  including  systemic  lupus  erythematosus  (SLE) 
222, 
inflammatory bowel disease 
223, Sjogren’s syndrome 
222 and rheumatoid arthritis 
(RA)
224,225. In the case of RA, successful disease modulation was achieved when 
arthritic mice were treated with either MAb or polyclonal antibodies to mouse 
CD23 in the typeII collagen induced arthritis (CIA) mouse model 
226. This clearly 
establishes  the  therapeutic  importance  of  CD23  in  these  disease  conditions. 
Although  the  disease  amelioration  in  the  CIA  mouse  by  using  anti CD23 
antibodies is attributed to blocking of cytokine production by macrophages, the 
variety of roles for CD23 in B cell activation and growth indicate a strong role for 
CD23 on B cells in diseases where there is clonal expansion of malignant B cells 
such as CLL or in autoimmune diseases such as SLE.  
The  pleiotropic  activities  of  soluble  CD23  fragments  and  particularly  the 
activities relating to B cell activation and growth, have not been shown in vitro 
in  mouse  cell  lines  or  in  genetically engineered  mice.  Studies  in  mice  have 
confirmed the negative regulatory effects of CD23 in IgE production. Targeted 
deletion  of  both  CD23  alleles  (CD23
 / )  in mice  was  shown  to  produce  higher 
levels of IgE than wild type equivalents on immunisation with thymus dependent 
antigens 
227.  Moreover,  over expression  of  CD23  under  certain  genetic 
backgrounds showed reduced IgE production in response to antigenic stimulation 
228. Recently, a naturally occurring dominant negative CD23 allele in NZB mice 
was shown to have reduced IgE binding and failed to produce negative feedback 
regulation for IgE responses 
229. 
 However these mice had normal B lymphocyte 
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Several  differences  in  structure  and  cellular  expression  may  account  for  the 
differences in function between the human and murine CD23. Murine CD23 has 2 
instead of 1 N linked glycoslation sites, 4 instead of 3 consensus repeats in the 
leucine zipper motif 
173,178 and is also not known to form trimers as it lacks the 
DGR motif by a naturally occurring truncation and the sCD23 fragments bind IgE 
with much lower affinity 
230. Murine CD23 is expressed only on B cells, follicular 
dendritic cells and some T cells. Interestingly the mouse CD21 does not bind EBV  
and mouse and human CD23 could also have evolved with different function in 
relation to EBV infection 
231. 
Previous work from our laboratory identified the vitronectin receptor avβ5 as a 
CD23 receptor on SMS SB cells. SMS SB cells do not express CD21 or any other 
CD23 receptors identified and do not produce CD23 mRNA for autocrine CD23 
activity. aVβ5 was shown to bind to an RKC motif (arg lys cys) on human CD23 
and this interaction sustained proliferation of the pre B cell line, SMS SB 
232. The 
growth promoting effects of sCD23 described so far have been in the mature B 
cells  whether  it  is  EBV transformed  LCLs,  germinal  centre  B  cells  or  normal 
mature  B  cells  and  these  effects  have  been  attributed  to  CD23 CD21 
interactions. With regard to haematopoiesis, a role for CD23 has been suggested 
either in the myeloid precursors or T cell precursors.  CD40 ligation together 
with  IL 3  was  indeed  shown  to  induce  CD23  expression 
169  in  human    B  cell 
precursors  and  induce  proliferation 
169,233.  Considering  the  important  role  of 
CD23 in mature B cells and other haematopoietic precursors and the expression 
of CD23 by bone marrow stromal cells, it is conceivable that CD23 plays some 
role during B cell development in the bone marrow. However, the precursor B 
cells do not express CD21 and therefore any effects of CD23 on these cells would 
have  to  be  via  another  receptor.    As  shown  by  the  previous  work  in  our 
laboratory  on  SMS SB  cells,  the  CD23 αVβ5  integrin  interaction  could  be  an 
important  mechanism  for  survival  of  B  cell  progenitors  in  the  bone  marrow, 
independently or together with other cytokines and adhesion molecules. 
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1.3.2 Integrins 
Integrins are heterodimeric transmembrane adhesion receptors composed of non 
covalently bound a and β subunits 
234 237. They mediate cell to cell and cell to 
extracellular matrix (ECM) interactions and are involved in fundamental cellular 
processes such as cell proliferation, migration, differentiation and apoptosis 
237. 
The  integrin  family  is  composed  of  18a and  8β  subunits  and  each  a and  β 
combination has its own binding characteristics. The integrins are expressed in a 
cell  type specific  manner  and  despite  a  high  degree  of  redundancy  most 
integrins  have  specific  biological  functions  and  differences  exist  in  signalling 
between integrins.  
Ligands  for  integrin  receptors  are  diverse  and  ligand  binding  can  induce 
structural  changes  in  the  integrin’s  interaction  with  other  molecules.  For 
example, vitronectin inhibits sCD23 binding to the integrin αVβ3 
203. Integrins 
mediate adhesion upon binding to specific adhesion proteins such as vitronectin, 
fibronectin and collagen, often through the recognition of the tripeptide arg gly 
asp  acid  (RGD)  motif.  In  addition,  they  also  bind  to  soluble  ligands  such  as 
fibrinogen or counter receptors on adjacent cells such as intracellular adhesion 
molecules (ICAMs) 
234. Although many integrins recognise the RGD sequence in 
their  matrix  ligands  they  are  also  capable  of  distinguishing  different  RGD 
containing proteins such that some integrins bind primarily to fibronectin and 
others to vitronectin. 
1.3.2.1  Integrin Signalling  
Integrins  not  only  transduce  signals  to  cells  in  response  to  the  extracelluar 
environment but they also respond to intracellular cues that alter the integrin 
response  to  the  extracellular  environment.  Ligand  binding  leads  to  integrin 
clustering, assembly of cytoskeletal proteins (such as vinculin, talin, paxilin), 
reorganisation of the actin cytoskeleton, all resulting in the formation of focal 
adhesions 
238.  In  addition  to  forming  a  structural  link  between  ECM  and  the 
cytoskeleton, focal adhesions are also important sites of signal transduction. The 
signalling  pathways  activated  by  integrins  are  similar  to  the  kinase  cascades 
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integrins activate one or more intracellular pathways. Because integrins, like all 
adhesion receptors, do not have intrinsic kinase activity, activation of signalling 
pathways requires recruitment of non receptor kinases. These kinases typically 
involve phosphorylation of focal adhesion kinase (FAK) or the related kinase PyK2 
and activate a number of Src homology domain SH2 and SH3 containing adapter 
proteins 
238.  FAK  is  activated  by  integrin mediated  adhesion  and  localises  to 
focal adhesions, creating a binding site for Src family of tyrosine kinases and 
adaptor proteins such as Grb 2, and subsequent activation of mitogen activated 
protein kinase (MAPK) cascades such as the Ras/ERK pathway
 239,240. FAK is also 
known to bind to  PI3K and can activate PI3K mediated pathways for cell survival 
241.  
Signals  from  the  integrin  receptors are also  integrated  with those  originating 
from  growth  factor  and  cytokine  receptors  and  association  of  integrins  with 
other  membrane  proteins  has  been  shown  to  provide  additional  coordinate 
signals to cells that are specific for individual integrins 
242. Integrin dependent 
adhesion and signalling is important in regulation of multiple processes such as 
tissue  development,  inflammation,  angiogenesis,  tumour  cell  growth  and 
metastasis 
237. 
1.3.2.2  Vitronectin receptors 
The vitronectin receptors (VnRs) are members of the integrin family comprising 
the αV chain in non covalent association with one of five β subunits β1, β3, β5, 
β6 and β8 and bind a broad spectrum of ligands, including fibrinogen, fibronectin 
and vitronectin, typically by recognition of the arg gly asp (RGD) motifs 
236,237. 
The integrins αVβ5 and αVβ3 are the vitronectin receptors currently defined as 
CD23 receptors. 
The  αVβ3  and  αVβ5  integrins  have  been  studied  for  their  roles  in  tumour 
progression,  metastasis,  angiogenesis  and  inflammation
237.  Moreover,  mice 
lacking these integrins have been shown to have enhanced tumour growth and 
angiogenesis 
243. Studies using antibodies to β3 and β5 domains have shown that 
antibodies  to  the  region  of  β3  proximal  to  the  ligand  binding  site  failed  to 
recognise β5 
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ligand  binding,  primarily  to  vitronectin,  while  αvβ3  binds  to  vitronectin, 
fibronectin, fibrinogen and von Willebrand factor 
245. These integrins may also 
have  different  signalling  functions  as  both  αVβ3  and  αvβ5  localise  to  focal 
adhesions  but  only  β5  containing  complexes  undergo  endocytosis  and  are 
capable  of  sustaining  focal  adhesion  kinase  activity  at  high  levels  in  a  Src 
dependent  manner 
245.  These  differences  in  ligand  specificity  and  activation 
patterns indicate that these integrins may have specialised function in different 
cellular processes. 
The integrin αVβ3, consists of 125kDa αV subunit and 105 kDa β3 subunit and has 
been a focus of intensive research because of its major role in several distinct 
processes,  such  as  osteoclast mediated  bone  resorption,  angiogenesis, 
pathological neovascularisation and tumour metastasis 
246. The engagement of 
this integrin is shown to enhance cell invasion in human multiple myeloma 
247 and 
it has also been shown to be involved in proliferation and migration of lymphoid 
tumours 
248.  The  crystal  structure  of  αVβ3  binding  an  RGD  ligand  has  been 
determined, giving more insight into integrin conformation and activation states 
249.   
1.3.2.3  Integrin Structure 
Integrins  are  large  glycoproteins  with  multiple  domains  and  integrin  ligand 
binding is tightly linked to molecular conformation. Each of the a and β subunits 
comprises  a  large  extracellular  domain,  single  transmembrane  domain  and  a 
short cytoplasmic tail. The N terminal portions of the a and β subunits fold into 
a  globular  headpiece  (containing  the  ligand  binding  site)  which  is  connected 
through the a and β tailpiece domain to the membrane (Figure 1.3). Activation 
of the integrin results in  rearrangement in the orientation of these domains 
236.  
Structural  studies  have  revealed  that  the  integrins  exist  in  at  least  three 
different conformational states. A bent conformation, an extended conformation 
with  a  closed  headpiece  and  an  extended  conformation  with  an  open 
headpiece
250.    It  has  been  suggested  that  the  bent  conformation  is  the  low 
affinity state while the open conformation corresponds to the ligand bound high 
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become exposed in the extended conformation and ligand binding induces the 
high affinity conformation 
250. For example, cyclic RGD peptides bind to the low 
affinity  bent  conformation  of  αVβ3  and  induce  conversion  to  the  extended 
conformation  with  open  headpiece 
250.  The  model  proposed  is  that  the  bent 
conformation represents an inactive physiologically relevant conformation and 
that  activation  would  be  accompanied  by  a  switchblade like  opening  of  the 
headpiece  and  tailpiece  interface  into  an  extended  state 
236.  The  crystal 
structure of αVβ3 revealed a bent conformation where the αV and β3 subunits 
are bent acutely at the knee region (in between the head piece and tail piece). 
The ligands were shown to bind at the major interface between the αV and β3 
subunits making extensive contacts with both 
249. 
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Figure    1.3  Representation of bent and  extended  conformation of extracellular  regions of 
integrin αvβ3. 
 
(A) Shows the ribbon diagram of the integrin in the bent conformation with closed headpiece and 
(B) shows the extended conformation with open headpiece. The headpiece and the tailpiece region 
are indicated. The β-propeller region in the headpiece which is found in the ligand binding site and 
the thigh and calf regions are also indicated. This representation is based on the crystal structure of 
αvβ3 and the figure is reproduced from Takagi et.al., (2002)
250. 
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In solution or on the cell surface, the integrins are thought not to be fixed in a 
particular  conformation  but  are  in  equilibrium  between  them 
250.  Whether 
equilibrium favours the bent or extended conformation depends on the presence 
of  activating  intracellular  factors  and  concentration  of  extracellular  ligands.  
Activation  by  signals  within  the  cell,  known  as  inside out  signalling,  induces 
straightening and stabilises the extended form and binding of the extracellular 
ligand  also  stabilises the extended  form  enhancing  the  separation  of integrin 
tails, resulting in transmission of signals to the cytoplasm (outside in signalling) 
250.  
1.3.2.4  Integrins in hematopoiesis 
Interactions  of  haematopoietic  precursors  with  the  stromal  microenvironment 
are critical for controlling their migration, self renewal and differentiation, and 
many of these interactions are mediated by integrins 
251. Aside from retaining 
stem  and  progenitor  cells  in  the  bone  marrow,  engagement  of  adhesion 
receptors  on these cells also plays an important role in modulating growth and 
survival signals
252. Among the integrins, β1 and the β2 ‘leucocyte integrins’ have 
been  identified  on  haematopoietic  progenitor  cells.  The  b1  integrins, 
particularly  α4β1  (VLA 4)  and  α5β1  (VLA 5)  and  β2  integrin  LFA 1  have  been 
studied  extensively  for  their  roles  in  cell  adhesion  and  migration  in 
haematopoietic cells. Both β1 and β2 integrins are responsible for interactions 
between cells and ECM components such as fibronectin, collagen, laminin and 
thrombospondin or the cell surface expressed adhesion molecules VCAM 1 and 
ICAM 1 
158,253 257. A number of studies have assessed the expression of both the 
β1 and β2 integrins in CD34
+ HSCs as well as cells from different types of B cell 
leukaemias.  
In  vitro  experiments  demonstrated  that  adhesion  of  HSCs  and  HPCs 
(haematopoietic progenitor cells) to fibronectin is mediated by α4β1 and α5β1 
257,258. α4β1 also mediates binding to VCAM 1 expressed on bone marrow stromal 
cells
259.  Contact  between  normal  and  leukemic  hematopoetic  progenitors  and 
bone marrow adherent layers has also been shown to be maintained in vitro by a 
combination of both β1 and β2 integrins 
112,126,255,260.  In vivo experiments have 
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the  bone  marrow and  for  trafficking  of  stem cells  and,  as  mentioned  above, 
these  functions  are  modulated  by  the  cytokine  SDF 1 
113,261.  Moreover,  α4β1  
mediated  attachement  of  HPC  to  fibronectin  was  also  shown  to  promote 
proliferation 
262,263 and prevent apoptosis 
264.  
Gene knockout studies have also indicated important roles for both the α4 and 
β1 subunits during hematopoiesis. Studies by Hirsch, et. al., and Potocnick, et. 
al., have demonstrated that β1 integrin is an essential adhesion receptor for 
homing and retention of HSCs in the foetal and adult haematopoietic tissuses 
265 
267.  Similarly,  genetic  studies  from  α4  null  chimeric  mice  revealed  that    α4 
integrins are essential for normal development of lymphoid and myeloid lineages 
and homing of lymphocytes to Peyer’s patches 
268,269. 
1.3.2.5  αVβ5 integrin in B lymphopoiesis  
The importance of VnRs in general, and αVβ5 in particular, in lymphopoiesis is 
unclear.  The interaction between CD23 and integrin αVβ5 suggests a role for 
this  integrin  in  B  cell  development.  The  β5  and  β3  knock  out  mice  do  not 
indicate any perturbances in B cell development 
270; however, the murine and 
human system may have differential requirements for αvβ5 function as murine 
CD23  does  not  show  the  cytokine like  activities  shown  by  the  human 
counterpart.  Moreover,  the  functioning  of  the  integrins  may  be  different  in 
normal systems and in knock out mice.  
Previous results for the staining of αVβ5 integrins on B lymphocytes derived from 
peripheral  blood,  bone  marrow  and  ALL  patients  demonstrate  that  αVβ5  is 
expressed exclusively on normal or leukaemic B cell precursors (Borland, et. al., 
2008  manusript  submitted).  No  αVβ5  expression  was  seen  on  CD19
+  B 
lymphocytes in peripheral blood from normal individuals while normal human 
bone  marrow  showed  CD19
+  cells  that  were  αVβ5
+.  αVβ5  was  shown  to  be 
expressed universally on ALL derived samples whereas no αVβ5 expression was 
shown on B–CLL samples. No αVβ3 expression was seen on the precursor cells 
(normal or leukaemic) indicating that αVβ5 is the only CD23 receptor expressed 
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by ALL cells strongly suggests a significant role of αVβ5 expression and function 
during B cell development.   
1.4 Research aims 
The main aim of the research work presented in this thesis was to assess the role 
of αVβ5 integrin during B cell development by testing the hypothesis that the 
integrin αVβ5 delivers a pro survival signal at all stages of antigen independent B 
cell development in the bone marrow via the αVβ5 CD23 interaction.  
The specific aims were to: 
(a)  Define the expression of αVβ5 integrin (and related αV integrins) during 
specific B cell developmental stages. This was investigated by using cell 
lines representative of different B cell developmental stages and B cells 
from human bone marrow. Cell lines expressing αVβ5 integrin were used 
to address αVβ5 function by assessing proliferation response stimulated 
by the αVβ5 CD23 interaction.  
(b)  Explore the role of cytokines chemokines and growth factors important in 
B cell development in regulating αVβ5 function and expression. Cytokines 
(IL 7, IL 3, IL 4, IL 7), the chemokine SDF 1 and platelet derived growth 
factor (PDGF) were used to assess αVβ5 expression and αVβ5 mediated 
cell proliferation as well as signalling pathway activation in different pre 
B cell lines. 
(c)  Determine  whether  murine  B  cell  precursors  could  respond  to  soluble 
stimuli delivered by the αVβ5 integrin. This series of experiments would 
demonstrate  whether  the  data  from  the  human  studies  could  be 
transferred to a murine model that would allow an analysis of the in vivo 
biology of αVβ5 integrin in the haematopoietic system.  
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2  Materials and Methods  
2.1 Antibodies and Reagents 
All routine chemicals used were purchased from Sigma Chemicals Co. Poole, UK 
unless otherwise stated. Recombinant cytokines human (IL 7, IL 3, IL 11, IL 4) 
and  mouse  (IL 3)  were  purchased  from  R&D  Systems,  Abingdon,  UK.  Biotinyl 
murine  IgG1  and  recombinant  SDF 1β  were  purchased  from  Chemicon, 
Hampshire,  UK.  PI 3K  inhibitor  LY294002  and  platelet derived  growth  factor 
(PDGF β)  were  supplied  by  Cell  Signalling  Technologies,  Beverly,  MA,  USA. 
Streptavidin PE, streptavidin APC and annexinV FITC were from BD Bioscience, 
Oxford, UK. Anti actin and horseradish peroxidase (HRP) conjugated anti rabbit 
immunoglobulins, AMD3100, propidium iodide (PI), Trypan blue, NHS LC biotin, 
mouse IgG1 and IgG2a isotype control antibodies, IgG1 PE secondary antibody, 
DMEM (Dulbecco’s Modified Eagle’s Medium), L Glutamine 200mM and Penicillin 
Streptomycin  solution  were  purchased  from  Sigma  Chemicals  Co,  Poole,  UK. 
Isotype control antibody IgG1 FITC was purchased from DAKO, Cambridgeshire, 
UK. Normal Armenian hamster IgG1 FITC was purchased from Autogen Bioclear, 
Witshire, UK. Foetal Calf serum was supplied by TCS Cellworks, Buckingham, UK 
The MEK inhibitor U0126 and Access RT PCR System kit were purchased from 
Promega, Southampton, UK. Tritiated thymidine was obtained from Amersham 
International plc, Amersham, Buckinghamshire, UK. Recombinant 25 kDa
 sCD23, 
encompassing residues Met
151 Ser
231 with an N terminal
 His6 tag, was purchased 
from  R&D
  Systems,  Abingdon,  UK.  A  CD23 GST  fusion  protein
  preparation 
comprising residues Asp
48 Gly
248 of CD23 (referred
 to as sCD23
48 248) was obtained 
from Assay designs (Cambridge Bioscience, Cambridge, UK). Der CD23 was a kind 
gift from Dr. Jim McDonnell (University of Oxford, UK). RPMI 1640 medium and 
protein free  hybridoma  medium II  (PFHM)  were  from  GIBCO BRL  (Paisley, 
Scotland, UK). 
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The antibodies used and their suppliers were as follows:  
Target Antigen  Monoclonal or 
polyclonal 
Clone  Isotype  Supplier  Other 
Human CXCR4  Mouse 
Monoclonal 
12G5  IgG2a  R&D Systems, Abingdon, 
Oxford, UK 
Biotinylated 
Human αVβ5  Mouse 
Monoclonal 
P1F6  IgG1  Chemicon, Hampshire, UK   
Human αVβ5  Mouse 
Monoclonal 
15F11  IgG2a  Chemicon, Hampshire, UK   
Human αVβ3  Mouse 
Monoclonal 
23C6  IgG1  Chemicon, Hampshire, UK   
Human αVβ3  Mouse 
Monoclonal 
LM609  IgG1  Chemicon, Hampshire, UK   
Human αV  Mouse 
Monoclonal 
AMF7  IgG1  Chemicon, Hampshire, UK   
Human αV  Mouse 
Monoclonal 
LM142  IgG1  Chemicon, Hampshire, UK   
Human αVβ6  Mouse 
Monoclonal 
10D5  IgG2a  Chemicon, Hampshire, UK   
Human β1  Mouse 
Monoclonal 
47BR  IgG1  Autogen Bioclear, 
Buckinghamshire, UK 
 
Human αV  Rabbit  
polyclonal 
-  IgG1  Chemicon, Hampshire, UK   
Human β5  Rabbit  
polyclonal 
-  -  Chemicon, Hampshire, UK   
Human β3  Goat  
polyclonal 
-  -  Autogen Bioclear, 
Buckinghamshire, UK 
 
Human Phospho-
p44/42 MAP kinase 
(Thr202/Tyr204) 
Rabbit  
polyclonal 
-  -  Cell Signalling 
Technologies, Beverly, 
MA, USA 
 
Human p44/42 
MAP kinase 
Rabbit 
 polyclonal 
-  -  Cell Signalling 
Technologies, Beverly, 
MA, USA 
 
Human IgM ( -
chain) 
Mouse 
Monoclonal 
SA-DA4  IgG1  Southern Biotech, 
Birmingham, Alabama, 
USA 
 
Human κ-chain  Mouse 
Monoclonal 
L1C1  IgG1  Ancell Corporation, 
Bayport, USA 
FITC 
conjugated 
Mouse β3  Armenian 
hamster-
Monoclonal 
2C9.G2  IgG1  Autogen Bioclear, 
Buckinghamshire, UK 
 
Human IgM ( - 
chain) 
Goat 
 polyclonal 
-  -  Sigma Chemicals Co, 
Poole, UK 
FITC 
conjugated 
Human CD38  Mouse 
Monoclonal 
HI157  IgG1  Sigma Chemicals Co, 
Poole, UK 
 
Human CD10  Mouse 
Monoclonal 
SS2/36  IgG1  DAKO, Cambridgeshire, 
UK 
FITC 
conjugated 
Human CD9  Mouse 
Monoclonal 
P/33/2  IgG1  DAKO, Cambridgeshire, 
UK 
FITC 
conjugated 
Human CD19  Mouse 
Monoclonal 
HIB19  IgG1  BD Bioscience,  Oxford, 
UK 
PE 
 conjugated 
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The following antibodies were used for FACS sorting experiments and were all 
ordered from BD Biosciences, Oxford, UK. All antibodies were mouse monoclonal 
IgG1 isotype. 
Target 
Antigen 
Clone  Conjugated 
to  
Human CD19  SJ25C1  PerCP Cy5.5 
Human CD10  HI10A  PE 
Human CD38  HIT2  FITC 
Human CD5  UCHT2  FITC 
Human CD7  M T701  FITC 
 
2.2   Buffers 
The following buffers were routinely used: 
Buffers   Compostion 
PBS  13mM NaCl, 27mM KCl, 4.3mM Na2HPO4, 
1.4mM KH2PO4  (pH 7.2) 
TBS  50mM Tris HCl (pH 7.4), 150mM NaCl 
TAE  40mM Tris.acetate, 2mM Na2EDTA pH8.5 
Transfer buffer  25mM Tris, 192mM Glycine , 20% (v/v) 
methanol 
Stripping buffer  62.5 mM Tris HCl pH 6.7, 2% (w/v) SDS, 
100mM 2-mercaptoethanol 
Blocking buffer   TBST (1X TBS with 0.1% (v/v) Tween) , 5% 
(w/v) BSA 
       
2.3 Cell lines and cell culture  
The
 SMS SB cell line was derived from a female patient at the leukaemic phase 
of lymphoblastic lymphoma 
271; SMS SB cells were cultured in PFHM  with 2 mM 
fresh glutamine, penicillin (100U/ml) and streptomycin (100 g/ml) at 37°C in 5% 
(v/v) CO2 in air in a humidified atmosphere, at 2.5 5 x 10
5 cells/ml ("normal
 cell 
density"). RS4;11 
272, 697, Nalm6, Blin1, Raji, Ramos, Daudi, IB4 and SKW  B cell
 
lines were from laboratory liquid nitrogen stocks. Cell lines were maintained
 in 
RPMI  1640  medium  supplemented  with  10%  (v/v)  heat inactivated
  foetal  calf 
serum, 2 mM fresh glutamine, penicillin (100U/ml) and streptomycin (100 g/ml),
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pro B cell line was also from laboratory stocks  
273  and this cell line was cultured 
in RPMI 1640 medium with 50 M 2 ME (mercapto ethanol) and 1ng/ml murine IL 
3. The stromal cell line hMSC Tert 
274 was maintained in DMEM {10% (v/v) FCS, 2 
mM fresh glutamine, penicillin (100U/ml) and streptomycin (100 g/ml)} and the 
murine stromal cell line OP9 
275 ( a kind gift from Dr. Alison Michie, Glasgow, UK) 
was  maintained  in  DMEM  {20%  (v/v)  FCS,  2  mM  fresh  glutamine,  penicillin 
(100U/ml) and streptomycin (100 g/ml) and 50 M 2ME} at 37 °C in  5% (v/v) CO2 
in air in a humidified atmosphere. 
The different B cell lines used and the stages of B cell development represented 
by these cell lines is summarised in table 2.1. The translocations well known for 
each of these cell lines is indicated in the case of the cell lines where these 
translocations and fusion gene products have been well characterised. 
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Table 1 Summary of the different B cell lines used for cell culture experiments. 
Cell 
Line 
Established From  Type of Cell 
Line 
Known 
Translocations 
SMS-
SB 
Blood mononuclear 
leuckocytes of 16-year old girl 
in leukaemic phase of 
lymphoblastic lymphoma 
Human Pre-B 
ALL 
None 
RS4;11   Bone marrow of a 32-year old 
woman with ALL 
Human Pre-B 
ALL/ Mixed 
lineage 
leukaemia (MLL) 
t(4;11)(q21;q23) 
MLL/AF4 fusion 
gene 
697  Bone marrow of a 12-year old 
boy with ALL (cALL) 
Human Pre-B 
ALL 
t(1;19)(q23,p13) 
E2A-PBX fusion 
gene 
Nalm6  Peripheral blood of a 19-year 
old man with ALL 
Human Pre-B 
ALL 
t(5:12)(q33.2;p 
13.2) 
Blin-1  Bone marrow aspirate of  11-
year old boy with ALL 
Human Pre-B 
ALL 
- 
Raji  Left maxilla of 12-year old 
African boy with Burkitt 
lymphoma 
Human Burkitt 
lymphoma 
t(8;14) 
translocation 
associated with 
Burkitt lymphoma 
Ramos  Ascitic fluid of a 3-year old boy 
with American type Burkitt 
lymphoma 
Human Burkitt 
lymphoma 
t(8;14) 
translocation 
associated with 
Burkitt lymphoma 
Daudi  Left orbital biopsy of a 16-year 
old African boy 
Human Burkitt 
lymphoma 
t(8;14) 
translocation 
associated with 
Burkitt lymphoma 
SKW  EBV infection of B cells   EBV transformed 
lymphoblastoid 
cell line (LCL) 
- 
IB4  EBV infection of umbilical cord 
B cells  
EBV transformed 
lymphoblastoid 
cell line (LCL) 
- 
BAF03  IL-3 dependent murine pro B 
cell line from peripheral blood 
derived from BALB/c mouse 
Mouse pro B cells  - 
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2.4 Proliferation assays 
SMS SB cells were harvested and washed in PFHM then plated at a density of 
2500 cells/100 µl culture {low cell density
 (LCD)}, a seeding density at which the 
cells are prone to apoptose
 276, in 96 well microtitre assay plates in PFHM. All 
other  cell  lines  were  washed  extensively  in  PFHM
  prior  to  culture  at  5000 
cells/100 µl cultures. Cultures
 were propagated in the presence or absence of 
cytokines, monoclonal antibodies (MAbs)
 or peptides, at 37 °C for 72 h followed 
by addition of 0.3
 µCi/well (5.5*10
 6 mmol) tritiated thymidine ([
3H] TdR) for 18 h 
prior
  to  harvest;  incorporation  was  determined  by  liquid  scintillation
 
spectrometry. Briefly, the cells from 96 well plates were harvested onto glass 
fibre mats (Wallac Oy, Truku, Finland) using a TomTec MachIII Cell Harvestor 
(PerkinElmer, Massachusets, USA). The mats were air dried, sealed in sample 
bags  with  Betaplate  Scintillin  (Wallac  Oy,  Truku,  Finland)  and  counted  using 
Wallac  1450  MicroBeta  Liquid  Scintillation  and  Luminescence  Counter  (Wallac 
Oy, Truku, Finland). Tritiated thymidine incorporation was measured as count 
per minute (cpm). All determinations were made in triplicates and at least 3 
repeats were performed for each experiment. Cytokines were used at 0.5 32nM 
concentration ranges and sCD23 was employed at 0.4 6nM. In experiments using 
inhibitors,  cells  were  incubated  with  the  inhibitors  (5 10µM  U0126,  50µM 
LY294002,  50µM  AMD3100)  for  30  min  at  37˚C  prior  to  the  introduction  of 
stimuli.  
Bone  marrow  B  cell  proliferation  assays  were  performed  with  stromal  cell 
support using hMSC Tert (human telomerised stromal cell line) or OP9 (murine 
stromal cell line) cells. Stromal cells were grown until confluent and irradiated 
in solution (30 Gy [3000rad]) using a cobalt irradiation source and plated at a 
density of 1.5 X10
4  cells/well at least 3 days before the addition of B cells for 
hMSC Tert  and  2  days  before  the  addition  of  B  cells  for  OP9  cells  in  their 
appropriate medium. Pre B cells, FACS sorted from human mononuclear bone 
marrow cells using anti CD19 and anti κ MAbs, were washed and plated on 96 
well plate containing hMSC Tert stromal cells at a density of 2500 3000 cells/ 
well  with  appropriate  antibody,  CD23  or  peptide treatment  in RPMI 1640  (2% 
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washed  extensively  with  RPMI 1640  immediately  before  plating  the  B  cells. 
Plates  were  incubated  at  37  °C  for  72  h  and  tritiated  thymidine  ([
3H] TdR) 
analysis performed as mentioned above.  
Murine bone marrow cells (a kind gift from Dr. Adam Lacy Hulbert, Boston, USA) 
were harvested from bone marrow of wild type or αV conditional knockout mice 
by flushing the bones in PBS and the cells were then washed with red cell lysis 
buffer (0.83% (w/v) NH4Cl in 50mM Tris HCl pH 7.6). To purify CD19
+ B cells, a 
single cell suspension of bone marrow cells were resuspended in MACS buffer 
(PBS pH 7.2, 0.5% (w/v) BSA and 2mM EDTA) (90 l buffer per 10
7 cells), with 
mouse CD19 micro beads (10 l/10
7 cells) (Miltenyi Biotech, Surrey UK) for 15 min 
at 4 °C. After incubation cells were washed and resuspended in MACS buffer. 
The cells were then positively selected using magnetic activated cell separation 
(MACS) LS columns according to manufacturer’s insctructions (Miltenyi Biotech, 
Surrey  UK).  Purified  CD19
+  cells  were  plated  on  to  OP9  cells  containing 
appropriate  treatments  at  2500 3000  cells/well  in  RPMI 1640  (10%  (v/v)  FCS, 
50 M  2ME,  1ng/ml  IL 7).  Medium  was  removed  and  OP9  cells  were  washed 
extensively with RPMI 1640 immediately before plating the B cells. Plates were 
incubated  at  37  °C  for  72  h  and  tritiated  thymidine  ([
3H] TdR)  analysis 
performed as mentioned above.  
2.5 Peptide Biochemistry  
We have previously shown that CD23 derived peptides containing the RKC motif 
recognised by αVβ5 integrin are biologically active. The peptides were used at 
0.5 3.33µM  and  are  numbered  according  to  their  position  in  the  original 
screening library 
232. The sequences of the specific peptides used in this study 
are  #9,  KWINFQRKC;  #10,  SGSGINFQRKCYY;  #12,  SGSGRKCYYFGKG;  #11, 
FQRKCYYFG;  LP  long  peptide,  KWINFQRKCYYFGKG;  Peptides  #8,  PEKWINFQR; 
#41, SGSGGEFIWVDGS;  #34, SGSGHTGSWIGLR  #17, SGSGKQWVHARYA; and #58 
SGSGGSGRWNDAF; which lack the RKC motif and do not bind to αVβ5 were used 
as negative control peptides. Peptides were synthesised with a common SGSG 
linker and N terminal biotin tail or as unlabelled peptides lacking the linker and 
biotin  tail  (Mimotopes,  Clayton,  Victoria,  Australia).  For  binding  experiments Mridu Acharya,2008     Chapter 2, 53 
using FACS, biotinylated peptides were used and for proliferation experiments 
unlabelled peptides were used.  
2.6 Flow cytometry 
Cells were harvested and washed twice with ice cold PBS and resuspended at 
5´10
6 cells/ml. 100µl of cell suspension was stained with either biotinylated,
 
unlabeled primary MAb or biotinylated CD23 derived peptides (10µg/ml) for 30 
60 min at 4 °C; unlabeled primary antibody
 was visualized using a secondary PE 
conjugated anti mouse
 IgG or, in the case of biotinylated antibody or peptides, 
using streptavidin PE. Cells were incubated in secondary antibody for 30 60 min 
at  4  °C  and  washed  twice  with  ice cold  PBS  before  anlaysis.  For  assay  of 
apoptosis, approximately 1 X 10
6 cells were washed twice with ice cold PBS and 
stained with 100µl labelling buffer (10mM HEPES NaOH pH7.4, 150mM NaCl, 5mM 
CaCl2, 5 g/ml propidium iodide and 5µl annexinV FITC) and incubated at room 
temperature for 20 min. The labelling buffer was aspirated and the cells were 
resuspended  in  400µl  binding  buffer  (10mM  HEPES NaOH  pH7.4,150mM  NaCl, 
5mM CaCl2). Cells were analyzed on a FACScan flow cytometer, using
 CellQuest 
software.
  
For  bone  marrow  analysis  and  cell  sorting  frozen  human  monounclear  bone 
marrow cells (Lonza Walkersville, Inc, Walkersville, MD, USA) were thawed in 
RPMI  1640 (10% (v/v) FCS and 20U/ml DNase I) and washed twice with ice cold 
PBS and processed as mentioned above. The cells were processed under sterile 
conditions. All antibodies were monoclonal IgG1 isotype except   FITC, which 
was a goat polyclonal antibody. Bone marrow mononuclear cells were counted 
and resuspended in PBS and stained with appropriate antibody mixtures and all 
cells  were  analysed  and  sorted  on  BD  FACSAria  cell  sorter  (BD  Bioscience, 
Oxford, UK). Cells were sorted on the basis of CD19
+/κ
+or CD19
+/κ
  and isotype 
control antibodies and control beads (BD Bioscience, Oxford,  UK) were used to 
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2.7 RNA extraction and reverse transcriptase polymerase 
chain reaction (RT-PCR)  
Total RNA was isolated using the Trizol reagent (GIBCO BRL, Paisley, Scotland) 
according to manufacturer’s instructions. Briefly, 10
6 10
7 cells were harvested 
and  resuspended  in  1ml  Trizol/10
7  cells  and  RNA  solubilised  by  passing  the 
lysates through a pipette a few times. Chloroform was added (0.2ml/1ml Trizol) 
and  the  sample  was  shaken  vigorously  for  15  seconds,  left  on  ice  for  5  min 
followed  by  centrifugation  at  12000  x  g  at  4  ºC  for  15  min.  The  colourless 
aqueous phase containing the RNA was removed from the red phenol chloroform 
phase and RNA was precipitated by incubating the sample in equal volume of 
ice cold isopropanol for 10 min followed by centrifugation at 12000 x g at 4 ºC 
for  15  min.  RNA  was  then  washed  with  70%  (v/v)  ethanol,  air dried  and 
resuspended  in  50 100 l  of  RNAse free  dH20  (Promega,  Southampton,  UK). 
Sample  concentrations  and  purity  were  determined  by  spectrophotometric 
readings of a 1/500 dilution of the sample and using the absorbance at 260nm 
and 280nm wavelengths.  
Total RNA extracted was used for RT PCR reactions to amplify transcripts using 
the  Access  RT PCR  system  kit  (Promega,  Southampton,  UK)  according  to  the 
manufactuer’s instructions. Briefly 1 g RNA was added to a mixture of AMV Tfl 
reaction buffer, dNTP mix (10mM each dNTP), 1 M each of forward and reverse 
primer, 25mM MgSO4,  AMV reverse transcriptase (5 units), Tfl DNA polymerase 
(5 units) and RNAse free water to make the volume up to 50 l.   
The primers used were as follows (MWG Biotech, London UK):  
Target 
transcript 
Forward Primer  Reverse Primer 
GAPDH  5’-TCCACCACCCTGTTGCTG-3’  5’-ACCACAGTCCATGCCATCAC-3’ 
Integrin αV  5’-CGGTTGCCGGGCAAGGTGAG-3’  5’-CAGGCATGGGCGCTGGCTGA-3’ 
Integrin β5  5’-GGCAGTGCCAATGCACGGAG-3’  5’-GGCCCTGGATCGCTCGCTCT-3’ 
Integrin β3  5’-GACTGCCTGTGTGACTCCGAC-3’  5’-TGAGCAGGGCGGCAAGGCCA-3’ 
Integrin β6  5’-TGGAGTGCTCTGCAGCGGGC-3’  5’-GGTTCCCGTTTGCCACTTGGC-3’ 
Integrin β8  5’-TGCACCGATCCCAGGAGCATC-3’  5’-CTCACGTCGGTAGGTGACTGC-3’ 
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The following programme was used on the thermal cycler  
·  For reverse transcription: 
     45 minutes at 45ºC for 1 cycle and  
·  For AMV RT inactivation and RNA/cDNA primer denaturation  
     2 minutes at 94ºC for 1 cycle. 
·  For PCR amplification: 
      30 seconds at 94ºC, 1 minute at 60 ºC and 2 minutes at 68ºC for 40 cycles 
      7 minutes at 68ºC for 1 cycle 
      Storage at 4ºC  
 
For RT PCR with the β5 primers in some cell lines, the annealing temperature 
was changed to 62 ºC for 1 minute to obtain a single specific band. PCR products 
were  analysed  by  agarose  gel  electrophoresis  using  2%  (w/v)  agarose  gel  in 
1XTAE buffer. 
 
2.8 Western blot analysis 
Approximately  3  X  10
7  cells  in  PFHM  were  stimulated  with  either  SDF 1 
(250ng/ml)  sCD23  (160ng/ml),  Long  peptide  (1µg/ml),  Peptide  #9  (5µg/ml), 
Peptide 8 (5µg/ml), 15F11 MAb (5µg/ml) alone or in combination for specified 
time  periods  at  37  ºC.  Stimulation  was  stopped  by  addition  of  RIPA  buffer 
without  detergents  (50mM  Tris HCl  pH7.4,  150mM  NaCl,  1mM  EGTA,  1mM 
Na3VO4).  Cell pellets were lysed in RIPA buffer with protease inhibitors (RIPA 
buffer  as  above  plus  1%  (v/v)  NP40,  1mM  Na  deoxycholate  and  protease 
inhibitors 1mM PMSF and 2mg/ml Leupeptin) and clarified by centrifugation at 
13,000 x g for 15 min. Protein concentrations were measured using the Bradford 
reagent (BioRad Laboratories Ltd, Hampstead, UK) with BSA as a standard. Equal 
amounts of protein (30 40µg) were loaded per lane and run on a  4 12% NuPAGE 
Novex Bis Tris gradient gels according to manufacturere’s instruction (based on 
standard SDS PAGE method as described by Laemmli, 1970) 
277 using the MOPS 
buffer supplied (Invitrogen, Paisely, UK). Proteins on the gel were transferred 
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and  the  membrane  was  blocked  for  1  h  in  blocking  buffer.    Phosphorylated 
protein was detected using specific primary antibodies used at 1/1000 dilution 
with overnight incubation; Blots were washed extensively in TBST and incubated 
for  1  h  in  secondary  antibodies  (1/10000  dilution)  conjugated  to  HRP.  All 
antibody  dilutions  were  made  in  TBST  with  1%  (w/v)  BSA.  Enhanced 
chemiluminescence  (ECL)  (Pierce,  Rockford,  USA)  was  used  according  to 
manufacturer’s instruction to develop the blots and blots were exposed to Kodak 
MXB  film  for  appropriate  time  depending  on  the  siganl  to  detect  antibody 
binding.  The  same  membrane  was  stripped  using  stripping  buffer  and  total 
protein was detected using specific primary and secondary antibodies as with 
the phoshphorylated proteins. Bands were quantified by densitometry using the 
ImageJ software. 
2.9 Biotinylation and immunoprecipitation of cell surface 
integrin β5  
10
8  cells  were  harvested  and  washed  extensively  in  PBS.  The  cells  were 
resuspended at 10
7 cells/ml in 5mM sulfosuccinimidyl 6 (biotinamido) hexanoate 
(NHS LC Biotin)/PBS (Sigma Chemicals Co, Poole, UK) and incubated on a roller 
for 30 60 min at room temperature in the dark. The cell pellet was resuspended 
and washed in 50mM Tris HCl pH 7.4/150mM NaCl and then resuspended in 5ml 
RIPA buffer with protease inhibitors (see section 2.7) for 30 min on ice. The cell 
extract was pelleted by centrifugation 12000 x g for 15 min. 1ml of the cell 
lysate  was  added  to 100 l  of  packed  streptavidin  beads  (in  RIPA  buffer)  and 
incubated at room temperature for 1 h with gentle agitation. The beads were 
pelleted  and  washed  with  RIPA  buffer  and  resuspended  in  25 l  5X  SDS PAGE 
loading dye (0.225M Tris HCl pH 6.8, 50% (v/v) Glycerol, 5% (w/v) SDS, 0.05% 
(w/v) Bromophenol blue), boiled for 5 min followed by centrifugation at 12000 x 
g for 1 3 min and the supernatant was loaded on 4 12% NuPAGE Novex Bis Tris 
gels  and  transferred  onto  nitrocellulose  membrane.  Membranes  were  probed 
separately using primary anti αv, β5 and β3 antibodies to detect biotinylated 
integrins.  Secondary  antibodies  conjugated  to  HRP  and  enhanced 
chemiluminescence were used to visualise the appropriate bands as mentioned 
in section 2.7. Mridu Acharya,2008     Chapter 2, 57 
2.10 Staistical Analysis 
Results are shown as mean plus or minus standard deviation (SD) or standard 
error  of  the  mean  (SEM)  of  triplicate  results.  Statistical  comparision  was 
performed using the Students paired t test. The minimal level of significance 
was  P<0.05.  Each  result  is  representative  of  at  least  3  experiments  unless 
otherwise stated.   
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3  αV Integrin Expression and Function in Human 
B Lymphocytes 
3.1  Introduction 
The proliferation and differentiation of B lymphocytes is regulated by numerous 
growth factors and adhesive interactions. During development, B cells undergo 
stepwise  maturation  through  different  defined  stages.  Each  stage  of  this 
developmental process is regulated by stage specific signals that modulate B cell 
growth/survival and differentiation. HSCs in the bone marrow committed to the 
B  lineage  go  through  the  pro B,  pre B  and  immature  B  cell  stages  of 
development in the bone marrow. Perturbation of this developmental process in 
the bone marrow leads to malignancies such as ALL. Leukaemias represent a 
heterogenous  group  of  disorders  and  ALL  is  a  malignant  disease  of  the  bone 
marrow  in  which  proliferating  early  lymphoid  progenitors  replace  the  normal 
haematopoietic  population.  It  is  a  common  malignancy  in  children  and  
approximately  80%  of  childhood  ALL  constitutes  pre B  ALL.  In  pre B  ALL  the 
malignant cells are arrested at an early stage of development 
278. 
Previous  work  in  the  laboratory  demonstrated  that  the  αVβ5  integrin  is  a 
receptor  for  the  sCD23  molecule  and  the  αVβ5 CD23  interaction  sustains 
proliferation of pre B cell line SMS SB 
232. Furthermore it was also shown that  
αVβ5 is expressed significantly in B cells from patients with ALL (Borland, et. 
al.,  2008  manuscript  submitted).  This  led  to  the  hypothesis  that  the  αVβ5 
integrin expression and function has important roles during B cell development 
and malignancies that arise at this stage. Therefore the expression of different 
αV  integrins  and  function  of  particulary  αVβ5  integrin  was  investigated  in 
different pre B cell lines and some bone marrow B cell precursors. 
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3.2 Results 
3.2.1 Phenotypic characterisation of different pre-B cell lines and 
mature B cell lines  
During  development,  B  cells  undergo  stepwise  maturation  through  defined 
stages. Various cell surface markers have been identified that allow the precise 
identification of B cells at specific stages in the developmental process. B cell 
lines established from patients with different types of leukaemias are arrested 
at a certain stage in the developmental process and therefore provide a good 
model to study each developmental stage. From a range of cell lines that were 
available in the laboratory, cell lines were chosen as representative of major B 
cell developmental stages. Cell lines were classified as early pre B, late pre B, 
immature,  transitional  or  mature  B  depending  on  cell  surface  marker 
expression.  
CD19 expression was used to confirm all the cell lines as B lineage cells and 
surface expression of the µ chain was used to identify the cell lines as B cells in 
Figure 3.2. Surface expression of CD9 was seen in all the pre B cell lines and the 
pre B/immature B cell line 1E8 while the transitional and more mature B cell 
lines did not express this molecule (Figure 3.1 and 3.2). The CD38 marker was 
expressed in all the cell lines from pre B to through to transitional B cell stages 
although the SMS SB cell line showed lower levels of CD38 expression than other 
pre B  cell  lines  (Figure  3.1).  The  mature  cell  lines  SKW  and  IB4  were  CD38 
negative (Figure 3.2).  
SMS SB and RS4;11 cells were both negative for CD10 (CALLA antigen) (Figure 
3.1) which is a marker for pre B cells 
279,280. SMS SB cells expressed low levels of 
surface immunoglobulin heavy chain (µ) and RS4;11 cells also were low/negative 
for surface expression of µ chain (Figure 3.1). Therefore, these cell lines were 
designated as early pre B cells. The 697, Blin1 and Nalm6 cell lines were positive 
for CD10, expressed high levels of surface µ chains and were designated as late 
pre B  cells.  The  1E8 cell  line  was derived  originally  from Blin1  cells 
281  after 
spontaneous  re arrangement  of  the  kappa  (κ)  light  chain  genes,  leading  to Mridu Acharya,2008     Chapter 3, 60 
differentiation of surface κ negative pre B cells into surface kappa positive B 
cells. This is depicted by down regulation of CD10 expression and the expression 
of immunoglobulin κ light chain by 1E8 cells and these cells were termed as 
immature B cells (Figure 3.1). The cell lines Daudi and Ramos were considered 
to be transitional B cell lines because they were CD10
+ and CD38
+ but had lost 
CD9 expression, which was characteristic of pre B cell lines (Figure 3.2).  Both of 
these three cell lines express immunoglobulin light chains κ (Daudi) or λ (Ramos) 
(Figure  3.2).  These  cell  lines  were,  however,  CD21
   and  IgD
 .  CD21  and  IgD 
expression is a characteristic of transitional and mature B cells. CD21 expression 
was not noted even in the mature B cell lines SKW and IB4. SKW cells were κ 
positive but the IB4 cells were not clearly positive for either a clear kappa or 
lambda light chains (Figure 3.2). This could be because they were more mature 
immunoglobulin secreting cell types. Both these cell lines were CD38
  and lacked 
CD9 or CD10 expression (Figure 3.2) and therefore were designated as mature B 
cells. 
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Figure   3.1 Phenotypic characterisation of different human pre-B cell lines. 
 
Pre-B cell lines were categorised into different stages of B cell development (early pre-B or late 
pre-B) based on expression of surface markers CD19, CD9,  , CD10 and CD38 using monoclonal 
antibodies (MAbs). FACS staining for the each MAb is shown as grey shaded area and the isotype 
control for the specific antibody is shown as a black line. Data are representative of at least three 
independent staining procedures. 
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Figure   3.2 Phenotypic characterisation of different human immature and mature B cell lines. 
 
B cell lines were categorised into different stages of B cell development (immature, transitional or 
mature B cells) based on expression of surface markers CD9,  , CD10, CD38 and κ or λ light chain 
expression, using monoclonal antibodies (MAbs). FACS staining for the each MAb is shown as 
grey shaded area and the isotype control for the specific antibody is shown as a black line. Data 
are representative of at least three independent staining procedures. 
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3.2.2  αV integrin expression in pre-B cell lines and mature B cell 
lines  
αV integrin expression was assessed in cell lines representing different stages of 
B cell development. The αV subunit is known to pair with 5 different β subunits 
(β1, β3, β5, β6, β8) and monoclonal antibodies are available for all of these 
heterodimers except for αVβ8. P1F6 and 15F11 are two monoclonal antibodies 
which bind the αVβ5 heterodimer at different epitopes 
282, so both antibodies 
were  used  to  assess  αVβ5  expression.  The  23C6  antibody  was  used  to  assess 
surface  expression  of  the  αVβ3  heterodimer  and  the  10D5  antibody  detected 
αVβ6  expression.  The  anti β1  antibody  (4B7R)  was  used  to  assess  β1  integrin 
expression. However, since the β1 subunit can pair with other α subunits, such 
as α4 and α5, staining with 4B7R could not be considered to demonstrate αVβ1 
expression definitively. 
Figure 3.3 clearly shows that all the pre B cell lines from RS4;11 through to Blin1 
show  high  surface  expression  of  αVβ5  as  shown  by  P1F6  antibody  staining. 
However, the pattern of staining using 15F11 antibody was very different to the 
P1F6  staining.  In  general,  P1F6  staining  was  much  higher  than  the  15F11 
staining. Although 15F11 antibody showed staining for αVβ5 in all the pre B cell 
lines, the cell lines RS4;11, SMS SBs and 697 cell lines had higher 15F11 staining 
when compared with Nalm6 and Blin1 cell lines. In fact, the cell line 697 had the 
highest expression of the 15F11 epitope.  
αVβ3  integrin  expression  was  more  difficult  to  define  accurately  as  there 
seemed to be very low level expression in most of the cell lines and this made it 
difficult to conclude whether the cell lines were negative or positive for this 
integrin  (Figure  3.3).  The  three  cell  lines  staining  well  with  15F11  antibody 
showed very low or negative staining with the 23C6 antibody, while Blin1 and 
Nalm6 cell lines had clearly started to express αVβ3. (Figure 3.3). All the pre B 
cell lines were clearly negative for αVβ6 integrin and positive for β1 integrin 
expression.  
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Figure  3.3  also  depicts  an  obvious  decrease  in  staining  for  αVβ5  using  P1F6 
antibody in the immature B 1E8 cell line when compared to the pre B cell line 
Blin1. A similar decrease is seen with the 15F11 antibody although this is less 
pronounced  than  P1F6  staining.  αVβ5  integrin  expression  is  significantly 
decreased in the transitional and more mature B cell lines as shown by P1F6 
staining  (Figure  3.4).  The  transitional  cell  line  Daudi  shows  low  but  positive 
staining for αVβ5, as does the mature B cell line SKW, while the cell lines Ramos 
and IB4 are clearly negative for αVβ5. Among the transitional cell lines, Daudi is 
slightly positive and Ramos is either negative or very slightly positive for αVβ3 
expression, while the more mature cell lines SKW and IB4 very clearly show high 
surface expression of αVβ3. Interestingly, the Ramos cell line seemed to express 
low levels of αVβ6 which could not be detected on the other cell lines (Figure 
3.4). Staining for the β1 integrin was significantly reduced in the transitional as 
well as the mature B cell lines (Figure 3.4).  
 
 
 
 
 
 
 
 
 
 
 Mridu Acharya,2008     Chapter 3, 65 
 
 
 
 
RS4;11
SMS-SB
697
Nalm6
Blin1
1E8
P1F6 15F11 23C6 4B7R 10D5
RS4;11
SMS-SB
697
Nalm6
Blin1
1E8
P1F6 15F11 23C6 4B7R 10D5
 
Figure   3.3 Expression of different αV integrins on human pre-B cell lines. 
 
Surface expression of αV integrins was assessed by FACS staining using monoclonal antibodies 
P1F6 and 15F11 for αVβ5, 23C6 for αVβ3, 10D5 for αVβ6 and 4B7R for the β1 subunit, in the 
different pre-B or immature B cell lines. Histograms illustrate staining for the integrin antibody as 
grey shaded area and staining for the specific isotype control antibody as a black line. Staining 
data  was  not  available  for  β1  staining  of  Nalm6  cells  and  β6  staining  of  Blin1  cells.  Data  are 
representative of at least three independent staining experiments. 
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Figure   3.4 Expression of different αV integrins on human mature B cell lines. 
 
Surface expression of αV integrins was assessed by FACS staining using monoclonal antibodies 
P1F6 for αVβ5, 23C6 for αVβ3, 10D5 for αVβ6 and 4B7R for the β1 subunit, in the different mature 
B cell lines. Histograms illustrate staining for the integrin antibody as grey shaded area and staining 
for the specific isotype control antibody as a black line. Data are representative of at least three 
independent staining experiments. 
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3.2.3 RT-PCR analysis of integrin transcripts in different B lineage 
cell lines 
The low levels of αVβ5 and αVβ3 integrin expression found in certain cell lines 
(Figure  3.5)  were  further investigated  using  primer  pairs  specific  for  integrin 
subunits by RT PCR. Figure 3.5 shows an RT PCR product of 460 bp for the β5 
integrin  subunit  in  SMS SB,  697,  RS4;11,  Daudi,  SKW  and  IB4  cells  and  the 
expression was compared to the PCR product from the β5 plasmid. Daudi cells 
showed a very faint band at 460bp but there was a more prominent larger band 
of  a  higher  size.  Only  the  Ramos  cell  line  showed  no  expression  for  the  β5 
subunit and the IB4 cell line, which showed no cell surface expression of αVβ5 by 
FACS, had transcripts for β5 subunit. The pre B cell lines SMS SB, 697 and RS4;11 
showed no transcript for the β3 subunit while the pre B cell line Blin1 possesed 
transcripts  of  504  bp  (just  above  500bp  marker)  for  β3  subunit  (Figure  3.5); 
interestingly, there was no transcript for the β3 subunit detected in the 1E8 cell 
line although we observed staining for αVβ3 by FACS. Nevertheless there is a 
product of higher size in the lane for 1E8. In the transitional cell line category, 
Daudi cells expressed transcript for the β3 subunit but Ramos cells did not; both 
the  mature  B  cell  lines  SKW  and  IB4  clearly  showed  transcripts  for  the  β3 
subunits and this correlated with the results from FACS analysis. The product for 
β6 subunit was not of the correct size so no conclusions could be made from 
them (data not shown). Using the β8 primers a faint band for the correct size of 
transcript was observed in all the cell lines however, very prominent band of 400 
bp was seen in both the mature B cell lines SKW and IB4 (Figure  3.5). 
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Figure    3.5 RT-PCR analysis for αV  integrins β  subunit expression in the different  B  cell 
lines. 
 
Total RNA isolated from the different B cell lines was used as template for the RT-PCR reaction 
using primer pairs specific for each β subunit and PCR products were separated by agarose gel 
electrophoresis. For the β5 subunit a PCR product was amplified from β5 plasmid for comparison 
of the size. All the cell lines were previously shown to express the αV integrin subunit (data not 
shown). The size of each subunit was compared with a DNA ladder. * Indicates the position of the 
appropriate sized bands. RT-PCR analysis with GAPDH primers were performed with each cell line 
as a positive control.  Data represent three independent RT-PCR results. 
 
 
 
 
 
* 
* 
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Table 2 Summarises the expression of different cell surface markers (from FACS analysis 
data)  for  characterisation  of  different  cell  lines  together  with  pattern  of  expression  of 
individual αV integrins. 
 
  CD9  CD10  CD38  αvβ5  αvβ3  αvβ6  β1   -chain   κ or λ 
SMS-
SBs 
+++  -  +  +++  -  -  +++  +  - 
RS4;11  +++  -  ++  +++  -/+  -  +++  -  - 
697  ++  +  ++  +++  -/+  -  +++  +  - 
Nalm-6  ++  +++  +++  +++  ++  -  NA  +  - 
Blin-1  ++  +++  +++  +++  ++  NA  +++  +  - 
1E8  ++  -  ++  ++  +  +  ++  ++  + 
Ramos  -  ++  +++  -  -  -  +++  ++  ++ 
Daudi  -  ++  +++  +  -  -  +++    ++ 
SKW  -  -  -  +  +++  -  +  ++  ++ 
IB4  -  -  -  -/+  +++  -  +  ++  ? 
 
**NA  Not available 
 
 
 
 
 
 
 
 
 
 Mridu Acharya,2008     Chapter 3, 70 
 
3.2.4 αV Integrin function in human B cell Lines  
Previous data have demonstrated that the integrin αVβ5 is a receptor for sCD23 
on precursor B cells 
232. αVβ5 binds an RKC motif on CD23 and this interaction 
was  shown  to  sustain  proliferation  of  the  SMS SB  cell  line.  This  effect  on 
proliferation was mimicked by CD23 derived peptides containing the RKC motif 
and by specific monoclonal antibodies (MAbs) known to bind to αVβ5. The AMF7 
MAb, which binds the αV subunit, and the 15F11 MAb, which binds the assembled 
aVβ5 heterodimer, sustained proliferation in manner similar to sCD23; however, 
the P1F6 MAb that also binds to the αVβ5 heterodimer had no effect on cell 
proliferation. Therefore, sCD23, CD23 derived peptide (long peptide) and MAbs 
AMF7 and 15F11 were used to assess αVβ5 mediated proliferation across the B 
cell lines representing different stages of B cell development. 
3.2.4.1  Proliferation in response to sCD23 
Figure  3.6  shows  that  SMS SB  cells  proliferate  in  response  to  a  range  of 
recombinant sCD23 types. The optimal concentration for a proliferative response 
varies  according  to  the  type  of  sCD23  used  and  other  constituents  in  the 
medium.  Previous  work  in  the  laboratory  showed  that  gel  filtration purified 
recombinant  sCD23  induces  a  bell shaped dose response curve with  maximum 
growth stimulation seen on addition of approximately 200 500 ng/ml (White, LJ, 
PhD thesis, University of Glasgow, 1995), therefore the concentration range of 
20 250 ng/ml was chosen to assess sCD23 driven SMS SB cell proliferation. The 
two commercially available sCD23 (R&D systems) and sCD23
48 248 (Assays Designs) 
showed an almost identical dose dependent increase in tritiated thymidine ([
3H] 
TdR) uptake when added to SMS SB cells (Figure 3.3A). However the derCD23 
(from D. J. McDonnell, University of Oxford) showed optimal increase in cell 
proliferation at 20ng/ml and no effect at 250 or 120ng/ml.  
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Furthermore, as  indicated  in  Materials  and  Methods,  (Chapter  2)  protein free 
medium was always used to assess SMS SB cell proliferation but some of the pre 
B cell lines used did not survive in protein free medium alone and therefore, 1% 
FCS  was  added  to  the  medium.  When  sCD23 induced  cell  proliferation  was 
assessed  in  SMS SB  cells  with  addition  of  1%  FCS  to  the  medium,  an  optimal 
increase in cell proliferation was seen at 2ng/ml derCD23. Proliferation induced 
by derCD23 in the presence of 1% FCS was of lesser degree than proliferation 
induced in PFHM (SI of 1.6 vs. SI of 3), (Stimulation index, SI was calculated as 
mean of cpm in presence of treatment/mean cpm untreated cells). Constituents 
of serum such as vitronectin and growth factors such as PDGF will obviously have 
some regulatory effects on this proliferative response therefore the proliferation 
response may differ in the two cases. 
SMS SB cell proliferation was demonstrated with a commercially available CD23, 
sCD23 
48 248. This is a truncated form of the full length sCD23 and lacks the IgE 
and  CD21  binding  sites  present  on  the  full  length  CD23.  A  structural 
representation of the IgE binding site (in red) and CD21 binding site (in blue) is 
depicted  in  Figure  3.3B.  The  RKC  motif  bound  by  the  αVβ5  integrin  is 
represented  in  yellow  and  is  present  on  the  sCD23
48 248.  The  proliferative 
response induced by this sCD23 establishes that the sCD23 induced proliferation 
of human B cell precursors is independent of the presence of the IgE binding site 
or the CD21 binding site. 
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Figure   3.6 SMS-SB cell proliferation in response to a range of recombinant human sCD23. 
 
Low cell density (LCD) cultures of SMS-SB cells were propagated with the indicated concentrations 
of different types of sCD23. Proliferation was assessed after 72 h by 
3[H]-TdR incorporation. (A) 
Comparison of proliferation of SMS-SB cells in response to sCD23 from R&D systems, derCD23  
(PFHM) or derCD23 (in PFHM with 1%FCS). (B) Another recombinant sCD23 from Assay Designs 
termed sCD23 
48-248 was also used to assess proliferation of SMS-SB cells. The IgE binding site (in 
blue) and CD21 binding site (in red) are illustrated on the structural representation of sCD23. The 
RKC motif is depicted in yellow. Bars represent the standard deviation of triplicate determinations, 
with *p<0.05 or **p<0.005 indicating increase in proliferation in comparison to untreated cells. Data 
are representative of at least three independent experiments. 
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Figure 3.7 shows that the three pre B cell lines SMS SB, 697 and RS4;11 showed a 
robust dose dependent proliferation in response to sCD23 treatment. Both the 
cell lines SMS SB (SI at 250ng/ml and 120ng/ml of 3.2 and 2.1, respectively) and 
697 (SI at 250ng/ml and 120ng/ml of 3.5 and  3.5, respectively) show an almost 
identical  response  while  the  concentration  range  for  the  optimal  response  is 
slightly  different  for  RS4;11  cells  (SI  at  20ng/ml  and  2ng/ml  of  2.5  and  3.2, 
respectively) which show a strong response at 2ng 20ng/ml and no response at 
250ng/ml. However, the sCD23 used in the case of RS4;11 was derCD23 and that 
could be the reason for the difference in the effective concentration range. This 
is  verified  by  the  different  concentration  range  at  which  the  697  cells  show 
optimal effect in cell proliferation in response to derCD23 (Figure 3.7).  
The Blin1 cell line showed a slight proliferative response to sCD23 treatment at 
2ng/ml and 20 ng/ml  (SI of 1.5 and 1.4, respectively). Interestingly, the cell 
line 1E8 which is more mature than Blin1 also showed a slight increase in cell 
proliferation at 2ng/ml (SI of 1.9) (Figure 3.7). None of the transitional B cell 
lines (Daudi, Raji, Ramos) or the mature B cell lines (SKW and IB4) show a robust 
increase in cell proliferation with derCD23 when compared to early pre B cell 
lines (Figure 3.8). However, with the Daudi and SKW cell lines there is a slight 
but significant increase in cell proliferation observed at 2 20ng/ml (SI of 1.9 for 
Daudi and SI of 1.6 for SKW). Both of these cell lines express small amounts of 
αVβ5 integrin (Figure 3.4) and the effect on cell proliferation could be mediated 
via this integrin. The cell lines Raji, Ramos and IB4 clearly do not show any 
response in cell proliferation with any of the concentrations of derCD23 used and 
these  were  the  cell  lines  that  did  not  express  αVβ5  on  cell  surface  (αVβ5 
expression  data  not  shown  for  Raji  cells  which  were  αVβ5 negative  and 
expression of  other cell surface were identical to Daudi and Ramos; therefore 
this cell line was also considered to be a transitional B cell line).  
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Figure   3.7 Proliferation of different pre-B cell lines in response to human sCD23. 
 
LCD  cultures  of  SMS-SB  cells  in  PFHM  or  other  cell  lines  in  PFHM  with  1%(v/v)  FCS  were 
propagated with indicated concentration of sCD23 (R&D sCD23 for SMS-SB cells, derCD23 for 
RS4;11, Blin1 and 1E8 cells and either RND or derCD23 for 697 cells). Proliferation was assessed 
after  72  h  by 
3[H]-TdR  incorporation.  Bars  represent  the  standard  deviation  of  triplicate 
determinations,  with  *p<0.05  or  **p<0.005  indicating  increase  in  proliferation  in  comparison  to 
untreated cells. Data represent at least three independent experiments. 
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Figure   3.8 Proliferation of different mature B cell lines in response to human sCD23. 
 
LCD  cultures  (5000  cells/well)  of  the  indicated  cell  lines  in  PFHM  were  propagated  with  the 
indicated concentration of sCD23 (derCD23). Proliferation was assessed after 72 h by 
3[H]-TdR 
incorporation. Two sets of results are displayed for SKW cell line as in one experiment there was 
slight proliferative response with sCD23 at 2ng/ml whereas there was no significant response at the 
same  concentration  in  another  experiment.  Bars  represent  the  standard  deviation  of  triplicate 
determinations,  with  *p<0.05  indicating  increase  in  proliferation  with  sCD23  treatment,  in 
comparison to untreated cells. Data represent at least three independent experiments. 
 
0
2000
4000
6000
8000
10000
12000
14000
16000
18000
20000
0 250 120 20 2
sCD23 (ng/ml)
SKW *
0
100
200
300
400
500
600
700
800
0 250 120 20 2
sCD23 (ng/ml)
SKW
0
2000
4000
6000
8000
10000
12000
14000
16000
0 250 120 20 2
sCD23 (ng/ml)
DAUDI
0
500
1000
1500
2000
2500
3000
3500
0 250 120 20 2
sCD23 (ng/ml)
RAMOS
0
5000
10000
15000
20000
25000
30000
35000
40000
45000
0 250 120 20 2
sCD23 (ng/ml)
IB4
0
2000
4000
6000
8000
10000
12000
14000
16000
18000
0 250 120 20 2
sCD23 (ng/ml)
    *   * DAUDI
0
20000
40000
60000
80000
100000
120000
0 250 120 20 2
sCD23 (ng/ml)
RAJIMridu Acharya,2008     Chapter 3, 76 
 
3.2.4.2  Proliferation in response to Long peptide 
The  change  in  proliferative  response to  sCD23  in  the  different cell  lines  was 
verified by using the sCD23 derived long peptide (LP). This peptide contains the 
RKC motif bound by the integrin αVβ5 and previous surface plasmon resonance 
(SPR) analysis has confirmed the binding of this peptide to αVβ5. Consistent with 
the data for sCD23, the pre B cell lines SMS SB, RS4;11 and 697 showed a robust 
dose dependent proliferative response to LP treatment with stimulation indices 
(at 10ng/ml) of 7.6, 8 and 17.5 for SMS SB, RS4;11 and 697 cells, respectively 
(Figure 3.9).  In each case, the negative control peptides that do not contain the 
RKC  motif  (peptide  8,  13  or  58)  showed  no  effect  on  cell  proliferation.  
Proliferation induced by  LP  is  of higher  magnitude  (when  comparing  SI)  than 
sCD23, however since the peptides are smaller in structure compared to sCD23 
they might bind better to the integrin; the peptides are also used at a higher 
concentration than sCD23. 
The  late  pre B  cell  line  Nalm6  did  not  show  any  significant  increase  in  cell 
proliferation with LP but Blin1 cells showed a slight increase in cell proliferation 
at 5µg/ml. The proliferative response of the 1E8 cell line was more difficult to 
define because in one assay there was a slight response to LP at 10 and 5µg/ml 
(SI  2.3  and  2.6;  however  this  proliferative  response  was  not  statistically 
significant in comparison to negative control peptide #8 induced proliferation) 
but  in  another  assay  there  was  no  response  at  all  to  LP  (Figure  3.9).  Again 
consistent with the data observed for sCD23, the transitional B cell lines and the 
mature B cell lines did not show a significant increase in cell proliferation with 
LP treatment apart from a slight increase in proliferation in Daudi and SKW cell 
lines at 5 10ng/ml LP treatment (Figure 3.10). 
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Figure   3.9 Proliferation of different pre-B cell lines in response to the CD23-derived long 
peptide. 
 
LCD cultures of SMS-SB and Nalm6 cells in PFHM or other cell lines in PFHM with 1%FCS were 
propagated with indicated concentration of LP (KWINFQRKCYYFGKG ) or negative control peptide 
#8 (PEKWINFQR). Proliferation was assessed after 72 h by 
3[H]-TdR incorporation. Two sets of 
results are displayed for 1E8 cell line because different responses were observed in two different 
experiments. Bars represent the standard deviation  of triplicate determinations, with *p<0.05 or 
**p<0.005 indicating increase in proliferation in response to LP treatment in comparison to peptide 
#8 treatment at the same concentration. Data represent at least three independent experiments. 
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Figure   3.10 Proliferation of different mature B cell lines in response to CD23-derived long 
peptide. 
LCD cultures (5000 cells/well) of the indicated cell lines in PFHM were propagated with indicated 
concentrations  of  LP  (KWINFQRKCYYFGKG  )  or  negative  control  peptide  #8  (PEKWINFQR). 
Proliferation  was  assessed  after  72  h  by 
3[H]-TdR  incorporation.  Bars  represent  the  standard 
deviation  of  triplicate  determinations,  with  *p<0.05  indicating  increase  in  proliferation  with  LP 
treatment in comparison to peptide #8 treatment at the same concentration. Data represent at least 
three independent experiments. 
 
 
 
3.2.4.3  Proliferation in response to anti-αVβ5 monoclonal antibodies (MAbs) 
Figure 3.11 shows that the pre B cells lines (SMS SB, RS4;11 and 697) proliferate 
in response to αVβ5 ligation by 15F11 or AMF7 antibody. SMS SB cells showed a 
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significant  proliferative  response  when  stimulated  with  either  the  15F11 
antibody or the AMF7 antibody at 5µg/ml when compared with the respective 
isotype controls (Figure 3.11). RS4;11 cells showed significant proliferation with 
15F11 antibody when compared to the isotype control IgG2a antibody (Figure 
3.11), but these cells showed no response with AMF7 antibody (data not shown). 
The  697  cell  line  was  similar  to  SMS SB  cell  line  and  showed  a  significant 
response in cell proliferation with both the AMF7 and the 15F11 antibody. The 
P1F6 MAb failed to provoke a significant proliferative response in any of the cell 
lines (Figure 3.11).  
None of the other cell lines tested showed any response to any anti αVβ5 MAbs 
(AMF7, 15F11 or P1F6) (Figure 3.12 and 3.13). The mature B cell lines SKW and 
IB4  that  expressed  high  levels  of  αVβ3  but  little  or  no  αVβ5  were  used  to 
investigate if αVβ3 could regulate cell proliferation in a manner similar to αVβ5; 
both  the  cell  lines  showed  minimal  proliferation  in  response  to  the  23C6 
antibody challenge compared to the isotype control IgG1 antibody (Figure 3.13). 
No proliferative response was observed with a second αVβ3 antibody LM609 or 
the αV antibody LM142 (Figure 3.13). However, the case with the transitional 
cell  lines  was  slightly  more  complicated.  The  cell  lines  Raji  and  Daudi  both 
demonstrated significant cell proliferation when stimulated with 23C6 although 
αVβ3 expression was very low in these cell lines (Figure 3.12). In contrast, the 
Ramos cell line showed an inhibition of cell proliferation when treated with the 
23C6 antibody (Figure 3.12). No proliferative effect was noted when with the 
MAbs LM609 or LM142 were used to stimulate these cell lines (Figure 3.12). No 
proliferative response was seen in the Ramos cell line with the 10D5 antibody 
(Figure 3.12) although these cells showed some αVβ6 expression by FACS analysis 
(Figure 3.4) 
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Figure   3.11 Proliferation of  pre-B cell lines in response to αVβ5 monoclonal antibodies. 
 
LCD cultures of SMS-SB cells in PFHM or 697 and RS4;11 cell lines in PFHM with 1% FCS were 
propagated with indicated MAbs. All MAbs and their specific isotype controls were used at 5 g/ml. 
The AMF7 antibody was dissolved in a buffer containing BSA therefore BSA was used with the IgG 
isotype control antibody. Proliferation was assessed after 72 h by 
3[H]-TdR incorporation.  The 
inset on the results for SMS-SB cells displays proliferation in response to AMF7 and antibody and 
its isotype control. For SMS-SB cells, results are displayed for both the αVβ5 antibodies (P1F6 and 
15F11) while for 697 and RS4;11 results are shown only for the antibodies where we observed a 
proliferative  response.  Bars  represent  the  standard  deviation  of  triplicate  determinations,  with 
*p<0.05  or  **p<0.005  indicating  increase  in  proliferation  in  response  to  each  MAb  treatment  in 
comparison with specific isotype control antibody. Data are representative of three independent 
experiments. 
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Figure    3.12  Proliferation  of  mature  B  cell  lines  in  response  to  different  αV  integrin 
monoclonal antibodies. 
 
LCD cultures (5000cells/well) were propagated in PFM of cell lines Raji, Ramos and Daudi with the 
indicated MAbs and proliferation was assessed after 72 h by 
3[H]-TdR incorporation. All the MAbs 
and there isotype controls were used at 5 g/ml. Bars represent the standard deviation of triplicate 
determinations,  with  **p<0.05  indicating  increase  in  proliferation  with  antiboody  treatment  in 
comparison to the isotype control.  Data are representative of three independent experiments. 
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Figure   3.13 Proliferation of mature B cell lines in response to different αV integrin 
monoclonal antibodies. 
 
LCD cultures (5000cells/well) were propagated in PFM of cell lines SKW and IB4 with the indicated 
MAbs and proliferation was assessed after 72 h by 
3[H]-TdR incorporation. All the MAbs and there 
isotype  controls  were  used  at  5 g/ml.  Bars  represent  the  standard  deviation  of  triplicate 
determinations,  with  **p<0.05  indicating  increase  in  proliferation  with  antiboody  treatment  in 
comparison to the isotype control.  Data are representative of three independent experiments. 
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3.2.5 αV  integrin  expression  on  human    bone  marrow  B  cell 
precursors 
Frozen human bone marrow mononuclear cells were thawed and used for FACS 
analysis  using  a  panel  of  MAbs    for  CD19,  CD10,  CD9,   ,  κ,  αVβ5  and  αVβ3 
expression.  The  cell  surface  markers  were  chosen  to  delineate  the  different 
stages in B cell development in the bone marrow and to allow for correlation 
with the cell line data. In all cases lymphocyte populations were first gated from 
the forward scatter/side scatter dot plots and B cells were identified from the 
total population by using the anti CD19 antibody conjugated to PerCP Cy5.5 and 
further analysis was only done on the CD19
+ B cells. 
Figure  3.14  illustrates  that  bone  marrow  B  cell  precursors  express  both  the 
integrin αVβ5 and αVβ3 as shown by staining with the P1F6 MAb for αVβ5 and 
23C6 MAb for αVβ3 expression. However, αVβ5 expression was higher than αVβ3 
expression (25.9% of CD19
+/αVβ5
+ cells vs. 15.3% of CD19
+/ αVβ3
+ cells on the 
upper right quadrants of the dot plots). Some of the αVβ5 positive cells were 
CD10 positive (Figure 3.15) and majority of the αVβ5 positive cells were also 
positive for CD9 as shown in Figure 3.15. In both cases, positive staining for CD9 
or CD10 is represented by the blue histogram. This is in agreement with the cell 
line data and shows the bone marrow B cell precursors positive for CD9 or CD10 
are αVβ5 positive.  More importantly, Figure 3.16 depicts that CD10 negative B 
cells  are  αVβ5 negative  but  CD10 positive  B  cells  are  αVβ5 positive.  αVβ5 
staining in CD10 negative population is represented as a red histogram and was 
derived from  the upper left population on the dot plot and  αVβ5 staining in 
CD10 positive cells is shown as a red histogram and these cells represent the 
population  at  upper  right  quadrant.  CD10 positive  B  cells  represent  the 
precursor B cells in bone marrow while CD10 negative B cells represent the re 
circulating B cells. Therefore these data supports the hypothesis that αVβ5 is 
expressed on B cell precursors but not on more mature cells.  
Figure 3.17 shows the expression of αVβ5 or αVβ3 integrin in three different cell 
populations based on staining for the   chain. B cell populations were gated as  
either, CD19
  or CD19
+/   chain negative or CD19
+/  chain positive and αVβ5 or  Mridu Acharya,2008     Chapter 3, 84 
 
αVβ3 staining in each of these population is shown as a histogram overlay. Figure 
3.17A illustrates that αVβ5 expression is highest in the CD19
+/  chain negative B 
cell population and is lower in the CD19
+/  chain positive B cell population. The 
  chain negative B cell precursors probably represent pro B cells, and therefore 
these data support the hypothesis that αVβ5 expression is highest in the earlier B 
cell  precursors  and  decreases  as  the  cells  mature.  However,  no  staining  was 
observed with the CD34 MAb and, due to the lack of data on CD34 positive pro B 
cells, αVβ5 expression on pro B cell precursors cannot be confirmed. Moreover, 
αVβ3 integrin showed a very similar expression pattern to αVβ5 (Figure 3.17B). 
From  the  cell  line  data  it  would  be  expected  that  perhaps  αVβ3  expression 
increases as the B cells mature, since more mature cell lines showed more αVβ3 
expression.  However,  the  pre B  cell  lines  also  expressed  αVβ3  integrin  and 
therefore  it  is  possible  that  the  bone  marrow  B  cell  precursors  express  both 
these  integrins.  Analysis  of  αVβ3  integrins  in  more  mature  B  cells  would  be 
required to further confirm the expression pattern. 
Data shown in Figures 3.18A and 3.18B indicate that both   chain positive and κ 
chain positive B  cells  are also  αVβ5
+.  Since  κ chain positive  B cells  represent 
BCR positive  cells  it  was  surprising  to  see  αVβ5  expression  in  these  cells. 
However, the kappa positive immature B cell line 1E8 also expressed αVβ5 and 
the kappa positive population encompasses the immature and mature B cells and 
so  the  αVβ5  expression  could  be  because  of  an  immature  B  cell  population. 
Comparing the histograms for αVβ5 expression in    chain positive and κ chain 
positive B cells it is evident that there are more   chain positive cells expressing 
αVβ5  than  the  kappa positive  B  cells.  The  kappa  antibody  showed  some  non 
specific binding so it was difficult to analyse different B cell populations with 
varying κ chain expression. 
Finally,  Figures  3.19  A  and  3.19  B  indicate  that  both  αVβ5  and  αVβ3  are 
expressed  on  some  CD5
+  B  cells.  CD19
+/αVβ5
+  cells  were  analysed  for  CD5 
staining. CD19
+ but αVβ5 negative B cells are also CD5
+ (red histogram) however 
there  are  a  proportion  of  αVβ5
+  B  cells  are  CD5
+  (blue  histogram).  A  similar 
result was seen with αVβ3 staining (Figure 3.19B). 
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Figure   3.14 Expression of integrins αVβ5 and αVβ3 in bone marrow B cell precursors. 
 
Frozen  samples  of  BM  mononuclear  cells  were  thawed  and  prepared  for  FACS  analysis  as 
described in materials and methods. B cell precursors were identified from the mononuclear cell 
population  by  using  anti-CD19-PerCpCy5.5  MAb.  Compensation  gates  were  based  on  isotype 
control mouse IgG1-κ conjugated beads (BD Bioscience, Oxford, UK). Biotinylated P1F6 MAb with 
secondary streptavidin  APC was used to detect αVβ5 integrin and biotinylated 23C6 MAb  with 
secondary streptavidin APC was used to detect αVβ3 integrin.  
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Figure    3.15 Expression  of CD9 and CD10 markers on αVβ5 positive bone marrow B cell 
precursors. 
 
BM mononuclear cells were simultaneously stained with P1F6-biotin (and streptavidin APC), CD9-
FITC, CD10-PE and CD19-PerCPCy5.5. The CD19
+/αVβ5
+ population  was further analysed for 
CD10  and  CD9  expression  as  histograms.  The  twodot  plots  show  the  αVβ5
+  and  CD19
+ 
populations on the upper right quadrant and histgrams for CD10 (top) CD9 (bottom) were drawn 
based on this population. The histogram in red represents background staining for FITC or PE from 
unstained samples and the histogram in blue represents staining for CD10-PE or CD9-FITC. 
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Figure   3.16 Analysis of αVβ5 expression on CD10-negative and CD10-positive bone marrow 
B cell precursor populations. 
 
BM mononuclear cells were simultaneously stained with P1F6-biotin (and streptavidin APC), CD10-
PE and CD19-PerCPCy5.5. The dot plots show CD19
+ and CD10
+ population in the upper right 
quadrant and CD19
+ and CD10
- population in the upper left quadrant. These two populations were 
analysed for αVβ5 expression. The histogram shows staining for αVβ5 on CD19
+ /CD10
- population 
in red and αVβ5 staining for CD19
+  and CD10
+ population in blue.  
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Figure   3.17 Analysis of αVβ5 and αVβ3 integrin in bone marrow B cells at different stages. 
 
BM  mononuclear  cells  were  simultaneously  stained  with  either  P1F6-biotin  or  23C6-biotin  (and 
streptavidin APC),  -FITC and CD19-PerCPCy5.5. The dot plots show different populations gated 
on CD19 and   chain expression. In both dot plots the circular gate on the far left represents the  -
low or negative/CD19
+ population, the circular gate in the middle represents the CD19-negative 
population and the elliptical gate on the right represents  -positive /CD19
+ B cell precursors. αVβ5 
or αVβ3  expression in  each of these populations is represented as histograms. The plots on the 
top (A) represent staining for αVβ5 and plots on the bottom (B) represent staining for αVβ3. 
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Figure   3.18 Expression of αVβ5 integrin on  -positive and κ-positive bone marrow B cell 
precursors. 
 
BM mononuclear cells were simultaneously stained with P1F6-biotin (and streptavidin APC),  -
FITC or κ-FITC and CD19-PerCPCy5.5. The dot plots show the CD19
+ and αVβ5
+ B cell population 
on the upper right quadrants. αVβ5
+ and  -chain-positive cells are shown as histograms in (A) and 
αVβ5
+ and κ-chain postive cells are shown as histogram in  (B) 
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Figure   3.19 Analysis of αVβ5 or αVβ3 integrin expression on CD5
+ B cells from the bone 
marrow. 
 
BM mononuclear cells  were simultaneously stained  with MAbs P1F6-biotin  or  23C6-biotin (and 
streptavidin APC), CD5-FITC and CD19-PerCPCy5.5. The dot plots identify CD19+ and αVβ5
+ B 
cell population (A) or CD19
+ αVβ3
+ B cell population (B) on the upper right quadrants. These cell 
populations were analysed for expression of CD5 as shown by the histograms. The histogram in 
blue indicates CD5
+ αVβ5
+ cells (A) or CD5
+ αVβ3
+ cells (B) and the histogram in red shows CD5
+/ 
CD19
+ cells that are negative for either integrins; these are derived from the upper left quadrants as 
shown in the dot plots.  
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3.2.6 Proliferation  response  of  B  cell  precursors  in  the  bone 
marrow 
B cell precursors in the human bone marrow mononuclear cells were FACS sorted 
by using the CD19 and kappa MAbs. The CD19
+ population was sorted into kappa 
positive  and  kappa negative  populations.  The  kappa  negative  population 
represents precursor B (pro B to pre B) cells that have not started to express the 
kappa light chain while the kappa positive population encompasses immature, 
transitional  and  mature  B  cells  all  expressing  the  kappa  light  chain.  Both 
populations  were  separately  used  in  proliferation  assays  to  determine  their 
proliferation  response  to  αVβ5  ligands.  The  number  of  cells  sorted  were  not 
enough to confirm αVβ5 expression in the sorted population. However an aliquot 
of the bone marrow mononuclear cells was stained for CD19, αVβ5 and kappa 
light  chain  expression  to  make  sure  there were  significant numbers  of  αVβ5 
positive cells in the sorted populations. 
B cell precursors were cultured on irradiated stromal cells (hMSC Tert) in RPMI 
with  2%  (v/v)  FCS  with  different  treatments  and  proliferation  measured  as 
mentioned in materials and methods (Chapter 2). The CD19
+/κ
+ cells did not 
show a significant proliferation response with any treatment and did not survive 
for  too  many  days  in  the  culture.  The CD19
+/κ
   B  cell  precursors  survived  in 
culture for a few days and as shown in Figure 3.20 they showed a significant 
proliferative  response  with  sCD23  (250ng/ml)  and  with  the  CD23 derived  LP 
(5 g/ml).  The  negative  control  peptide  #8  did  not  cause  any  effect  in  cell 
proliferation. Proliferation with the LP was more robust than proliferation with 
sCD23 and this was seen in proliferation assays with the B cell lines as well.  
However, we did not see a significant effect in cell proliferation with the 15F11 
MAb which binds αVβ5 integrin and induces a proliferative response in pre B cell 
lines SMS SB, RS4;11 and 697. Perhaps, a higher concentration of this antibody 
could be required to see a response in the bone marrow B cell precursors.  The 
other αVβ5 antibody, P1F6, or the αVβ3 antibody 23C6 also failed to induce a 
proliferative  response.  Moreover,  these  data  are  representative  only  of  one 
experiment  so  this  experiment  would  have  to  repeated  to  obtain  conclusive 
data. Mridu Acharya,2008     Chapter 3, 92 
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Figure   3.20 Proliferation of human CD19
+/ κ
- B cells in response to LP and CD23. 
 
CD19
+/κ
-  B  cells  were  FACS  sorted  from  a  BM  mononuclear  cell  population  and  used  for 
proliferation experiments. 4000 sorted B cells/well were plated on γ-irradiated stromal cells in 96-
well  plates  and  proliferation  was  assessed  72  h  by 
3[H]-TdR  incorporation.  Bars  represent  the 
standard deviation of triplicate determinations, with *p<0.05 indicating increase in proliferation with 
CD23 or LP treatment in comparison to the negative control peptide #8 treatment. Data represent 
one experiment (n=1). 
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3.3 Discussion 
The  data  presented  in  this  chapter  indicate  that  αVβ5  expression  and  its 
influence on B cell proliferation is regulated in a developmental stage specific 
manner.  
Different B cell lines were chosen to represent a broad range of developmental 
stages, but it was not always possible to categorise each cell line into a specific 
stage definitively. RS4;11 is a well characterised MLL (mixed lineage leukaemia)  
bearing an MLL/AF4 rearrangement 
283, and known to be at the pro B stage; in 
agreement with this, it was surface µ
  , CD10
 . However, RS4;11 cells were not 
CD34
+ which is a common marker for pro B cells.  SMS SB cells were also CD10 
negative but expressed low levels of surface µ. Bertrand, et. al., have described 
another MLL rearranged Blin 3 cell line with the t(4;11) translocation that was  
µ
  and became  µ
+ in vitro 
284. Furthermore, the overall phenotype of the MLL 
rearranged  pro B  and  pre B  ALL  is  known  to  be  largely  identical.  Therefore, 
although  we  did  not  know  the  t(4;11)  translocation  status  of  SMS SB  cells, 
because of the similarities in surface marker expression, SMS SB cells and RS4;11 
cells were categorised together as early pre B cells.   
The CD10
+ pre B cell lines were designated as late pre B cell lines. However, 
CD10 expression was lower in the 697 cell line in comparison with Blin1 or Nalm6 
cell lines and therefore the 697 cell line could be at a slightly different stage 
than the Blin1 or Nalm6 cells. CD20 expression at the small pre B stage is known 
to  coincide  with  cessation  of  cell  division,  exit  from  the  bone  marrow  and 
maturation  towards  a  mature  B cell  phenotype 
285,  and  this  is  followed  by  a 
concomitant decrease in expression of CD10 and CD24 
286.  Therefore, other pre 
B  cell  markers  such  as  CD20  and  CD24  could  have  been  employed  to  more 
directly delineate the cell stages. The κ
+ and CD10 negativity showed that 1E8 
cells, although derived from the Blin1 cells, were at a more mature stage of 
development. 
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CD38, CD10 and CD24 antigens have previously been identified as immature B 
cell  markers  in  human  bone  marrow  and CD10  expression  is  characteristic  of 
human transitional (T1) B cells 
48 . As the cell lines Daudi, Raji and Ramos were 
all positive for immunoglobulin light chain expression, they were considered to 
be more mature than immature B cells and because of their CD10 expression 
they matched the transitional B cell phenotype. However, human transitional B 
cells are also known to be IgD positive but none of these cell lines showed IgD 
expression. These cell lines were also negative for CD21 expression, which is a 
marker for mature B cells. The mature B cell lines also lacked CD21 expression, 
therefore  it  is  not  clear  whether  the  antibody  was  not  able  to  detect  CD21 
expression or the cells were all indeed CD21 negative. The fact that the cell 
lines SKW and IB4 were CD10 negative indicated that they were a stage further 
from the transitional B cell lines and therefore were designated as mature B 
cells.  
It is clear from the P1F6 and 15F11 staining data that the pre B cells express 
high levels of αVβ5 and the integrin expression decreases as the cell mature. 
P1F6 staining showed similar levels of αVβ5 expression in the early and late pre 
B cells but with the 15F11 MAb early pre B cell lines and 697 cells showed higher 
levels of staining for αVβ5 than the late pre B cells Blin1 or Nalm6. In fact, the 
three pre B cell lines (SMS SB, RS4;11 and 697) showing significant 15F11 staining 
were the cells lines that showed a robust proliferative response to αVβ5 ligation. 
More importantly, there was a down regulation of αVβ5 expression in the 1E8 
cell line that had started to express immunoglobulin light chains when compared 
to the original cell line Blin1 from which they were derived, indicating that B 
cell maturation may be accompanied by αVβ5 down regulation. 
There was also a clear down regulation in αVβ5 expression in the transitional 
and mature B cell lines as shown by FACS analysis. However, this difference was 
not clear when assessing transcripts for β5 in the different cell lines. The β5 
transcript was present in all the cell lines tested except for the Ramos cell line. 
It  is  possible  that  in  the  cell  lines  such  as  IB4  although  they  have  the  β5 
transcripts they do not express the β5 protein on the cell surface. A western blot  
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analysis of β5 would be needed to confirm the presence of β5 protein in the 
cells. Nevertheless, the fact that cell lines such as Daudi and SKW still showed 
slight surface expression of αVβ5 indicates that the cell lines such as IB4 may 
also express small amounts of αVβ5 that was not detected by FACS analysis.  
In the case of αVβ3, it was difficult to conclude exactly at what stage αVβ3 
expression began and one can only conclusively say that the mature B cell lines 
like SKW and IB4 expressed high levels of αVβ3 in comparison with any of the 
other cell lines. A further complication in the analysis was the fact that the 
precise stage of development of the mature B cell lines SKW and IB4 could not 
be defined. Although they both expressed most of the surface markers tested, 
IB4 cell lines were not positive for surface light chain expression. These cell lines 
are both CD23 positive and both are EBV transformed cell lines. Therefore the 
high αVβ3 expression could also be because of EBV transformation as previous 
studies have shown that EBV transformation induces expression of αVβ3 integrins 
287.  
From the analysis of B cell precursors in the bone marrow, it was noted that the 
CD19
+/CD9
+ and CD19
+/CD10
+ cells expressed αVβ5 as well as αVβ3, but αVβ5 
expression was higher in comparison to αVβ3 expression. αVβ3 expression in the 
bone  marrow  B  cell  precursors  indicate  that  low  levels  of  αVβ3  might  be 
expressed in pre B cells, consistent  with data for αVβ3 expression in Blin1 and 
Nalm6 cells. The bone marrow data also indicates that CD10
+ B cell precursors 
are αVβ5
+ but CD10
  re circulating B cells are αVβ5 negative. We also observed 
in  the  bone  marrow  that  the  κ
+  B  cells  still  expressed  αVβ5  although  the 
expression was lower than the  
+ B cell precursors (Figure 3.18). A more rigorous 
study of bone marrow B cell precursors is required to obtain conclusive data. In 
our study we were also unable to detect CD34
+ pro B cells in the bone marrow 
and this could be because we were using frozen bone marrow samples. Analysis 
of pro B cells and pre B cells is particularly important, since it is in these early 
stages that αVβ5 expression seems to be highest and most functionally important 
from the cell line data and we could see a similar pattern from the bone marrow 
expression data (Figure 3.17).  
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Therefore, it cannot be conclusively said that αVβ5 expression is exclusive to the 
pre B cells but it can be concluded that αVβ5 expression decreases as the B cells 
mature.  This  is  also  in  agreement  with  previous  data  from  the  laboratory 
showing  that  αVβ5  expression  is  significantly  increased  in  cells  from  patients 
with  ALL  (Borland,  et.  al.,  2008  manuscript  submitted).  With  regard  to  the 
comparison of αVβ5 and αVβ3 expression, analysis of the mature B cells in the 
peripheral blood will also be necessary in order to identify and compare the 
pattern of expression of these two integrins. Since a similar expression pattern 
was seen between αVβ5 and αVβ3 integrins in the bone marrow B cell precursors 
it would be important to analyse the more mature B cells in order to identify if 
there  is  a  difference  in  expression  pattern  of  these  two  integrins.  Another 
interesting finding from the bone marrow expression study is that the CD5
+ B 
cells  are  positive  for  αVβ5  and  αVβ3  integrins  (Figure  3.19).  CD5
+  B  cells  in 
humans are considered to be equivalent to the murine B 1a cells. These cells 
represent a minor B cell population but have been implicated in malignanices 
such as CLL and in autoimmune diseases. The fact that these cells express αV 
integrins  implies  that  these  integrins  could  have  a  role  in 
proliferation/differentiation  of  these  cells  which  could  have  an  important 
impact on the development of CD5
+ cells associated B cell disorders. 
SMS SB cells proliferate in a similar manner in response to recombinant sCD23 
from  different  sources.  The  three  different  sCD23  proteins  were  slightly 
different in the amino acids they encompassed and this allowed the comparison 
of  different  motifs  in  inducing  a  proliferative  response.  The  amino  acid 
sequences of the three different sCD23 are presented in an aligned format in 
Figure 3.21. R&D sCD23 and sCD23 
48 248 encompassed nearly the same length of 
amino acids 48 321 and 48 248, respectively, and this could be the reason they 
both gave nearly identical proliferative responses. The derCD23 contained amino 
acids  156 298.  We  also  did  not  assay  the  specific  activities  of  these  sCD23 
proteins  so  they  could  be  inducing  proliferative  responses  at  different 
concentrations because of the difference in their specific activities. The sCD23
48 
248 lacks IgE and CD21 binding motif but contains the RKC motif bound by αVβ5.  
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The  proliferative  response  induced  by  this  sCD23  clearly  indicates  that 
proliferation mediated by sCD23 is independent of the need for CD21 and IgE 
binding. 
The  three  pre B  cell  lines  SMS SB,  RS4;11  and  697  showed  a  significant 
proliferative response when αVβ5 was ligated using sCD23 or the CD23 derived 
long peptide; a similar response was seen with the αVβ5 antibody, 15F11. The 
AMF7  MAb  which  binds  to  the  αV  subunit  shows  a  significant  response  in 
proliferation  in  SMS SB  cells  and  697  cells  but  not  in  RS4;11  cells.    The 
transitional and mature B cell lines that do not express αVβ5 did not show any 
response in cell proliferation with sCD23, LP or the MAbs. Moreover, the cell 
lines  Daudi and  SKW that  do  express  small  amounts of  αVβ5  showed a  slight 
response in cell proliferation with sCD23 and with LP. The αVβ5 staining in these 
cell lines was done using P1F6 antibody and it is possible that these cell lines 
have low expression of the epitope that is recognised by 15F11 antibody and 
therefore do not show any proliferative response with this antibody.  Moreover, 
both of these cell lines are EBV transformed cell lines and previous studies have 
demonstrated that sCD23 induces proliferation of EBV transformed cell lines 
215. 
This response is thought to be mediated by the CD23 CD21 interaction. Although 
we did not see any CD21 expression in these cell lines we cannot be sure they do 
not express this antigen because we did not see positive CD21 expression in any 
cell line. Furthermore, the fact that only sCD23 and LP induced a proliferative 
response in these cell lines, but not the αVβ5 MAbs (AMF7 or 15F11), indicates 
that perhaps the proliferative response we observed could be delivered via the 
CD23 CD21 interaction. 
Other αV integrin levels might also affect the proliferative response as the levels 
of different αV integrins change in the cells at different stages of development. 
The αVβ3 integrin was not associated with a proliferative response in the mature 
B cell lines that expressed high levels of this integrin and were low or negative 
for αVβ5. By contrast, in the transitional B cell lines Raji and Daudi, a significant 
increase  in  proliferation  with  the  23C6  MAb  that  is  known  to  bind  to  αVβ3 
heterodimer was noted; no response with any other anti αV MAbs was observed.  
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αVβ3 integrin and therefore it was surprising to see a proliferative response with 
this antibody on these cells; we did not see such an effect with 23C6 in the early 
pre B cell lines. However, it should also be noted that the cell lines that were 
used for the functional studies had been in culture longer than the cell lines that 
were used for expression studies and the integrin expression did vary in the cells 
as they were in culture for an extended period (data not shown).  
It is possible that as the cells had been in prolonged culture, the αV integrin 
levels had changed in these cells and therefore their proliferative response to 
23C6  was  different.  It  is  also  equally  possible  that  pattern  of  expression  of  
different αV integrin varies in the transitional and mature B cell lines and so the 
proliferative response is different depending on the αV integrins expressed. For 
example, it is clear from the RT PCR data that both the SKW and IB4 cell lines 
express high amounts of transcripts for the β8 subunit when compared to any of 
the  other  cell  lines.  It  is  not  known  whether  αVβ8  expression  has  a  role  in 
regulating proliferative responses when compared to the ligation of other αV 
integrins. Similarly, β1 integrin levels were characteristically different in cell 
lines at each of the developmental stages so αVβ1 integrin expression could also 
be affecting the function of other αV integrins.  
The Ramos cell line that was categorised to be of the same stage as Raji and 
Daudi  cell  lines,  showed  an  inhibition  in  cell  proliferation  with  the  23C6 
antibody. Among all the cell lines tested this cell line was the only cell line 
showing some staining for the αVβ6 heterodimer. Therefore, it is possible that 
the presence of αVβ6 negatively regulates the response through αVβ3. The αVβ6 
antibody  (10D5)  however  did  not  have  any  effect  on  this  cell  line.  Indeed  a 
previous  study  has  shown  that  β1  integrin  regulates  αVβ3  and  αVβ5  integrin 
expression 
288 and therefore cross talk between the different αV integrins could 
potentially have important roles in determining the function of each αV integrin.   
Extensive functional studies on bone marrow B cell precursors are required to 
confirm  the  effects  of  αVβ5  ligation  on  cell  proliferation  of  normal  B  cell 
precursors.  A  more  detailed  study  of  the  expression  of  all  the  different  αV 
heterodimers  together  with  the  functional  studies  would  also  be  required  to 
identify  exactly  the  stage(s)  of  development  at  which  αVβ5 mediated  cell Mridu Acharya,2008     Chapter 3, 99 
proliferation is critical and the role of different αV heterodimers in mediating 
this proliferative effect. Preliminary results for proliferation of normal human 
bone  marrow  B  cells  precursors,  FACS  sorted,  on  the  basis  of  κ  light  chain 
expression, showed that the CD19
+/κ
  precursors proliferated well in response to 
both sCD23 and long peptide. But we did not observe a proliferative response 
with the αVβ5 MAbs. However, the CD 19
+/κ
  cells encompass a heterogeneous 
population of both pre B, pro B cells and this could be the reason for not seeing 
any response with the 15F11 antibody. Therefore this needs to be repeated, and 
a  separate  comparison  of  pro  and  pre B  cells  would  be  required  in  order  to 
compare the proliferation data for normal bone marrow B cell precursors with 
the cell line data. The CD19
+/κ
+ cells expressing αVβ5 showed no proliferative 
response with αVβ5 ligation.  
These findings indicate that the αV integrins, αVβ5 and αVβ3 are expressed in 
bone marrow B cell  precursors and in B cell lines representing the precursor 
stages of development in the bone marrow. While the differential pattern of 
expression of these two integrins could not be identified, the proliferation data 
indicated  that  αVβ5  integrin  regulates  proliferation  of  B  cell  precursors  in  a 
stage specific manner. It remains to be investigated what is the exact difference 
in the function of αVβ5 and αVβ3 integrin and how their expression pattern is 
regulated. αV integrin expression and function could have important implications 
for growth and differentiation of normal and neoplastic B cell precursors and  
therefore it is important to identify mechanisms regulating the expression and 
function of these integrins in B cell precursors. 
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Figure   3.21 Alignment of amino acid sequences for the three different types of sCD23. 
 
The three different types of sCD23 used in the experiments are represented as RnDCD23 (R & D 
CD23), Assay design CD23 (Ad CD23) and Der CD23. The sequence highlighted in red represents 
the sequence for the CD23-derived long peptide (LP).  
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4  Modulation  of  αVβ5  Integrin  Function  by 
Chemokines, Cytokines and Growth Factors. 
4.1 Introduction  
Signals mediating growth and survival of B cells at any stage of development 
need  to  be  highly  regulated  for  normal  progression  through  each  stage  of 
development. The bone marrow microenvironment comprises a huge variety of 
cytokines,  chemokines,  growth  factors  and  adhesion  molecules  all  providing 
coordinated signals that allow maturation of B cells along the developmental 
pathway. Therefore, any growth/proliferation signal relating to B cell precursors 
in  the  bone  marrow  will  be  regulated  by  a  number  of  positive  and  negative 
mechanisms.  
The  integrin  αVβ5  was  shown  to  bind  to  an  RKC  motif  on  CD23 
232  and  this 
interaction  sustained  proliferation  of  precursor  B  cell  lines  expressing  αVβ5 
(Chapter 3). Therefore we used sCD23, CD23 derived peptides and MAbs AMF7 
and  15F11  to  assess  the  role of chemokines,  cytokines and  growth  factors  in 
modulating  αVβ5  function  and  expression.  The  chemokine  SDF 1  and  a 
combination of cytokines as well as PDGF were used in combination with the 
αVβ5 ligands to assess SMS SB cell proliferation. 
PDGFs are a family of closely related proteins which exist as disulphide bonded 
dimers of approximately 30 kDa and three isoforms of PDGF, αα, αβ, ββ are 
encoded by two genes termed PDGFA and PDGFB 
289. The PDGF receptor also 
comprises two isoforms, PDGFR α and PDGFR β. The α receptor binds all three 
isoforms with high and equal affinity whereas the β receptor preferentially binds 
ββ homodimers and interacts with αβ heterodimers with reduced affinity. PDGF 
is  a  major  growth  factor  in  serum  and  is  a  potent  mitogen  for  cells  of 
mesenchymal  origin.  Exaggerated  and  inappropriate  signalling  by  the  PDGF 
receptor tyrosine kinase has been implicated in a variety of diseases 
290. 
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A role for PDGF in the haematopoietic system has been shown by a number of 
studies.  It was shown that PDGF can alter the phenotype of stromal cells 
291 and 
PDGF has been implicated in myeloid leukaemias 
292 and in expansion of CD34
+ 
cord blood cells 
293. As SMS SB cells were previously shown to express PDGFRβ 
294 
and since PDGF has been extensively studied in the adherenet cell systems for 
integrin growth  factor  cross talk  we  assessed  the  role  of  PDGF  in  modulating 
αVβ5 function together with other cytokines and chemokines.  
4.2 Results 
4.2.1 SDF-1 Enhances Proliferation Induced by Ligation of αVβ5 
Integrin 
When treated with sCD23, SMS SB cells show an increase in cell proliferation in a 
dose dependent manner (Chapter 3). Other pre B cell lines cell lines such as 
RS4;11 and 697 show a similar effect in cell proliferation (Chapter 3). SMS SB 
cell proliferation induced by a sub optimal concentration of sCD23 (158ng/ml) 
was  enhanced  by  SDF 1  treatment  as  shown  in  figure  4.1A.  Optimal 
enhancement of cell proliferation was seen with 250ng/ml SDF 1 and 158ng/ml 
sCD23.  At  250ng/ml  sCD23  treatment  no  enhancement  of  proliferation  was 
observed with SDF 1 treatment and in fact there was a slight reduction in sCD23 
induced cell proliferation of SMS SB cells (data not shown)  SDF 1 alone did not 
show any effect on proliferation of SMS SB cells at any concentration used. The 
proliferative effect driven by the antibody 15F11 alone was also enhanced when 
SDF 1 was used together with 15F11 as shown in figure 4.1B. Peptide #9 (a CD23  
derived  peptide  containing  the  RKC  motif)  showed  a  similar  effect  in  cell 
proliferation  while  peptide  #34,  a  negative  control  peptide  (lacking  the  RKC 
motif)  showed  no  effect  in  cell  proliferation  (Figure  4.1C).  Similarly,  SDF 1 
enhanced proliferation of SMS SB cells, stimulated with the RKC containing long 
peptide  (LP)  (Figure  4.1D).  As  with  sCD23,  optimal  enhancement  of  cell 
proliferation was seen at 250ng/ml SDF 1. Both the peptides and sCD23 showed 
an enhancement in cell proliferation with SDF 1 at a concentration slightly lower 
than  the  optimal  concentration  at  which  they  themselves  induced  cell 
proliferation (Chapter 3).  Mridu Acharya,2008     Chapter 4, 103 
 
FACS analysis for surface expression of the receptors showed that in addition to 
expressing  the  CXCR4  receptor,  SMS SB  cells  also  expressed  CXCR7,  another 
receptor  known  to  bind  SDF 1  (data  not  shown).  In  order  to  show  that  the 
enhancement  of  αVβ5 mediated  cell  proliferation  was  indeed  mediated  via 
CXCR4 and SDF 1, we used the SDF 1 antagonist AMD3100 that is known to block 
binding  of  SDF 1  to  CXCR4.  Figure  4.2A  shows  that  when  SMS SB  cells  were 
treated with AMD3100 (50 M) there was no difference in proliferation induced by 
long peptide with or without SDF 1 treatment. In the AMD3100 treated cells, 
basal cell proliferation is slightly increased but LP induced cell proliferation is 
still  very  evident  but  there  is  no  enhancement  of  this  LP induced  cell 
proliferation in combination with SDF 1. 
A similar result was observed with the antibody 12G5 which is known to bind to 
CXCR4. There was no difference in proliferation induced by LP with or without 
SDF 1  in  presence  of  the  12G5  antibody  (Figure  4.2B).  However,  in  the  MAb 
12G5 treated  SMS SB  cells,  the  basal  proliferative  response  was  lower  than 
untreated cells or cells treated with IgG2a isotype control antibody. Although 
the 12G5 treated cells showed a proliferative response with LP treatment the 
cell count was much lower than in the untreated cells or IgG2a treated cells. 
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Figure   4.1 SDF-1 enhances proliferation mediated via the αVβ5 integrin in SMS-SB cells. 
 
(A) The proliferation of LCD cultures of SMS-SB cells in response to a sub-optimal concentration of 
sCD23 (158ng/ml) together with indicated concentrations of SDF-1 (black bars) and SDF-1 alone 
(hatched bars). Panels B-D illustrate the proliferative response of SMS-SB cells to stimulation with 
5 g/ml 15F11 MAb (B), 5 g/ml peptide #9 (C), and 1 g/ml long peptide (LP) (D), respectively, in 
combination with SDF-1. In each panel the treatment with SDF-1 alone is shown as a hatched bar, 
the combination of SDF-1 and stimulus as a black bar, and the combination of SDF-1 with either 
isotype control IgG2a (B) or irrelevant peptide #34 (C) is shown as a white bar. Bars represent the 
standard  deviation  of  triplicate  determinations,  with  *p<0.05  or  **p<0.005  indicating  increase  in 
proliferation in cells treated with different concentrations of SDF-1 and αVβ5 stimulants (sCD23, 
15F11MAb,  peptide  #9  or  LP)  in  comparison  to  SDF-1  treatment  alone,  and  #p<0.05  and 
##p<0.005 indicating enhancement in proliferation with 250ng/ml SDF-1 and αVβ5 stimulants when 
compared with αVβ5 stimulants alone. Data are representative of three independent experiments. 
 
 
 
 
D  C 
B  A Mridu Acharya,2008     Chapter 4, 105 
 
 
 
 
 
 
Figure   4.2 SDF-1 enhances proliferation mediated via the αVβ5 integrin in SMS-SB cells via 
the CXCR4 receptor. 
 
Proliferation response of LCD cultures of SMS-SB cells in presence of LP and CXCR4 antagonist 
AMD3100  or  anti-CXCR4  antibody  12G5.  (A)  represents  proliferation  with  sub-optimal 
concentration of LP (1 g/ml) and SDF-1 (250ng/ml) in untreated cells and cells treated with 50µM 
AMD3100 for 30 min prior to initiation of the assay. In both cases no stimulus is represented as 
grey bars, LP treatment is represented as black bars, the LP and SDF-1 combination as white bars 
and SDF-1 alone as hatched bars. (B) The proliferation response of SMS-SB cells to LP (1 g/ml) 
alone or with SDF-1(250ng/ml) in untreated cells, cells treated with 12G5 antibody or cells treated 
with  IgG2a  isotype  control  antibody.  In  all  cases  no  stimulus  is  represented  as  grey  bars,  LP 
treatment is represented as black bars, the LP and SDF-1 combination as white bars and SDF-1 
alone  as  hatched  bars  Bars  represent  the  standard  deviation  of  triplicate  determinations,  with 
*p<0.05 or **p<0.005 indicating increase in proliferation in cells treated with different concentrations 
of SDF-1 and αVβ5 stimulants (sCD23, 15F11MAb, peptide #9 or LP) in comparison to SDF-1 
treatment alone, and #p<0.05 and ##p<0.005 indicating enhancement in proliferation with 250ng/ml 
SDF-1 and αVβ5 stimulants when compared with αVβ5 stimulants alone. Data are representative 
of three independent experiments. 
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4.2.2 SDF-1  treatement  does  not  change  αVβ5  expression  and 
αVβ5 ligation does not change CXCR4 expression 
In  order  to  verify  whether  SDF 1  was  affecting  αVβ5  function  by  modulating  
expression levels of the latter, we monitored changes in αVβ5 expression after 
SDF 1 treatment. SMS SB cells were treated with 250ng/ml of SDF 1 and αVβ5 
surface expression was assessed after 24 and 48 hours. The two antibodies 15F11 
and P1F6 are known to recognise different epitopes on αVβ5 
282, therefore we 
used both the antibodies to assess changes in αVβ5 expression. However, there 
was no change in αVβ5 expression in cells treated with SDF 1 when compared to 
untreated  cells  (Figure  4.3A).  SDF 1  is  known  to  modulate  the  affinity  of 
integrins  for  their  ligands,  therefore  we  also  assessed  binding  of  the  CD23 
derived  peptides  to  SMS SB  cells  with  and  without  SDF 1  treatment.  A 
representative result (Figure 4.3B) shows that there was no change in binding of 
one of  the  sCD23 derived peptides  (peptide  #9)  to  SMS SB  cells  regardless  of 
SDF 1 treatment. On the other hand, ligation of αVβ5 did not have an effect on 
CXCR4 expression either. Figure 4.3C shows that treatment of SMS SB cells with 
either the LP (1 g/ml) or sCD23 (160ng/ml) does not cause a change in CXCR4 
expression after 24 hours of treatment of SMS SB cells.  
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Figure   4.3 Effects of SDF-1 on αVβ5 expression and αVβ5 ligation on CXCR4 expression. 
 
SMS-SB cells cultured in the presence or absence of 250ng/ml SDF-1 (24 h) were stained for αVβ5 
expression  using  the  anti-αVβ5  MAbs,  P1F6  and  15F11  (Figure  4.3A).  Fluorescence  intensity 
histograms for the relevant αVβ5 MAb are represented as grey shaded area and isotype control 
antibody staining is represented by the black line. Figure 4.3B illustrates the fluorescence intensity 
plots for binding of 1 g/ml peptide #9 or #11 (grey shaded area), the negative control peptide #41 
(black line) to SMS-SB cells following 24 h treatment with 250ng/ml SDF-1 or no treatment. Figure 
4.3C represents CXCR4 staining in untreated SMS-SB cells or cells treated for 24 h with sCD23 
(160ng/ml), LP (1 g/ml) or the negative control peptide #8 (1 g/ml). CXCR4 was stained using 
biotinylated-12G5  antibody  and  detected  using  streptavidin-PE  (grey  shaded  area);  the  isotype 
control IgG2a–biotin is shown as a black line.  
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4.2.3 The effect of SDF-1 on αVβ5-driven proliferation is specific 
to early B cell precursors 
We assessed CXCR4 expression in different precursor B cell lines and observed 
that CXCR4 expression varied in the precursor cell lines at different stages of B 
cell  development.  The  cell  lines  representing  earlier  stages  of  B  cell 
development had lower levels of CXCR4; CXCR4 expression increased in pre B 
cell lines such as Blin1 and mature B cell lines like Daudi, and declined again in 
the more mature B cell lines such as IB4. CXCR4 expression in comparision to 
αVβ5  expression  in  the  different  cell  lines  is  represented  in  Figure  4.4A  and 
4.4B. In particular, the pre B cell lines (SMS SB, RS4;11) which proliferated well  
in response to αVβ5 ligation had lower levels of CXCR4 and the expression of 
CXCR4 increased  in  the cell lines that were less responsive to αVβ5. Moreover, 
the enhancement of αVβ5 mediated cell proliferation by SDF 1 was only seen in 
pre B cell lines, such as SMS SB and RS4;11, with low CXCR4 expression (Figure 
4.4C).  Proliferation was not assessed with SDF 1 for the 697 cell line, but CXCR4 
staining in this cell line was also low, similar to SMS SB or RS4;11, and we would 
predict that their proliferative response would be similar to SMS SB or RS4;11 
cells. A representative result from the cell line RS4;11 is shown in figure 4.4C. 
SDF 1 enhances the proliferation induced by LP in a manner similar to that noted 
in SMS SB cells. By comparison, SDF 1 had no effect on the cell line Daudi which 
shows  little  or  no  proliferative  response  to  αVβ5  ligation  and  had  higher 
expression of CXCR4 (Figure 4.4A and C). Furthermore, SDF 1 had no effect on 
the very modest response to αVβ5 ligation noted in the Blin1 cell line (Figure 
4.4C).  
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Figure   4.4 CXCR4 expression and cell proliferation in different precursor and mature B cell 
lines. 
 
Panels (A) and (B) show the fluorescence intensity histograms for staining of CXCR4 (12G5) and 
αVβ5 (P1F6) respectively, in five cell lines. In both cases antibody staining is shown in the grey 
shaded area and the isotype control staining by the black line. The cell lines are represented as 
early or late pre-B and transitional or mature B, cell stage depending on surface marker expression 
as described in chapter 3. (C) In the different cell lines shown, proliferation driven by αVβ5 ligation 
(either with 2ng/ml sCD23 or with 1 g/ml LP) and SDF-1 is shown by black bars and proliferation 
induced with SDF-1 alone is shown as hatched bars. Bars represent the standard deviation of 
triplicate  determinations,  with  *p<0.05  indicating  increase  in  proliferation  in  cells  treated  with 
different concentration of SDF-1  and αVβ5 stimulants (sCD23, 15F11MAb, peptide #9 or LP) in 
comparison to SDF-1 treatment alone,  and #p<0.05 indicating enhancement in proliferation with 
250ng/ml  SDF-1  and  αVβ5  stimulants  when  compared  with  αVβ5  stimulants  alone.  Data  are 
representative of three independent experiments. 
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4.2.4 Other cytokines do not mimic SDF-1 but PDGF may have a 
similar role to  SDF-1 in modulating αVβ5 function  
Many other cytokines are known to be important during B cell development, and 
we therefore examined the effects of the cytokines IL 7, IL 11, IL 3 and IL 4 to 
determine  if  they  mimicked  the  effects  of  SDF 1  on  αVβ5 induced  cell 
proliferation. None of the above mentioned cytokines showed similar effects to 
SDF 1.  IL 7  showed  varied  effects  on  cell  proliferation  induced  via  αVβ5  but 
there  were  no  consistent  data  to  show  that  it  enhanced  αVβ5 induced  cell 
proliferation (Figure 4.5A). IL 11 itself induced an increase in cell proliferation 
(Figure 4.5B) but had no effect on αVβ5 induced cell proliferation and neither 
IL 3 nor IL 4 enhanced αVβ5 induced proliferation (Figure 4.5C and 4.5D).  
αVβ5  expression  was  also  analysed  in  presence  of  the  above mentioned 
cytokines. The cytokines were used at the same concentrations as SDF 1 (5nM) 
and αVβ5 expression was again analysed using P1F6 and 15F11 antibody. IL 7 did 
not influence the levels of αVβ5 expression as depicted in Figure 4.6A nor did IL 
11 (Figure 4.6B). With IL 3 treatment although the biotinylated isotype control 
staining  was  lower  than  the  untreated  cell,  P1F6  staining  was  of  the  same 
intensity  as  the  untreated  cells.  There  was  no  change  in  αVβ5  staining  in 
untreated  cells  and  IL 3 treated  cells  with  15F11  antibody,  whereas  IL 4 
treatment  resulted  in  decreased  αVβ5  expression  as  shown  by  P1F6  staining 
(Figure  4.6B).  But,  when  these  experiments  were  repeated  IL 4  seemed  to 
increase αVβ5 expression on one instance and no change was seen in another 
instance, therefore no conclusion could be made from these data. It could be 
that IL 4 influences αVβ5 expression depending upon the stage the cells are in 
culture, and therefore we observed different results in different experiments. 
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However, we noted that the platelet derived growth factor (PDGFβ) was, like 
SDF 1, able to enhance SMS SB cell proliferation driven by αVβ5. PDGF has been 
studied in connection with the SMS SB cells previously and this cell line is known 
to express the PDGF receptor β (PDGFRβ) 
294.  Figure 4.7A and 4.7B show that 
PDGFβ significantly enhanced both LP and sCD23 induced proliferation in SMS SB 
to  a  very  similar  extent  as  SDF 1.  Similar  to  SDF 1,  PDGF  treatment  did  not 
result in any changes in αVβ5 expression (Figure 4.7C). 
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Figure   4.5 αVβ5-mediated cell proliferation in the presence of other cytokines. 
 
Figures  4.4  (A),  (B),  (C)  and  (D)  represent  proliferation  of  LCD  cultures  of  SMS-SB  cells  in 
response to 1 g/ml LP or 5 g/ml peptide #9, together with the indicated concentrations of IL-7, IL-
11, IL-3 and IL-4, respectively. In each case, proliferation induced by the peptides and the cytokine 
is shown in black bars, cytokine alone is shown as hatched bars and cytokine with negative control 
peptide # 41or #8 is shown as white bars. The concentrations of each cytokine are equivalent 
molar concentrations. Data are representative of three independent experiments. 
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Figure   4.6 αVβ5 expression in presence of the cytokines IL-7, IL-3, IL-11 and IL-4. 
 
SMS-SB  cells  were  treated  with  5nM  of  the  indicated  cytokines  or  left  untreated  and  αVβ5 
expression was analysed by FACS using P1F6 or 15F11 antibody. (A) Represents histograms for 
staining  of  αVβ5  in  untreated  cells  or  cells  treated  with  IL-7  and  IL-3.  (B)  Represents  αVβ5 
expression in cells treated with IL-11 and IL-4 or untreated cells. In all cases the staining with 
relevant αVβ5 MAbs is represented as grey shaded area and staining with isotype control antibody 
is represented as a black line. 
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Figure   4.7 αVβ5-mediated cell proliferation in the presence of PDGFβ. 
 
LCD SMS-SB cultures were stimulated with the indicated concentrations of PDGFβ and 1 g/ml LP 
(Figure  4.7A)  or  160ng/ml  sCD23  (Figure  4.7B)  for  72  h  prior  to  addition  of  [
3H]-TdR  and 
determination of proliferation. Proliferation induced by PDGF and LP or sCD23 in combination with 
PDGF is shown as black bars and proliferation driven by PDGF alone is shown as hatched bars. 
Bars  represent  the  standard  deviation  of  triplicate  determinations,  with  *p<0.05  or  **p<0.005 
indicating  increase  in  proliferation  in  cells  treated  different  concentrations  of  PDGF  and  αVβ5 
stimulants  (sCD23,  LP)  in  comparison  to  PDGF  treatment  alone,  and  #p<0.05  and  ##p<0.005 
indicating enhancement in proliferation with 250ng/ml PDGF and αVβ5 stimulants when compared 
with αVβ5 stimulants alone. (C) SMS-SB cells, untreated or treated with 250ng/ml PDGF (24 h), 
were  stained  for  αVβ5  expression  using  the  anti-αVβ5  MAbs  P1F6  and  15F11.  Fluorescence 
intensity histograms for the relevant αVβ5 MAbs represented by the grey shaded area and isotype 
control  antibody  staining  is  represented  by  the  black  line.  Data  are  representative  of  three 
independent experiments. 
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4.2.5 SDF-1  enhances  ERK  phosphorylation  induced  via  sCD23 
and other αVβ5 ligands and PDGF shows a similar effect. 
We next examined the signalling pathways that might be involved in synergistic 
activation  of  cell  proliferation  by  αVβ5  ligation  and  SDF 1  treatment,  paying 
particular attention to ERK phosphorylation since SDF 1 is known to target this 
pathway 
121.  
Treatment of SMS SB cells with sCD23 promoted an early (0 2 min) and transient 
rise  in  phospho ERK  levels  that  was  followed  by  a  later  (30 60  min)  more 
sustained  and  robust  level  of  ERK  phosphorylation  (Figure  4.8A).  SDF 1  alone 
provoked an early, modest increase in phospho ERK levels with no evidence of a 
later, stronger increase in phosphorylation of ERK  (Figure 4.7A). By contrast, 
combined  treatment of  SMS SB  cells  with  SDF 1  and  sCD23  stimulated  a  very 
robust initial phase of ERK phosphorylation that was sustained until 10 minutes 
post stimulation,  yielding  phospho ERK  levels  that  were  some  15 fold  greater 
than either stimulus alone (Figure 4.8B). The 15F11 MAb induced a modest initial 
level of phospho ERK, followed by a more pronounced second phase and in this 
case  co stimulation  with  SDF 1  promoted  a  more  sustained  wave  of  ERK 
phosphorylation over the first 30 minutes of the experiment (Figure 4.8C).   
The  RKC containing  CD23 derived  peptide  #9  behaved  similarly,  inducing  a 
biphasic  response  by  itself  and  a  more  robust  and  sustained  response  when 
added together with SDF 1; peptide #8, which lacks  the RKC motif, failed to 
induce robust phosphorylation either alone or in association with SDF 1 (Figure 
4.8D).  Finally,  the  RKC containing  pentadecameric  LP  induced  sustained  and 
robust ERK phosphorylation that was enhanced in magnitude and persistence by 
SDF 1 co stimulation (Figure 4.8E). LP has an affinity for αVβ5 that is an order of 
magnitude  greater than that of  CD23  itself  (~  10
 7  M  vs  6  x  10
 6  M)  and  this 
greater  affinity  may  explain  the  higher  and  more  sustained  levels  of  ERK 
phosphorylation noted with LP.   
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The data are consistent with the interpretation that ligation of αVβ5 by a soluble 
ligand alone promotes a biphasic pattern of ERK phosphorylation, with a modest 
initial peak of phosphorylation followed by a later phase of higher and more 
sustained phosphorylation. The data also indicate that SDF 1 enhances the initial 
αVβ5 driven  early  activation  of  ERK  phosphorylation  and  maintains  this  at  a 
robust level for a sustained period, the length of which may reflect the affinity 
of  the  ligand  used  to  challenge  the  αVβ5  integrin.  A  similar  pattern  of 
enhancement  of  ERK  phosphorylation  was  observed  with  PDGF  treatment. 
Treatment of SMS SB cells with 250ng/ml of PDGF resulted in significant ERK 
phosphorylation  (2 10  min)  (Figure  4.9A).  However  this  phosphorylation  was 
significantly  enhanced  when  PDGF  was  used  together  with  160ng/ml  sCD23 
(Figure 4.9B) with a sustained increase in ERK phosphorylation from 0 30 min. 
This enhancement in ERK phosphorylation correlates well with the enhancement 
in cell proliferation observed with PDGF and sCD23 treatment of SMS SB cells. 
The MEK inhibitor U0126 was used to confirm the role of ERK phosphorylation in 
SMS SB cell proliferation. Treatment of SMS SB cells with U0126 (5µM or 10 M) 
prior to the initiation of the proliferation assay completely abolished any effect 
of sCD23 or its peptides on cell proliferation (Figure 4.10A). Moreover, U0126 
abolished  the  basal  survival  of  SMS SB  cells  in  low density  cultures  after  few 
hours  of  initiation  of  the  culture.  U0126  treatment  abrogated  the  ERK 
phosphorylation  driven  by  SDF 1  or  sCD23  individually  and  also  completely 
prevented the enhancement of ERK phosphorylation seen with SDF 1 and sCD23 
(Figure 4.10C).  
The  PI3K  inhibitor  LY294002  was  employed  to  confirm  that  the  inhibition  of 
proliferation  and  survival  was  specific  to  U0126.  LY294002  also  inhibited  the 
proliferation of SMS SB cells in response to αVβ5 ligation, but the inhibition was 
less complete than that observed with U0126 (Figure 4.10B). Indeed, after 48 
hours  of  treatment  a  small  increase  in  cell  proliferation  was  still  evident  in 
response  to  LP  treatment  in  cells  pre treated  with  LY294002  (Figure  4.10B), 
whereas  proliferation  was  absent  by  12  h  following  U0126  treatment.  Also, 
unlike U0126, LY294002 treatment does not inhibit the basal survival of SMS SB 
cells. We confirmed this difference by measuring survival of SMS SB cells after  Mridu Acharya,2008     Chapter 4, 117 
 
U0126 and LY294002 treatment. Analysis of SMS SB cell survival using annexinV/ 
propidium iodide (AV/PI) staining demonstrated that U0126 treatment results in 
a higher proportion of AV/PI double positive cells than LY294002 after a 12 h 
treatment (Figure 4.10D), illustrating that U0126 leads to increased apoptosis in 
comparison to LY294002 treatment. This indicates that the ERK phosphorylation 
pathway is important for SMS SB survival and cell proliferation. 
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Figure   4.8 ERK phosphorylation in SMS-SB cells treated with SDF-1 alone or in combination with αVβ5 ligands. 
Lysates from treated SMS-SB cells were separated by SDS-PAGE and transferred to nitrocellulose. Membranes were probed with antibodies to phosphorylated ERK and 
subsequently stripped and reprobed with antibodies to total protein (either ERK or actin). (A) Western blots of phosphorylated and total ERK in untreated SMS-SB cells and 
cells treated with sCD23 (160ng/ml), SDF-1 (250ng/ml) or a combination of sCD23 and SDF-1, at the time points shown. The increase in phosphorylation was quantitated by 
densitometric analysis of the bands (B). Figure (C) represents western blots for phosphorylation of ERK and of total actin in SMS-SB cells treated with 15F11 MAb alone or in 
combination with SDF-1. (D) and (E) Western blots for phosphorylated and total ERK in SMS-SB cells treated with peptide #9 (5 g/ml), negative control peptide #8 (5 g/ml) or 
LP (1 g/ml) alone or in combination with SDF-1 (250ng/ml).  Data are representative of three independent experiments.  
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Figure   4.9 ERK phosphorylation in SMS-SB cells treated with PDGF alone or in combination 
with αVβ5 ligands. 
 
Lysates  from  treated  SMS-SB  cells  were  separated  by  SDS-PAGE  and  transferred  to  nitrocellulose. 
Membranes were probed with antibodies to phosphorylated ERK and subsequently stripped and reprobed with 
antibodies to total protein (either ERK or actin). (A) Western blots for phosphorylated ERK or actin in SMS-SB 
cells treated  with PDGF (250ng/ml). (B) Western blots for phosphorylated ERK and actin in SMS-SB cells 
PDGF (250ng/ml) with sCD23 (160ng/ml). Data represent three  independent experiments. 
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Figure   4.10 Effect of inhibition of ERK and PI-3K signalling on αVβ5-mediated proliferation 
of SMS-SB cells. 
 
SMS-SB cells were treated with 10µM U0126 or 50µM LY294002 or left untreated for 30 min prior 
to plating at LCD; proliferation was assessed by 
3[H]-TdR incorporation after 72 h of culture. Panel 
A shows cell proliferation with LP (1 g/ml) and/or SDF-1 (250ng/ml) in untreated cells and cells 
treated with U0126. Panel B shows cell proliferation with long peptide and/or SDF-1 in untreated or 
cells treated with LY294002. In both cases, unstimulated cells are represented as grey bars, LP-
treated as black bars, the LP and SDF-1 combination as white bars and SDF-1 alone as hatched 
bars. Bars represent the standard deviation of triplicate determinations, with *p<0.05 or **p<0.005 
indicating increase in proliferation in cells treated with different concentrations of SDF-1 and αVβ5 
stimulant (LP) in comparison to SDF-1 treatment alone, and #p<0.05 and ##p<0.005 indicating 
enhancement in proliferation with 250ng/ml SDF-1 and αVβ5 stimulants when compared with αVβ5 
stimulants alone. Data are representative of three independent experiments. Panel C Western blot 
analysis of phosphorylated ERK and total actin in SMS-SB cells pre-treated with U0126 (10µM) 30 
min before stimulation with SDF-1 (250ng/ml) or sCD23 (160ng/ml) or a combination of SDF-1 and 
sCD23. Panel D shows contour plots for PI/annexinV staining of cells exposed to U0126 (10µM), 
LY294002 (50µM), DMSO (vehicle) or no treatment for 12 h. Quadrant gates in the insets are  
based  on  unstained,  annexinV  or  PI  stains  alone.  Data  are  representative  of  3  independent 
experiments. 
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4.3 Discussion 
It is well established that chemokines dynamically regulate the positioning of 
cells of the immune system by influencing the structure of integrin molecules to 
ensure  cells  attracted  to  a  specific  niche  are  retained  there  via  adhesion 
reactions with tissue matrix proteins.  Chemokines can also positively influence 
signalling via integrins in such adhesion dependent interactions, as exemplified 
by the action of SDF 1 on haematopoietic precursors at the level of the VLA 4  
ICAM 1 interaction 
114,295. The results presented in this chapter demonstrate that 
SDF 1 positively influences signalling events delivered to integrins in a soluble, 
adhesion independent manner. Thus, ligation of αVβ5 using specific MAbs, sCD23 
or RKC containing peptides derived from sCD23 all provoke ERK phosphorylation 
and  proliferation  responses  in  B  cell  precursors  that  are  enhanced  by  SDF 1. 
Remarkably,  PDGF  also  enhances  signalling  delivered  via  soluble  ligation  of 
αVβ5,  suggesting  that  both  tyrosine  kinase  and  G  protein coupled  receptor 
linked pathways may modulate adhesion independent signalling by αVβ5. 
Soluble CD23 mediated proliferation of SMS SB cells was enhanced by addition of 
SDF 1 and identical effects were seen with sCD23 derived peptides (containing 
the  RKC  motif  bound  by  αVβ5)  and  the  anti αVβ5  MAb  15F11,  all  of  which 
promote  proliferation  of  these  cells.  Blocking  the  binding  of  SDF 1  to  CXCR4 
using the previously  described SDF 1 antagonist AMD3100 
296,297 abolished this 
enhancement. However SDF 1 did not influence proliferation induced by the MAb 
AMF7 which binds to αV subunit and sustains proliferation of SMS SB cells. In 
relation to this as mentioned in chapter 3 we did not observe any proliferative 
response with this antibody in RS4;11 cell line which showed similar proliferation 
to SMS SB cells in response to αVβ5 ligation. Moreover, the response to AMF7 
might also be dependent on other αV integrins expressed.   
Interestingly, SDF 1 mediated enhancement of cell proliferation was seen only in 
the cell lines SMS SB and RS4;11, both of which represent the early precursor 
stage of B cell development (CD19
+, CD10
  and surface   low or negative). It is in  
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these early precursors that the most robust proliferative response to ligation of 
αVβ5  with  sCD23,  or  CD23 derived peptides,  was  observed  (Chapter  3). Blin1 
cells,  which  showed  a  slight  but  comparatively  modest  proliferative  response 
following sCD23 treatment, did not show any enhancement of proliferation with 
SDF 1. Higher CXCR4 expression did not influence the lack of response to αVβ5 
ligation noted in the more mature cell lines. SDF 1 mediated modulation of αVβ5 
function seems to be important in early B cell precursors, which express lower 
levels  of  CXCR4.  This  is  consistent  with  data  showing  that  although  B cell 
precursors express higher levels of CXCR4 with increasing maturation, the cells 
chemotactic response to SDF 1 itself is apparently blunted 
298.  
CXCR4 is continuously expressed on the surface of B cells. It has been shown 
that when B lymphocytes mature and start to express IgM at the cell surface 
they lose their chemotactic response to SDF 1 despite sustained expression of 
CXCR4 
298 300.  Glodek et. al., showed that SDF 1 triggers a sustained adhesion 
response specifically in progenitor (pro and pre B) cells that diminishes during 
maturation in the bone marrow; circulating mature B cells exhibit only transient 
SDF 1 induced  adhesion 
301.  Furthermore,  recent  studies  have  linked  the 
expression of CXCR4 with the potentiation of plasma cell long term survival in 
the bone marrow 
302 304. This developmental stage specific function of SDF 1 is 
interesting in relation to the data showing that αVβ5 function and expression is 
important in early B cell precursors and decreases as the cell mature (Borland, 
et.  al.,  2008  manuscript  submitted)  This  supports  a  developmental  stage 
specific role for adhesion molecules and growth factors in B lymphopoiesis.  
SDF 1 modulation of αVβ5 integrin function does not involve changes in receptor 
expression. SDF 1 treatment did not change αVβ5 expression (Figure 4.3A) and 
αVβ5  ligation  does  not  change  CXCR4  expression  (Figure  4.3C).  Although  the 
15F11 and P1F6 MAbs recognise different epitopes on αVβ5 
282, it is not known 
what conformational states of the integrin are recognised and so no conclusions 
can be drawn concerning the effects of SDF 1 on the conformational state of 
αVβ5.  Furthermore,  treatment  of  SMS SB  cells  did  not  influence  the  CD23 
derived peptides binding to SMS SB cells (Figure 4.3B) indicating that SDF 1 does 
not alter binding of these peptides to αVβ5. Mridu Acharya,2008     Chapter 4, 123 
 
SMS SB cells undergo apoptosis in LCD culture conditions 
276, therefore we used 
these culture conditions to study their survival and subsequent proliferation. The 
inhibition  of  cell  proliferation  by  U0126  demonstrated  that  basal  ERK 
phosphorylation is necessary for the survival of SMS SB cells; in the presence of 
U0126 the cells rapidly undergo apoptosis. The ERK phosphorylation observed 
following  sCD23,  RKC containing  peptides  and  15F11  treatment  demonstrated 
that the proliferation induced by ligation of αVβ5 with sCD23 is induced via the 
ERK signalling pathway. The enhancement in proliferation noted with SDF 1 and 
sCD23 correlated well with the sustained increase in ERK phosphorylation with 
SDF 1 and sCD23. This was verified by similar enhancement seen with the CD23 
derived peptides and 15F11 antibody. Moreover, PDGF showed the same effect 
as SDF 1 in enhancement of sCD23 driven ERK phosphorylation. As in the case of 
SDF 1,  this  enhancement  of  ERK  phosphorylation  correlated  well  with  the 
potentiation  of  cell  proliferation  seen  with  PDGF  and  sCD23  co stimulation 
(Figure  4.7A  and  B).  Other  signalling  molecules  could  also  be  involved  in 
regulating SMS SB cell proliferation and the observation that LY294002 inhibited 
the enhancement of αVβ5 mediated proliferation by SDF 1 indicates that AKT 
could be involved in regulation of adhesion independent signalling by integrins. 
This  would  be  consistent  with  other  studies  that  have  reported  that  SDF 1 
activates both ERK and AKT 
123,124,305,306.  
Many  other  cytokines  are  known  to  modulate  integrin  function  and  B cell 
precursor  survival.  We  noted  no  similar  enhancement  in  αVβ5 mediated 
proliferation by the cytokines IL 7, IL 3, IL 4 and IL 11. Therefore, we did not 
assess  ERK  signalling  pathway  activation  following  treatment  with  these 
cytokines.  However, it is possible that some combination of these cytokines, 
with  or  without  SDF 1,  might  influence  αVβ5 mediated  proliferation.  For 
example, recent work by Juarez, et al., shows that interaction of SDF 1, IL 3 
and IL 7 induce proliferation of ALL cells co cultured with stromal cells. This 
study  shows  that  IL 7  alone  does  not  induce  ERK  activation  but  there  is 
synergistic ERK activation following IL 7 and SDF 1 co stimulation 
306. However, 
the ALL cells were propagated on stromal cells and the effects on ERK and other 
signalling  pathways  would  have  been  affected  by  multiple  adhesion  contacts 
between the ALL cells and stromal cells. Therefore, the Juarez data illustrate  Mridu Acharya,2008     Chapter 4, 124 
 
convincingly  that  ERK  phosphorylation  can  occur  in  an  adhesion dependent 
manner, while our data demonstrate the synergistic activation of ERK signalling 
can also occur when αVβ5 is stimulated using soluble ligands in an adhesion 
independent assay.  
With regard to the influence of other cytokines it was particularly interesting to 
observe that IL 3 and IL 4 potentially could influence αVβ5 expression although 
these  cytokines  did  not  influence  αVβ5 mediated  proliferation.  IL 4  has 
previously  been  shown  to  inhibit  pre B  cell  proliferation 
307  and  to  induce 
differentiation  of  murine  precursor  B  cells 
308  and  therefore  it  would  be 
interesting to assess further the role of IL 4 on  αVβ5 expression. Although these 
cytokines tested differ from SDF 1 which is a chemokine, because of the well 
established role of these cytokines in precursor B cell growth and development 
we  assessed  their  role  in  the  same  manner  as  SDF 1  instead  of  investigating 
other chemokines.  
Finally, PDGF enhanced the proliferation induced via αVβ5 in a manner similar to 
that observed with SDF 1. Interestingly, a previous study showed that early pre B 
cells,  but  not  mature  B  cells,  express  the  PDGFRβ 
309.  PDGF  was  shown  to 
promote proliferation of these cells and not of more mature or even immature 
pre B cells 
309. PDGF has previously been shown to interact with the integrin 
αVβ3  and  to  stimulate  proliferation  of  oligodendrocytes  by  activation  of  this 
integrin in adhesion dependent manner 
310. Therefore it is plausible that PDGF 
and  αVβ5  also  interact  and  are  involved  in  mediating  adhesion independent 
proliferation.  Further  studies  would  be  needed  to  investigate  interaction  of 
PDGF  and  αVβ5  integrin.  Moreover,  further  experiments  are  also  required  to 
assess αVβ5 mediated proliferation after blocking the PDGF receptor in order to 
confirm the role of PDGF in enhancing αVβ5 mediated proliferation. 
The data indicate that αVβ5 synergises with two distinct signalling pathways, via 
a tyrosine kinase receptor (PDGFR β) and G protein coupled receptor (CXCR4), 
to promote ERK phosphorylation and pre B cell growth. It will be important to 
determine the common molecules downstream of both these pathways leading 
to ERK phosphorylation to understand further the mechanisms involved in αVβ5 
mediated  cell  proliferation.  Both  PDGFR β  and  CXCR4,  as  well  as  the  ERK Mridu Acharya,2008     Chapter 4, 125 
signalling pathway are targets for drug therapies, and the interaction of these 
receptors  with  the  αVβ5  integrin  need  to  be  explored  in  order  to  evaluate 
whether
 they have potential as a new therapeutic strategy for ALL since αVβ5 
was shown to be highly expressed in ALL cells (Borland, et. al., 2008 manuscript 
submitted). 
B  cell  development  in  different  compartments  of  the  haematopoietic 
microenvironment  is  accompanied  by  various  stage specific  changes  that  are 
critical for proliferation, differentiation and maturation of the cells into later 
developmental stages.  A range of adhesion and signalling molecules controlling 
each  stage  are  not  only  key  to  understanding  the  progression  into  the 
developmental pathway but also in developing therapies for neoplasias that arise 
in different stages of B cell development.   
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5  CD23-αVβ5 Interactions in Murine B Cells 
5.1 Introduction 
Cytokine like activity is known to be unique to human CD23 
231. The RKC motif 
on human CD23 that is bound by the integrin αVβ5 is QKC (gln lys cys) in the 
murine  CD23  sequence.  This  suggested  the  hypothesis  that  the  arginine  172 
(R172) on the RKC motif is critical for the cytokine like activity of human CD23. 
We  investigated  the  importance  of  the  RKC  motif  for  CD23  and  integrin 
interaction by assessing the activity of human sCD23 and CD23 derived peptides 
on murine B cell precursors. 
5.2 Results 
5.2.1 Human sCD23-derived peptides bind to murine B cells  
Figure 5.1 shows that the human CD23 derived, biotinylated peptides (#9 12), all 
containing the RKC motif, bind significantly to murine bone marrow B cells when 
compared with the negative control peptide #17 that lacks the RKC motif. The B 
cell population in the bone marrow was identified using the B220 antibody and 
similar binding to peptide #9 is seen in B220
+ B cells from murine spleen. In both 
the  bone  marrow  and  spleen  there  are  B220
   populations  that  also  bind  the 
peptides (Figure 5.1), indicating other cell types apart from  B cells also bind the 
peptides. In the B220
+ compartment from the bone marrow, the majority of the 
cells bind to the peptides, but there is a small percentage of cells in the bone 
marrow that are B220
+ but do not bind the peptides (especially in the cases of 
peptide  #10  and  #11).  As  the  bone  marrow  cells  comprise  a  heterogenous 
population  of  cells  at  different  stages  in  development,  this  could  indicate  a 
difference in αVβ5 expression in cells of different stages. Binding of the CD23 
derived peptides was also shown in a murine pro B cell line, BAF03. As shown in 
figure 5.2A the CD23 derived peptides (#9 #12) bind significantly to BAF03 cells 
(shown  in  grey)  in  comparison  the  negative  control  peptide  #58  (shown  as  a 
black line). BAF03 cells displayed a characteristic feature of two populations, 
one with strong peptide staining and the other negative for peptide binding. This  Mridu Acharya,2008     Chapter 5, 127 
 
feature has also been observed in some human cell lines previously and could 
reflect  the  cell  cycle  status  of  the  cells.  We  also  assessed  the  binding  of 
biotinylated  sCD23  to  the  BAF03  cells.  Figure  5.2B  illustrates  the  binding  of 
sCD23  to BAF03 cells in comparison to binding of the peptides. At 1µg/ml sCD23 
showed significant binding to the BAF03 cells, although the binding was less than 
that observed for the peptides. Furthermore, no binding of sCD23 was observed 
at  250ng/ml,  which  was  the  concentration  of  sCD23  used  for  functional 
experiments in human cell lines. Therefore, the higher concentration  of sCD23 
was used for functional studies in the BAF03 cell line.  
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Figure   5.1 Binding of CD23-derived peptides to murine bone marrow and splenic B cells. 
 
Primary murine bone marrow cells and spleen cells were stained simultaneously with B220-PE 
antibody and biotinylated peptides {visualised with Streptavidin-QR (SA-QR)}. Peptide #17 lacking 
the RKC motif was used as a negative control peptide and quadrant gates on the insets are based 
on the unstained sample and staining for the negative control peptide.The upper right quadrant 
represents  B220
+  cells  that  bind  the  peptides.  Data  represent  three  independent  staining 
procedures. 
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Figure   5.2 Binding of CD23-derived peptides and sCD23 to BAF03 murine pro-B cell line. 
 
 (A) Fluorescence intensity histograms for binding of biotinylated peptides #9-#12 to BAF03 cells 
was detected using SA-QR.  The top row in panel A represents antibody staining for BAF03 cells 
with CD19 and B220 antibodies as B cell specific markers and Thy 1.2 as T- cell marker. Binding of 
peptides with the RKC motif is shown as grey shaded area and binding of the negative control 
peptide #58 is shown as black line. (B) Binding of sCD23 (1 g/ml) in comparison to binding of 
peptide #9 and #11 (1 g/ml) to BAF03 cells. Peptide binding was detected using streptavidin-PE. 
In each case binding of the peptides or sCD23 in grey shaded area is compared with binding to the 
negative control peptide shown as black line. 
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5.2.2  Arginine  172  (R172)  influences,  but  is  not  mandatory  for, 
peptide binding 
In order to assess further the importance of the RKC motif on human CD23, the 
effect upon binding of various substitutions in the RKC motif of peptide #9, #11 
or #12 was assessed. As shown by the mean fluorescence index (MFI) for binding, 
peptides  with  scrambled  sequences  (9SCR,  11SCR)  and  peptides  without  the 
arginine in the RKC motif (peptides with 9R Q, 11R Q and 11R K mutations) all 
bind  to  BAF03  cells,  indicating  that  the  arginine  172  itself  is  not  critical  for 
binding  (Figure  5.3A).  However,  binding  of  these  peptides  is  significantly 
reduced when compared to the MFI for binding of wild type peptides #9 #12. 
Peptides  #9  and  #12  with  replacements  (R A,  RK AA,  K A and  C S)  were  also 
assessed  for  binding  to  BAF03  cells.  The  peptides  with  R A,  RK AA  and  K A 
mutations bind to the cells but peptides with RK AA and C S mutations showed 
significantly reduced binding (Figure 5.3B).   
Peptide 9R Q, representing the sequence at the αVβ5 binding motif in murine 
CD23 also binds to the cells, but the binding is lower compared to peptide #9 
(Figure 5.3A). Peptide 11R Q representing the same substitution shows a greater 
reduction in binding when compared to wild type peptide #11. These peptides 
have  different  affinities  of  binding  to  the  integrin  αVβ5  (A.  Edkins,  personal 
communication) and 
232 and therefore the replacements might affect the binding 
of  each  peptide  in  a  different  manner.  Furthermore,  the  peptide  9C S 
substitution almost completely inhibits the binding ability of both  peptide #9 or 
#12 (Figure 5.3B) suggesting that perhaps the peptides work best as disulphide 
bonded dimers. Previous SPR analysis have also demonstrated that peptide 9C S 
does not bind to the to αVβ5 integrin (A. Edkins, personal communication) 
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Figure   5.3 Importance of the RKC motif in CD23-derived peptides for binding to BAF03 cells. 
 
Mean fluorescence Index (MFI) data derived from FACS analysis for  binding of the peptides #9-
#12 to BAF03 cells was compared with the MFI for binding of peptides with different substitutions in 
the  RKC  motif.  Peptide  #58  was  used  as  a  negative  control  peptide  to  assess  binding.  (A)  A 
comparison  of  binding  of  wild  type  peptides  #9-#12  and  peptides  with  the  original  sequences 
scrambled as well as peptides with R-Q and R-K substitution. (B) Depicts comparison of peptide #9 
or #12 wild-type with peptides with indicated substitutions in the RKC motif. Data are representative 
of 3 independent experiments. 
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5.2.3 BAF03 cells express the integrin αVβ5 but not αVβ3 
Well characterised  antibodies  for  the  murine  αVβ5  heterodimer  are  not 
commercially available, therefore we used a rabbit anti human β5 antibody to 
confirm the expression of this subunit on BAF03 cells. Surface expression of the 
β5  subunit  was  confirmed  by  cell  surface  biotinylation  of  BAF03  membrane 
proteins  followed  by  western  blot  using  the  anti human  β5  antibody  (Figure 
5.4B).  The  murine  β5  subunit  is  known  to  be  of  approximately  95  kDa  and 
western blot with the human anti β5 resulted in a product of slightly less than 97 
kDa. Since the β5 subunit cannot reach cell surface membrane without pairing 
with the αV subunit 
311 expression of the β5 subunit was used as an indication of 
expression  of  the  αVβ5  heterodimer.  Expression  of  the  β3  subunit  was 
determined  by  FACS  analysis  using  a  commercially  available  anti mouse  β3 
antibody. As shown in figure 5.4A there was no staining for the β3 antibody when 
compared to the isotype control antibody in BAF03 cells. 
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Figure   5.4 Expression of the β3 and β5 integrin subunits in murine pro-B cell line BAF03. 
 
 (A) FACS staining for the murine anti-β3 antibody is shown as grey shaded area and the isotype 
control antibody staining is shown as black line. (B) Lysates from surface biotinylated BAF03 cells 
were  incubated  with  streptavidin-agarose  beads  and  separated  by  SDS-PAGE,  transferred  to 
nitrocellulose membrane and probed with either anti- β5 or β3 antibodies. A band of less than 97 
kDa was detected in western blot using anti- β5 antibody and no band was detected with the anti-
β3 antibody (data not shown). 
 
 
  
A  B Mridu Acharya,2008     Chapter 5, 133 
 
5.2.4 BAF03 cells proliferate in response to human sCD23-derived 
peptides or sCD23 
 Data from the human cell line work (Chapters 3 & 4) indicated that the αVβ5 
CD23 interaction sustains proliferation of some of the cell lines expressing the 
αVβ5 integrin. We also assessed proliferation of the murine BAF03 cell line in 
response to sCD23 or peptide treatment 
BAF03 cells are IL 3 dependent for survival 
273 and the cells did not survive in 
culture without IL 3 in the presence of the CD23 derived peptides alone. In the  
presence  of  IL 3  alone,  the  BAF03  cells  proliferated  effectively  in  a  dose 
dependent manner without any addition of serum (Figure 5.5A). However, when 
the peptides were used with a sub optimal concentration of IL 3 (1ng/ml), cell 
proliferation was greatly enhanced in the presence  of 10 or 5 g/ml peptides 
(Figure 5.5A and 5.5 B). Figure 5.5B depicts the proliferative response of BAF03 
cells in response to the human sCD23 derived peptides #9, #12 and long peptide 
(LP).  In  the  human  cell  line  system,  peptide  #9  and  LP  induced  the  best 
proliferative response, and the proliferation response of the BAF03 cell line is 
similar  to  this.  The  negative  control  peptide  #8  showed  no  effect  in  cell 
proliferation either alone or in combination with sub optimal IL 3. At 1ng/ml IL 
3 there is a very slight proliferative response in comparison to untreated cells 
and  this  response  is  significantly  enhanced  in  the  presence  of  the  peptides. 
Stimulation  of  BAF03  cells  with  1ng/ml  IL 3  supplemented  with  5µg/ml  or 
10µg/ml peptide #9 induced a sustained increase in proliferation compared to 
cells  exposed  to  1ng/ml  IL 3  only  (SI  of  4  and  2  respectively  for  peptide  #9 
induced cell proliferation).  
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Figure 5.6A illustrates that proliferation of BAF03 cells induced by peptide #9 is 
reduced when the RKC motif is replaced by QKC in the 9R Q peptide. This is 
important because the 9R Q peptide represents the QKC motif present in murine 
CD23.  The decrease in proliferation is obvious at 10µg/ml but less so at 5µg/ml 
of peptide. At 5µg/ml peptide #9R Q also has some significant effect on cell 
proliferation but nevertheless it is slightly less than peptide #9 (P<0.05).  Figure 
5.3B  demonstrated  that  the  C S  substitution  in  the  RKC  completely  inhibited 
binding of peptide #9 or #12 to BAF03 cells. This inhibition of binding correlates 
well with the inability of the peptide 9C S to induce proliferation compared to 
peptide 9 as illustrated in figure 5.6B. This indicates that the cysteine residue in 
the  RKC  motif  influences  the  binding  and  activity  of  these  peptides.  The 
peptides would be expected to form intermolecular disulphide bonds and the 
fact  that  the  substitution  of  cysteine  with  serine  inhibits  the  proliferative 
capapcity of peptide #9 is consistent with the interpretation that the formation 
of  disulphide  bonded  peptide  dimers  is  necessary  for  biological  activity.  The 
existence  of  the  peptide  as  disulphide  bonded  dimers  was  also  tested  by   
Ellman’s test for free sulphydryl groups, (A . Edkins, personal communication). 
This notion was further tested by using 2 Mercaptoethanol (2 ME) to reduce the 
inter peptide disulphide bonds as BAF03 cells grow in culture with 2 ME and it 
does not interfere with their growth capacity. Reduction with 12mM 2 ME greatly 
reduced peptide #9 bioactivity but 6mM 2 ME did not. The data strengthen the 
idea  that  the  disulphide  bonded  peptide  dimers  may  be the optimally  active 
form.  
 
 
 
 
 
 Mridu Acharya,2008     Chapter 5, 135 
 
 
 
 
 
 
Figure   5.5 Proliferation of BAF03 cells in response to CD23-derived peptides. 
 
(A) Cultures of BAF03 cells (5000 cells/well) were propagated with the indicated concentration of 
peptides #9 and IL-3 alone or in combination with 1ng/ml IL-3. Proliferation with peptide #9 alone is 
shown as grey bars, peptide #9 with 1ng/ml IL3 as black bars, peptide #33 with 1ng/ml IL3 as 
hatched bars and proliferation with different concentrations of IL3 alone is shown as white bars. 
Proliferation was assessed after 72 h by 
3[H]-TdR incorporation (B) Proliferation of BAF03 cells in 
response  to  indicated  concentrations  of    peptide  #9  #12,  LP  or  peptide  #8  with  sub-optimal 
concentrations  of  IL-3  (1ng/ml).  1ng/ml  IL3  was  used  together  with  the  different  peptides  and 
proliferation with peptide  #9  is shown as black bars, peptide #12 as grey bars, LP as hatched bars 
and peptide #8 as white bars. Bars represent the standard deviation of triplicate determinations, 
with  **p<0.005 indicating increase in proliferation in comparison to the negative control peptide at 
the same concentration or in comparison to untreated cells (in case of IL-3 treatment alone). Data 
are representative of at least three independent experiments. 
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Figure   5.6 Importance of the RKC motif on peptide #9 in mediating proliferation of BAF03 
cell line. 
 
Peptide #9 and 9R-Q and 9C-S were used to assess the difference in proliferation resulting from 
these replacements. (A)  BAF03 cell proliferation in response to the indicated  concentrations of 
peptide #9, 9R-Q and negative control peptide #33 in presence of 1ng/ml IL-3. Proliferation with 
peptide #9 alone is shown as grey bars, peptide #9 with 1ng/ml IL3 as black bars, peptide #33 with 
1ng/ml  IL3  as  hatched  bars  and  peptide  9R-Q  with  1ng/ml  IL3  as  white  bars  (B)  BAF03  cell 
proliferation in response to 5 g/ml  peptide #9, 9C-S or 9A and B (peptide #9 dissolved in buffer 
supplement with 12mM (A) or 6mM (B) 2-ME); all in presence of IL-3 1ng/ml. Bars represent the 
standard  deviation  of  triplicate  determinations,  with  *p<0.05  or  **p<0.005  indicating  increase  in 
proliferation in comparison to the negative control peptide at the same concentration and 
#p<0.05 
indicating a significant difference between proliferation induced by peptide #9 and peptide 9R-Q at 
5 g/ml. Data are representative of at least 3 independent experiments. 
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The  effect  on  proliferation  of  BAF03  cells,  mediated  by  the  CD23 derived 
peptides was verified by assessing proliferation induced by recombinant human 
sCD23. As shown in Figure 5.7, human sCD23 induces a robust increase in cell 
proliferation at 5µg/ml. We observed no significant effect on cell proliferation 
at lower concentrations of 1µg/ml or 0.5µg/ml. The proliferation data clearly 
indicate that human sCD23 derived peptides containing the RKC motif and sCD23 
itself are able to sustain proliferation of murine B cell line BAF03.  
 
 
Figure   5.7 Proliferation of BAF03 cells in response to human sCD23. 
 
Cultures of BAF03 cells (5000cells/well) were propagated in PFHM with the indicated concentration 
of  recombinant  sCD23  (R&D  Systems).  Proliferation  was  assessed  after  72  h  by 
3[H]-TdR 
incorporation. Bars represent the standard deviation of triplicate determinations, with *p<0.05 or 
**p<0.005  indicating  increase  in  proliferation  in  comparision  to  the  untreated  cells.  Data  are 
representative of 3 independent experiments. 
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Proliferation assays with murine bone marrow B cells isolated from mice bearing 
a B cell specific knockout of the αV gene (CD19 cre) were used to investigate 
the  role  of  sCD23  in  proliferation  of  murine  bone  marrow  B  cell  precursors.  
CD19
+ B cells from bone marrow of control or αV knockout mice were harvested 
and grown on OP9 stromal cells with 10% FCS and 1ng/ml IL 7 and used to assess 
proliferation in the presence of human sCD23. As shown in figure 5.8 there was a 
significant increase in cell proliferation following sCD23 treatment (5µg/ml) in B 
cells from control mice but there was no change in proliferation of B cells from 
αV knockout mice with or without sCD23 treatment. Surprisingly, the untreated 
B  cells  from  αV  knockout  mice  had  a  slight  increase  in  proliferation  when 
compared  to  the  untreated  B  cells  from  control  mice  but  sCD23  induced  no 
change in their survival.  
 
 
Figure   5.8 Proliferation of control and αV knockout murine bone marrow B cells in presence 
of human sCD23. 
 
Bone marrow B cells purified from either the control or the knockout mice bone marrow  were 
propagated in the proliferation assay culture on γ-irradiated stromal cell line OP9 and stimulated 
with  5 g/ml  sCD23  or  left  untreated.  Proliferation  was  assessed  after  72  h  by 
3[H]-TdR 
incorporation. Bars represent the standard deviation of triplicate determinations, with *p<0.05 or 
**p<0.005 indicating increase in proliferation in comparision to untreated cells. Data represent one 
experiment (n=1). 
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5.2.5 ERK  phosphorylation  in  response  to  sCD23-derived 
peptides in BAF03 cells 
In the human cell line SMS SB, sCD23 mediated cell proliferation was shown to 
be associated with the activation of ERK phosphorylation pathway (Chapter 4). 
We  therefore  investigated  whether  there  was  a  similar  role  for  ERK 
phosphorylation in BAF03 cells.  
Figure  5.9A  shows  that  peptide  #9  alone  induces  a  very  slight  ERK 
phosphorylation.  However,  IL 3  alone  induces  a  significant  increase  in  ERK 
phosphorylation from 5 30 min. When peptide #9 is used together with IL 3 there 
is a significant increase in ERK phosphorylation from 2 30 min, but this pattern 
of phosphorylation is not very different from ERK phosphorylation stimulated by 
IL 3 alone. Although an earlier onset of ERK phosphorylation is noted (at 2 min) 
with peptide #9 and IL 3, when compared to IL 3 alone, this difference in ERK 
phosphorylation does not clearly explain the enhancement in cell proliferation 
seen with peptide #9 and IL 3 together. 
In  the  proliferation  assays,  an  obvious  difference  in  survival  of  BAF03  cells 
treated  with  peptide  and  IL 3  compared  to  cells  exposed  to  IL 3  treatment 
alone, was observed only after approximately 12 h of initiation of the assay. 
Therefore, we investigated if there was a difference in ERK phosphorylation in a 
longer time course experiment (24 h). Figure 5.9B illustrates that with IL 3 alone 
or with IL 3 plus peptide #9 there is a significant increase in ERK phosphorylation 
from 30 60 min. However, in the cells treated with IL 3 and peptide #9, ERK 
phosphorylation was observed at 4 h and 12 hr that was absent in cells treated 
with  IL 3  alone.  This  could  be  the  reason  we  observe  an  enhancement  in 
proliferation with addition of IL 3 and peptide #9 in comparison to proliferation 
with IL 3 alone.  
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Figure   5.9 ERK phosphorylation in BAF03 cells in response to treatment with CD23-derived 
peptide #9 or IL-3 alone or in combination. 
 
Lysates from treated BAF03 cells were separated by SDS-PAGE and transferred to nitrocellulose. 
Membranes were probed with antibodies to phosphorylated ERK and subsequently stripped and 
reprobed with antibodies to ERK. (A) Western blots for phosphorylated and total ERK in BAF03 
cells treated with peptide # 9 (5 g/ml) alone, IL-3 (1 g/ml) alone or combination of both, at the time 
points shown. Figure 5.8 (B) illustrates western blots for phosphorylated and total ERK in BAF03 
cells unstimulated, stimulated with peptide #9 (5 g/ml) and IL-3 (1ng/ml) or IL-3  (1 g/ml) alone, for 
a longer time course up to 24 hr. Blots represent three independent experiments. 
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We also assessed cell proliferation in the presence of the MEK inhibitor U0126 in 
order  to  elucidate  further  the  role  of  the  ERK  phosphorylation  pathway  in 
mediating proliferation and/or survival of BAF03 cells. As shown in figure 5.10, 
LP induced a significant increase in cell proliferation in comparison to untreated 
cells (cultured with 1ng/ml IL 3 alone) or cells exposed peptide #8 treatment. 
This  proliferative  effect  was  abrogated  by  treatment  with  the  MEK  inhibitor 
U0126.  DMSO  was  used  as  a  vehicle  control  as  it  was  the  solvent  for  the 
inhibitors  and  was  without  any  effect.  Although  the  MEK  inhibitor  abolished 
proliferation  we  also  observed  total  inhibition  of  proliferation  of  BAF03  cells 
with  the  PI3K  inhibitor  LY294002.  Therefore,  the  enhancement  in  cell 
proliferation observed via IL 3 and the CD23 derived peptides or CD23 could also 
be potentially mediated via the PI3K signalling pathway. 
 
Figure   5.10 10 Effect of inhibition of ERK and PI-3K signalling on LP-induced proliferation of 
BAF03 cells. 
 
BAF03 cells were treated with (10µM) U0126, 50µM LY294002, equivalent volume of DMSO or  left 
untreated for 30 min prior to plating at 5000 cells/well; proliferation  was assessed by 
3[H]-TdR 
incorporation after 72 h of culture. Proliferation induced by the long peptide in presence of 1ng/ml 
IL-3 was compared with the cells treated with the two different inhibitors or vehicle control DMSO. 
Peptide #8 was used as a negative control peptide. 
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5.2.6 Discussion 
Human sCD23 displays pleiotropic cytokine like activities and in pre B cell lines 
the  sCD23 αVβ5  interaction  was  shown  to  sustain  proliferation  (Chapter  3). 
However, the cytokine like activities of sCD23 in vitro have not been shown in 
murine  cells.  Murine  CD23  is  a  49  kDa  sialoglycoprotein  and  shares  only  57% 
amino  acid  homology  with  the  human  CD23  molecule.  CD23
 /   mice  display 
normal  lymphocyte  development,  normal  B  cell  proliferation  and  germinal 
centre formation but have impaired IgE dependent functions 
312. 
Murine CD23 lacks the inverse RGD motif present on human sCD23, as a natural 
truncation and there are other known structural differences between human and 
murine  CD23;  these  differences  could  provide  more  understanding  into  why 
human CD23 and not murine CD23, possesses cytokine like activity. In relation to 
human sCD23 αVβ5 interaction it was interesting to observe that the RKC motif 
bound  by  αVβ5  is  present  as  QKC  on  murine  CD23.  We  investigated  whether 
murine  B  cell  precursors  could  bind  and  respond  to  human  CD23 derived 
peptides and how important arginine 172 on the RKC motif of the peptides was 
in regulating their activity. 
We first compared the binding of various CD23 derived peptides and sCD23 to 
murine B cells and then assessed proliferation mediated by the peptides and 
sCD23  itself.  Binding  of  the  CD23 derived  peptides  and  sCD23  to  αVβ5  has 
already  been  studied  in  human  cell  lines  and  also  the  interactions  of  the 
peptides  and  sCD23  to  αVβ5  has  been  extensively  characterised  using  SPR 
analysis (A. Edkins, personal communication) and 
232. Therefore, we used the 
different peptides available to assess their binding to murine B cells.   
 
 
 
 
 Mridu Acharya,2008     Chapter 5, 143 
 
CD23 derived peptides #9 #12 containing the RKC motif bound to murine bone 
marrow B cells, splenic B cells and to BAF03 cells, a murine pro B cell line.  In 
all the cell populations, peptides with the RKC motif showed strong binding and 
peptides with substitutions in the RKC motif showed reduced binding. As the 
substitutions (R Q and R K) and scrambled sequences did not abolish binding, 
peptides with further replacements in the RKC sequence were also assessed for 
binding.  In  figure  5.3B  peptides  with  9RK AA  mutation  show  greatly  reduced 
binding compared to peptides with 9K A mutations. In comparison to binding of 
peptide #9, binding of peptide #9R K is reduced by about 20 30% while binding of 
peptide 9RK AA is further reduced by about 50%.  Peptides with K A substitution 
retain  slightly  more  basic  characteristic  compared  to  peptides  with  RK AA 
substitutions  where  both  the  basic  amino  acids  (arginine  and  lysine)  are 
converted to alanine. This indicates that the integrins require the basic domains 
on the peptides for binding. This could also explain the binding seen in peptides 
with R Q and R K mutations as these peptides still retain some basic residues and 
peptides with the scrambled RKC sequences also retain the basic characteristics 
of the RKC motif. Similar results have also previously shown the importance of 
the basic residues for binding in human B cell line 
232.  
CD23 derived  peptides  #9,  #12  and  the  LP  all  induced  a  strong  proliferative 
response  in  the  BAF03  cells  when  used  in  combination  with  sub optimal 
concentrations of IL 3. The data indicate that the peptides synergise with IL 3 to 
induce  a  proliferative  response.  A  strong  effect  in cell  proliferation  was  also 
confirmed with the commercially available recombinant human sCD23.  These 
cells express the αVβ5 integrin as shown in figure  5.4B and the proliferation 
results indicate that the αVβ5 CD23 interaction is important for proliferation of 
murine  B  cells.  Peptide  #9R Q,  representing  the  sequence  in  murine  sCD23 
showed  reduced  binding  to  the  cells  in  comparison  to  peptide  #9  and  in 
functional  experiments  proliferation  induced  by  peptide  #9  is  significantly 
reduced by substitution of the glutamine for arginine in the RKC motif; although 
the  proliferative  effect  is  not  completely  inhibited  with  peptide  9R Q.  This 
implies  that  the  arginine  on  the  RKC  motif  is  important  for  the  binding  and 
inducing cell proliferation but not critical since replacement of the arginine still 
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the lack of ability to induce proliferation by peptide 9C S and peptide #9 treated 
with  2 ME  indicated  dimers  of  these  peptides  may  be  necessary  for  their 
activity.  
Interestingly, a higher concentration of human sCD23 was required to produce a 
response in the BAF03 cells in comparison to human cells (5 g/ml vs. 250ng/ml). 
The binding affinity of human sCD23 to the murine integrin could be much lower 
than  the  equivalent  affinity  for  human  integrin  and  therefore  a  higher 
concentration  of  ligand  might  be  required.  These  results  establish  the 
importance of human sCD23 and the CD23 derived peptides with the RKC motif 
in mediating cell proliferation; however we did not have access to any murine 
sCD23 protein and proliferation data with murine sCD23 would be important to 
verify the unique role for human sCD23. 
In order to confirm that the CD23 mediated proliferation was via αVβ5 integrin 
we performed preliminary experiments with B cell precursors from the B cell–
specific αV conditional knockout mice. The data showed that sCD23 mediated 
proliferation was not seen in B cell precursors from bone marrow of αV knockout 
mice, but B cell precursors from the control mice showed an enhancement in 
cell  proliferation  after  sCD23  treatment.  These  experiments  will  have  to  be 
repeated to confirm the effect of the αVβ5 sCD23 interaction. Due to the lack of 
an  effective  RNAi  system  in  human pre B cell  lines,  the  B cells  from  the  αV 
knockout mice provide an important model to confirm αVβ5 CD23 interactions. 
The  ERK  phosphorylation  data  indicated  that  perhaps  ERK  phosphorylation  at  
later time points (4 h and 12 h) could be responsible for the enhancement in 
proliferation  noted  with  peptide  #9  and  IL3  together.  However,  inhibition  of 
peptide #9 mediated cell proliferation by both U0126 and LY294002 indicated 
that  both  the  ERK  and  the  PI3K/AKT  pathway  could  be  responsible  for 
enhancement  of  cell  proliferation.  Therefore,  it  will  also  be  important  to 
investigate AKT phosphorylation in the same way as ERK phosphorylation. 
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CD23 is reported to interact with the b2 integrins on murine monocytes
204 and 
avb3 expression in murine B cell precursors has been reported 
313 but there are 
no data to suggest that murine CD23 interacts with the av family of integrins. 
Previous studies have shown that CD23 or its soluble fragments have potential 
regulatory effects on hematopoiesis. It was shown to promote differentiation of  
T cell precursors in synergy with IL 1α 
207 and also to induce proliferation of 
myeloid stem cells and down regulate proliferation of  myeloid leukemic cells 
210.  It  is  important  to  understand  the  differences  in  the  role  of  human  and 
murine  sCD23  not  only  because  sCD23 αVβ5  interactions  can  have  profound 
implications in the growth of human B cells but also because human sCD23 and 
the sCD23 derived peptides can be used in a mouse model system, to study the 
effects of avb5 on B cell precursors. 
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6  Discussion 
The  data  presented  in  this  thesis  demonstrate  that  the  αVβ5  integrin  is 
expressed on pre B cell lines and B cell precursors in the bone marrow and that 
the  αVβ5 CD23  interaction  sustains  proliferation  of  some  pre B  cell  lines. 
Previous work in the laboratory demonstrated that αVβ5 is a receptor for sCD23 
and that this interaction sustains proliferation of the pre B cell line SMS SB.  The 
main  aim  of  this  project  was  to  identify  exactly  at  what  stage  of  B  cell 
development αVβ5 is expressed and is functional.  
Results  in  Chapter  3  demonstrated  that  αVβ5  is  expressed  on  and  sustains 
proliferation of early pre B cell lines. Transitional and more mature B cell lines 
down regulated  αVβ5  expression  and  did  not  proliferate  in  response  to  αVβ5 
ligation. Data in Chapter 4 indicated that this proliferative function of αVβ5 was 
modulated by the chemokine SDF 1 and PDGF, both important molecules in early 
B cell development. This regulation of αVβ5 mediated proliferation was shown 
to be via modulation of the signalling pathways activated downstream of integrin 
and the growth factor or chemokine receptors.  SDF 1 and PDGF treatment both 
enhanced ERK phosphorylation induced via αVβ5 ligation. The role of αVβ5 CD23 
interaction in mediating proliferation of B cell precursors was further confirmed 
in a murine pro B cell line BAF03 as shown by the results in Chapter 5.  
6.1 αVβ5 Expression  
Different  pre B  cell  lines  were  characterised  into  distinct  stages  of  B  cell 
development based on cell surface marker expression, and αVβ5 expression was 
assessed at each stage of development (Chapter 3). All pre B cell lines showed 
significant levels of αVβ5 expression and transitional B cell lines such as Raji, 
Daudi and Ramos showed low levels or no αVβ5 expression (Figure 3.3 and 3.4). 
Mature B cell lines like SKW and IB4 also showed low or no αVβ5 expression 
(Figure 3.4). These data indicate that αVβ5 expression is down regulated as the 
pre B cells differentiate into transitional B cells and more mature B cells. This 
was supported by the finding that αVβ5 expression decreases in the immature B 
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cell line from which 1E8 was derived (Figure 3.3). The expression of integrin 
αVβ3, which is closely related to αVβ5 and is also known to bind sCD23, was 
more difficult to define. Although it was obvious that the levels of this integrin 
were higher in the mature B cell lines SKW and IB4, in comparison to other cell 
lines, most of the cell lines seemed to express low levels of this integrin.  
In  order  to  correlate  the  data  from  the  cell  lines  to  bone  marrow  B  cell 
precursors,  αVβ5/αVβ3  expression  was  analysed  in  bone  marrow  B  cell 
precursors, using a similar panel of cell surface markers used to characterise the 
pre B cell lines. The data indicated that αVβ5 was expressed in a percentage of 
pre B  cells  in  the  bone  marrow  (CD19
+/CD9
+  and  CD19
+/CD10
+)  (Figure  3.15). 
Furthermore the data also indicated that αVβ3 integrin was expressed in similar 
pattern to αVβ5 (Figure 3.14, 3.17). Although αVβ5 expression was higher than 
αVβ3 expression, the general pattern of expression was similar with relation to 
most of the markers. A clear down regulation of αVβ5 expression could not be 
detected in the bone marrow B cell precursor population as αVβ5 expression was 
noted in CD19
+/κ
+ cells (Figure 3.18), which are more mature than the pre B 
cells owing to the expression of the kappa light chains. Therefore we could not 
conclude that αVβ5 expression is exclusive to pre B cells. We could not stain any 
CD34
+ pro B cells or any mature B cells from the blood, and so a more extensive 
staining of B cell precursors from the bone marrow and B cell populations from 
peripheral blood is required to confirm αVβ5 expression and down regulation of 
this expression in mature B cells.  
6.2 αVβ5 Function  
The sCD23 αVβ5 interaction was previously shown to sustain proliferation of the 
SMS SB cell line. Therefore, the proliferative response to sCD23 treatment was 
used to assess αVβ5 function in the different cell lines (Chapter 3). The pre B 
cell lines SMS SB, RS4;11 and 697 proliferated robustly in response to sCD23 and 
sCD23 derived LP treatment (Figure  3.6,  3.7  and  3.9),  and this  response  was 
mimicked  by  the  15F11  MAb  which  binds  to  αVβ5  integrin  (Figure  3.11), 
indicating that the sCD23 dependent proliferation is mediated via this integrin. 
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response and the MAb AMF7 which binds the αV subunit induced proliferation in 
SMS SB cells but failed to induce a proliferative response in the RS4;11 cell line. 
A slight proliferative response to sCD23 treatment was observed in the pre B cell 
line Blin1 and in the cell lines Daudi and SKW (Figure 3.7 and 3.8). However, all 
of these responses were much lower in comparison to the response of SMS SB, 
RS4;11 and 697 cells.  
The  SMS SB  and  RS4;11  cell  lines  had  very  low  levels  or  lacked  surface    
expression  (Figure  3.1),  suggesting  that  perhaps  very  early  B  cell  precursors 
(either pro B cells or  pre BI) respond well to αVβ5 stimulation. The CD10
  status 
of  both  these  cell  lines  (Figure  3.1)  also  indicated  that  the  αVβ5 mediated 
growth  response  was  restricted  to  cells  at  a  specific  stage  of  development. 
However, B cell precursors in the normal bone marrow, including the pro B cells 
are CD10
+ and the cell line 697 which was CD10
+ also responded well to αVβ5 
stimulation, indicating that it is not only the CD10
  cells that respond to αVβ5 
stimulation. However, a common feature of these three cell lines was that they 
all stained well with the 15F11 antibody that recognises the αVβ5 heterodimer 
(Figure 3.3). While the αVβ5 MAb P1F6  indicated similar levels of staining in all 
the pre B cell lines tested, 15F11 staining for αVβ5 was higher in SMS SB, 697 
and RS4;11 and lower in all other pre B cell lines (Figure 3.3).  
Another  common  characteristic  of  these  three  responding  cell  lines  was  that 
they all expressed very low levels or none of the integrin αVβ3 in comparison to 
the other pre B cell lines (Figure 3.3). These data indicate that αVβ5 mediated 
proliferation is important in early B cell precursors at a specific stage in B cell 
development. However, a confirmation of this proliferative response from bone 
marrow B cell precursors would be needed to define the exact window of B cell 
development where αVβ5 mediated proliferation is important. The proliferation 
data presented for bone marrow B cell precursors was on CD19
+/κ
  B cells (Figure 
3.20). These data indicated that B cell precursors in the bone marrow that have 
not begun to express the κ light chain but express αVβ5 integrin, can proliferate 
in response to sCD23 stimulation but the κ positive B cell precursors do not. This 
is  in  agreement  with  the  hypothesis  that  αVβ5 mediated  proliferation  is 
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detailed analysis of the proliferation of bone marrow B cell precursors in the 
pro B and pre B stage would be required to make specific conclusions relating to 
the stage of B cell development where αVβ5 mediated proliferation could have 
important implications. Together with this, a study of proliferation of B cells 
from patients with ALL would also be needed to establish the importance of 
αVβ5 mediated cell proliferation in neoplastic cells. Previous results from the 
lab demonstrated that αVβ5 is highly expressed in B cells from patients with 
ALL. As ALL is malignancy of early B cell precursors in the bone marrow, αVβ5 
could be delivering an important proliferative signal to these cells depending on 
their maturation stage. 
The cell line data clearly indicate that some pre B cells proliferate in response 
to αVβ5 stimulation and this could have important implications for growth and 
proliferation  not  only  of  bone  marrow  B  cell  precursors  expressing  αVβ5  but 
more importantly, of leukemic B cell precursors. Moreover, the cell line RS4;11 
is a well known MLL rearranged leukemic cell line and the SMS SB cells have a 
similar  phenotype  to  RS4;11.  The  fact  that  both  of  these  cell  lines  show  a 
significant  proliferative  response  to  αVβ5  indicates  that  this  stage specific 
proliferative  response  to  αVβ5  could  be  very  important  in  survival  of  some 
specific  types  of  leukemic  cells.  Human  ALL  frequently  represents  clonal 
expansion  of  a  CD19
+  B lineage  cells  at  one  of  several  stages  of  B cell 
development and the t(4;11)(q21;q23)
 cytogenetic abnormality, characterized by 
expression of the MLL/AF4
 fusion protein is a frequent subtype of infant acute 
leukaemia and some adult leukaemia. Leukemic blasts expressing MLL/AF4
 are 
arrested  at  an  early  progenitor  stage  with  lymphoid  or  monocytoid
 
characteristics.  MLL rearranged  B  cell  precursor  ALL  represents  a  more 
aggressive  leukaemia,  particularly  in  infants,  and  is  associated  with  a  poor 
prognosis 
272,314. Therefore, the fact that αVβ5 stimulates proliferation of these 
cell types indicates that this integrin may have a  very important therapeutic 
potential in the treatment of these leukaemias. 
The proliferative function mediated via αVβ5 was confirmed in the mouse cell 
line BAF03 which expressed the integrin αVβ5 but not αVβ3 (Chapter 5). BAF03 
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survival 
273 and offer a good model to test the proliferative function of αVβ5. 
Due to the lack of murine αVβ5 antibody, αVβ5 expression was confirmed via 
surface biotinylation and αVβ3 expression was confirmed by flow cytometry for 
the expression of the β3 subunit (Figure 5.4). In the presence of sub optimal IL 3 
concentrations,  BAF03  cells  showed  significant  proliferation  in  response  to 
human sCD23 treatment (Figure 5.7)  or stimulation with sCD23 derived peptides 
(Figure 5.5), thus indicating that the proliferative function of human sCD23 can 
be detected in murine B cell studies. In support of this, murine bone marrow  B 
cell precursors also proliferated well in response to sCD23 treatment and murine 
B cells from αV knockout mice did not show similar enhancement in proliferation 
with sCD23 treatment when compared to the B cells from the bone marrow of 
wild type mice (Figure 5.8). These results indicate the importance of the αV 
integrin and sCD23 in mediating this proliferative response. 
6.3 Modulation of αVβ5-mediated proliferative effects by 
molecules important in early B cell development.  
A  variety  of  soluble  factors  as  well  as  contact  interactions  between  the 
precursor  cells  and  the  stromal  microenvironment  dictate  the  fate  of  B  cell 
progenitors. A number of growth factors, chemokines, cytokines and adhesion 
molecules have been described that regulate the survival, differentiation and 
migration of B cell progenitors. In order to assess the importance of the αVβ5 
mediated  proliferation  during  B  cell  development,  the  role  of  cytokines, 
chemokines and growth factors in modulating αVβ5 function was investigated.  
SDF 1, a chemokine with established roles during B lymphopoiesis, enhanced the 
proliferative effect mediated via αVβ5 (Figure 4.1). Furthermore, PDGF had a 
similar effect to SDF 1 in enhancing αVβ5 mediated cell proliferation in SMS SB 
cells (Figure 4.7). As both PDGF and SDF 1 have been implicated in early B cell 
development  these  data  further  support  a  role  for  αVβ5 mediated  cell 
proliferation  in  early  B  cell  developmental  stages.  However,  surprisingly,  the 
cytokine  most  implicated  in  early  B cell  proliferation,  IL 7,  did  not  show  a 
similar effect to SDF 1 (Figure 4.5). Although the requirement for IL 7 in human 
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have shown that IL 7 induces proliferation of early human B cell precursors 
1,12. 
It  could  be  that  the  requirement  for  IL 7  and  requirement  for  αVβ5  are  at 
slightly different stages of development and they do not overlap, or it could also 
be that concentrations of IL 7 used in the experiments here were different from 
the concentrations of IL 7 required for enhancing the proliferative effect. The 
cytokines  were  all  used  in  the  same  concentration  range  as  SDF 1  and  it  is 
possible  that  these  cytokines  produce  a  response  at  different  concentration 
ranges. Similarly, IL 3 and IL 4 have both been implicated in having different 
roles in B cell development but neither affected the function of αVβ5 in the 
experimental context used (Figure 4.5). Expression data indicate that perhaps 
IL 4 could modulate αVβ5 expression, which might have important implications, 
and none of the other treatments used affected αVβ5 expression (Figure 4.6).   
A number of other molecules, such as Flt3 ligand 
90, are known to be important 
in early B cell development and are also known to influence integrin function 
and  therefore  could be  regulating  αVβ5  function.  Similarly,  the  role  of  αVβ5 
integrins  cannot  be  studied  in  isolation  from  other  integrins.  Not  only  could 
other αV integrins be modulating αVβ5 function but also other integrins such as 
the β1 and β2 families have been implicated in hematopoiesis in an adhesion 
dependent manner. Therefore, these integrins could be having an important role 
in modulating αVβ5 function in an adhesion dependent or independent manner. 
So,  it  would  also  be  important  to  assess  whether  ligation  of  the  β1  and  β2 
integrins influences αVβ5 mediated cell proliferation. Moreover, the role of the 
αVβ5 integrin function also cannot be assessed without considering the matrix 
proteins and in particular, vitronectin since αVβ5 is known to bind primarily to 
vitronectin.  
Previous work regarding the αVβ5 CD23 interaction indicated that αVβ5 binds to 
the  RKC  motif  on  sCD23  and  that  RGD  peptides  do  not  influence  the  αVβ5 
mediated proliferation of SMS SB cells. Furthermore, the αVβ5 MAb P1F6 that 
blocks binding to vitronectin did not elicit a proliferative response and did not 
influence  sCD23 mediated  proliferation  either  (data  not  shown).  Vitronectin 
coated on to 96 well plates and soluble vitronectin were both used to assess 
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conclusive data to suggest either increase or decrease in αVβ5 mediated cell 
proliferation  in  the  presence  of  vitronectin,  and  vitronectin  itself  did  not 
influence the proliferation of SMS SB cell (data not shown) 
232. Fibronectin alone 
also  did  not  influence  SMS SB  cell  proliferation  or  αVβ5 mediated  cell 
proliferation (data not shown).  
A key molecule guiding B cell development is the pre BCR on precursor B cells 
and BCR on mature B cells. Pre BCR signalling has not only been implicated in B 
cell differentiation but cross linking the pre BCR in the presence of other soluble 
factors such as IL 7 is known to induce B cell proliferation 
315,316. Therefore, it 
will  be  important  to  determine  whether  pre BCR  ligation  influences  αVβ5 
mediated cell proliferation.  
Proliferation  and differentiation  are interlinked and  interdependent  events  in 
many ways. Therefore, it was hypothesised that αVβ5 expression was linked to B 
cell differentiation. This seemed particularly plausible as αVβ5 function seemed 
to be important in early B cell precursors. The influence of pre BCR on αVβ5 
expression was assessed in the pre B cell lines SMS SB and Blin1. However, pre 
BCR  cross linking  by  anti    MAb  did  not  influence  αVβ5  expression  and  αVβ5 
stimulation did not influence surface   expression (data not shown). A signalling 
complex, termed pro BCR, competent in transducing signals has been recently 
reported and it was demonstrated that cross linking of pro BCR on pro B cells 
isolated  from  bone  marrow  induced  phosphorylation  of  various  signalling 
molecules including Syk, PI3K and ERK and that the pro B cells could be induced 
to  differentiate  to  the  pre B  stage  of  development 
15.  Since  αVβ5  seems  to 
regulate proliferation of early B cell precursors it is possible that it regulates 
differentiation  of  the  pro B  cells  and  therefore  it  would  be  interesting  to 
investigate if ligation of the pro BCR and the subsequent differentiation induced, 
influences αVβ5 function or expression. 
Some preliminary results indicated that expression of κ light chains on Blin1 cells 
resulted in down regulation of αVβ5 expression (data not shown) but cultures of 
Blin1 cells expressing κ light chains could not be established on a long term basis 
to assess this down regulation conclusively.  Evidence for the role of αV integrins 
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associated β integrin subunit during development in different cell systems. It has 
previously  been  shown  that  oligodendrocyte  progenitors  sequentially  express 
αVβ1, αVβ3 and αVβ5 integrins during differentiation in vitro with up regulation 
of αVβ5 and down regulation of αVβ3 
317. Furthermore it was also demonstrated 
that, in these cell types, αVβ3 may regulate cell proliferation and that both 
down regulation of αVβ3 expression and subsequent signalling through αVβ5 may 
be  critical  for  continued  differentiation  in  vitro 
318.  A  similar  developmental 
switch, with up regulation of αVβ3 and down regulation of αVβ5 expression, has 
also been established during osteoclast differentiation 
319. Therefore, it would 
be very interesting to characterise the role of both αVβ5 and αVβ3 and the other 
αV  integrins  during  B  cell  development  with  regard  to  proliferation  and 
differentiation.    This  information  would  be  valuable  in  understanding  B  cell 
malignancies that can arise at specific stages of development due to disruption 
in proliferation and differentiation mechanisms.  
6.4 Signalling via the αVβ5 integrin 
Although  integrins  and  growth  factor  receptors  can  independently  propagate 
intracellular signals, many of the signalling pathways and effectors which are 
activated by integrin ligation are also activated by growth factor stimulation. 
There are two major families of growth factor receptors that signal via distinct 
pathways  and  cooperate  to  regulate  cell  growth:  the  G protein coupled 
receptors (GPCRs) and the receptor tyrosine kinases (RTKs). The GPCRs signal by 
inducing  dissociation  of  heterotrimeric  G proteins  into  Gα  and  Gβγ  subunits, 
each  of  which  initiate  a  specific  response 
320,321,  while  RTKs  are  activated 
following binding of polypeptide growth factors which induces RTK dimerization 
239,322.  A  number  of  studies,  particularly  in  the  adherent  cell  system,  have 
demonstrated that the function of growth factors can be positively modulated by 
integrin mediated cell adhesion.  Both integrins and growth factors are known to 
activate  Rho  family  GTPases,  the  Ras Raf MAPK  pathway,  PI3K,  ribosomal  S6 
(RSK)  and  Jun  amino terminal  kinase  (JNK) 
323,324.  Synergy  between  growth 
factors  and  cell  adhesion  has  been  observed  in  the  activation  of  the  MAPK 
pathway 
325,326  and  PI3K/AKT  pathway 
327.  Coimmunoprecipitation  of  growth 
factor  receptors  with  integrins  has  also  been  shown  in  various  studies;  for Mridu Acharya,2008     Chapter 6, 154 
example,  αVβ3  has  been  found  to  associate  with  PDGFR  or  VEGFR  (vascular 
endothelial  growth  factor  receptor) 
328 331.  Studies  on  cross talk  between  the 
integrins  and  growth  factor  signalling  has  also  given  important  insights  into 
specific  functions  of  the  integrins.  For  example,  cell  adhesion  and  migration 
studies  have  identified  a  critical  role  for  cross talk  between  growth  factor 
receptors  with  the  integrin  αVβ5  but  not  with  αVβ3  during  adhesion  and 
migration on vitronectin 
332. Similarly, it was demonstrated in both chick and 
mouse  models  that  αVβ5 bearing  melanoma  cells  depend  on  ex vivo  pre 
stimulation with IGF (insulin like growth factor) for metastasis, whereas αVβ3 
bearing melanoma cells metastasize in the absence of growth factor treatment 
333. In the haematopoietic cell system, a number of studies have shown that SDF 
1 modulates signals for adhesion and migration via the β1 integrins VLA 4 and 
VLA 5 and the β2 integrin LFA 1 
295. Signalling data from the studies investigating 
modulation  of  αVβ5 mediated  proliferation  by  SDF 1  and  PDGF  (Chapter  4) 
indicated a role for growth factor integrin cross talk in an adhesion independent 
manner leading to enhanced proliferation of SMS SB cells. 
Stimulation of αVβ5 integrin using sCD23, LP or 15F11 MAb induced  significant 
ERK  phosphorylation  in  SMS SB  cells  showing  that  the  αVβ5 mediated 
proliferative response was probably regulated by the ERK, MAPK pathway (Figure 
4.8). A transient ERK phosphorylation induced by SDF 1 treatment in these cells 
was markedly enhanced when SDF 1 was added together with sCD23, LP or 15F11 
MAb. These results indicated that the synergy between SDF 1 signalling and αVβ5 
signalling  could  be  via  the  ERK  signalling  pathway.  Furthermore,  the  synergy 
between PDGF and sCD23 in mediating proliferation and ERK phosphorylation in 
a manner similar to SDF 1 indicated that αVβ5 mediated signalling mechanisms 
synergise  with  both  GPCR mediated  and  RTK mediated  signalling  to  produce 
proliferative responses. Further support for synergy of αVβ5 mediated signalling 
with  growth  factor  signalling  came  from  the  mouse  cell  line  data.  The  IL 3 
dependent cell line BAF03 proliferates in a dose dependent manner in response 
to IL 3 treatment. When sCD23 or CD23 derived peptides were added together 
with a sub optimal concentration of IL 3 there was a robust enhancement in cell 
proliferation  indicating  a  synergy  between  IL 3 mediated  and  αVβ5 mediated 
proliferative responses.  
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However,  in  the  BAF03  cells  it  was  not  clear  whether  this  proliferation  was 
mediated via the ERK signalling pathway. Although there was an enhancement in 
ERK  signalling  with  IL 3  and  sCD23 derived  peptides  on  a  longer  time  course 
experiment there was no difference in ERK phosphorylation induced by CD23 
derived  peptide  alone  or  in  combination  with  IL 3  on  a  shorter  time  course 
(Figure  5.9).  These  data  indicated  that  there  could  also  be  other  signalling 
pathways involved in regulating the synergistic effect on cell proliferation.  The 
PI3K/AKT mediated  pathway  could  potentially  be  involved  in  mediating  this 
synergy  and  it  needs  to  be  investigated.  In  the  SMS SB  cell  line,  the  PI3K 
inhibitor  LY294002  inhibited  the  proliferation  induced  by  stimulation of  αVβ5 
alone or in combination with SDF 1 (Figure 4.10). Although this inhibition was 
not  as  absolute  as  the  inhibition  seen  with  the  MEK  inhibitor,  these  results 
indicate that PI3K/AKT pathway could also be mediating this enhancement of 
αVβ5 mediated signalling by growth factor receptors.  
With regards to signalling mechanisms, it would be very useful to characterise 
the  signalling  pathways  or  patterns  induced  by  αVβ5  ligation  versus  αVβ3 
ligation.  Particularly  in  some  transitional  cell  lines  where  a  proliferative 
response was seen with 23C6 (anti αVβ3 MAb) ligation, it would be interesting to 
investigate whether there is a similar ERK phosphorylation pattern to that seen 
with  αVβ5 mediated  proliferation.  A  characteristic  biphasic  pattern  of  ERK 
phosphorylation was seen in SMS SB cells with ligation of αVβ5 and this pattern 
of  phosphorylation,  when  compared  with  ERK  phosphorylation  due  to  αVβ3 
ligation, could give important information regarding why αVβ5 but not the αVβ3 
integrin induces proliferation in some pre B cell lines.  
Similarly,  a  comparison  of  ERK  phosphorylation  due  to  αVβ5  ligation  in  the 
different pre B cell lines would further establish why a proliferative response is 
observed in some cell lines and not in others. αVβ5 and αVβ3 integrins may also 
regulate  different  signalling  pathways  leading  to  different  outcomes  in  cell 
proliferation,  therefore  comparison  of  other  signalling  pathways,  particularly 
PI3K/AKT pathway, could provide important information regarding the distinct 
function of these two integrins in B cells. Furthermore, signalling mechanisms 
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function. A comparison of ERK phosphorylation induced by soluble vitronectin, 
vitronectin  coated  on  plates  and  sCD23  could  give  important  information  in 
distinguishing the role of stimulation of αVβ5 by sCD23 and vitronectin.  
These data support a model in which signals from αV integrins together with 
signals  from  other  soluble  molecules  regulate  important  proliferation  and 
differentiation decisions during B cell development and can impact on B cell 
disorders that arise due to disruption of normal proliferation and differentiation 
pathways  (Figure  6.1).  As  indicated  by  the  proliferation  data,  the  model  in 
Figure  6.1  suggests  that  the  αVβ5 CD23  interaction  probably  regulates 
proliferation of B cell precursors at early pre B stage. The exact stage, whether 
it is at the pro B stage or just after this stage still needs to be verified. The 
expression  of  αVβ5  integrin  in  ALL  cells  and  the  role  of  the  αVβ5 CD23 
interaction in regulating pre B cell proliferation indicates that the αVβ5 CD23 
interaction might be important in the growth of ALL B cells. Although there are 
no data indicating a role for αVβ5 in B cell differentiation, the fact that αVβ5 
integrin  regulates  proliferation  and  is  expressed  in  stage specific  manner 
indicates  that  αVβ5  could  be  directly  or  indirectly  linked  with  B  cell 
differentiation.  Coordinated  signals  from  the  different  αV  integrins  probably 
regulate  the  B cell  proliferation/differentiation  balance.  The  role  of  αVβ5  in 
proliferation and differentiation could also implicate this integrin in the mature 
B cell malignancy CLL. As the CD5
+ B cell population is expanded in B CLL, and 
since the data suggested the presence of αVβ5 and αVβ3 integrins on CD5
+ B 
cells from bone marrow, there could potentially be a link between αV integrin 
expression and CLL (Figure 6.1).   
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Figure   6.1 Model for the role of αVβ5 integrin during B cell development and implications for 
B cell leukaemias. 
 
This model represents the potential role of αVβ5 integrin in B cell proliferation and differentiation 
based on the data available. Different stages in B cell development in the bone marrow and blood 
are depicted in yellow. Changes in αVβ5 integrin expression levels are presented in blue. B cell 
development  is  regulated  by  a  balance  between  cell  proliferation  and  differentiation  which 
determines the number and maturation stages of the cells in each compartment. ALL is a B cell 
malignancy that  arises  during early  B cell stages  in  the  bone marrow  due to  disruption in this 
balance and results in clonal proliferation of cells arrested at a certain stage. While CLL is a B cell 
malignancy that arises at a more mature stage of B cell development. The αVβ5-CD23 interaction 
regulates proliferation of B cell precursors at early stages of B cell development. The * indicates 
that the CD23 could either be found in the bone marrow stromal cells or could be soluble CD23 in 
blood. This stage specific role of αVβ5-mediated proliferation could be influenced by a variety of 
other molecules important in B cell development. Deregulation of αVβ5 or αV integrin  expression 
and function might also be implicated in pathogenesis of CLL. 
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The data from this thesis illustrate that stimulation of αVβ5 integrin via sCD23 or 
antibodies  such  as  15F11  activates  signalling  pathways  leading  to  cell 
proliferation.  Furthermore,  this  activation  is  probably  developmental  stage 
specific and is regulated by cross talk with signals from other soluble molecules 
important  during  B  cell  development.  Further  work  on  αVβ5 mediated  cell 
proliferation  could  establish  αVβ5  integrin  as  an  important  molecule  in 
proliferation of normal B cell precursors and in proliferation of leukemic B cells 
in ALL. Data from αV conditional knockout mice which have αV integrin deleted 
in the B cells (CD19 cre) indicate that αV integrin could regulate differentiation 
into the CD5
+ (B1) B cell development, as these subsets are increased in the 
knockout mice (Dr. Adam Lacy Hulbert personal communication). Therefore, αV 
integrins could not only have important roles in ALL but could be involved in 
autoimmune disease and malignancies such as chronic lymphocytic leukaemia, 
both of which involve a clonal proliferation of CD5
+ B1 B cells. Although the role 
of αV integrins could probably be slightly different in the mouse models and in 
humans, as indicated by the difference in activities of human and mouse CD23, a 
detailed study of αV integrins in mouse models relating them to human disease 
context is required. These studies can provide important information not only 
for  B  cell  disorders  but  will  place  αV  integrins  as  important  receptors  in 
regulating B cell development.  159 
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